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Introduction: Meningiomas are the commonest primary intracranial tumour (1). Meningiomas may 
be symptomatic and present with a range of clinical features. Alternatively, meningiomas may be 
asymptomatic and diagnosed incidentally. Symptomatic meningiomas are treated with surgery or 
radiotherapy. Incidental meningiomas are actively monitored for evidence of progression. The 
diagnosis and treatment of meningioma can affect a patient’s quality of life. There has been little 
research to evaluate the subjective experiences of meningioma patients following diagnosis and 
treatment. The aim of this thesis was to investigate the patient-reported and health-related quality of 
life (HRQoL) outcomes in intracranial meningiomas.  
 
Methods: A systematic review was completed to identify all studies evaluating Patient-Reported 
Outcomes (PROs) of meningioma. The following databases were searched: PubMed, EMBASE, 
Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, CINAHL, 
PsycINFO and AMED. Furthermore, long-term HRQoL outcomes were assessed by the QUALMS study. 
Patients diagnosed with a meningioma who had been surgically treated or were actively monitored 
by The Walton Centre hospital were invited to participate. The SF-36, EORTC QLQ-C30, EORTC QLQ-
BN20 and study-specific questionnaires were self-administered to participants. 
 
Results: The systematic review identified a total of 7,489 unique articles, of which 33 met the inclusion 
criteria. The studies evaluated a range of PRO domains: HRQoL (n=25), Health Status (n=2), Patient-
Reported Symptoms (n=9), Patient-Reported Functioning (n=8), Patient-Reported Feelings (n=2) and 
Other PROs (n=2). No meningioma-specific tool was used to evaluate PROs. The results of the 
systematic review show that the diagnosis and treatment of meningioma has an impact on a variety 
of PRO domains. Furthermore, there was a shortage of studies evaluating long-term HRQoL, 
particularly in patients with incidental meningioma. The initial, exploratory analysis of the QUALMS 
study included 54 patients who responded on average ten years after diagnosis. In comparison to the 
normative population values, patients had inferior HRQoL scores in the following domains: SF-36 
Physical Functioning, Role Physical, General Health and QLQ-C30 Cognitive Functioning. However, 
QLQ-C30 Diarrhoea scores were higher than normative values. Compared to patients who were only 
actively monitored for their meningioma, patients that received intervention had HRQoL impairments 
in the domains of the SF-36 (Role Physical, Energy and Fatigue, Emotional Wellbeing, Social 
Functioning, Pain), QLQ-C30 (Summary Score, Social Functioning, Fatigue, Cognitive Functioning, Pain) 
and QLQ-BN20 (Communication Deficit, Drowsiness). The study identified that meningioma patients 
did not report impairments for several items of QLQ-C30 and QLQ-BN20, raising the question about 
the content validity of these questionnaires for use in this population.   
 
Conclusion:  Patients with meningioma experience a range of issues which persist many years after 
diagnosis and treatment. Patients with incidental meningiomas and those followed-up with active 
monitoring alone are more likely to have better HRQoL. Future research should evaluate PROs  
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“There is today nothing in the whole realm of surgery more gratifying than the 
successful removal of a meningioma with subsequent perfect functional 
recovery, especially should a correct pathological diagnosis have been previously 
made. The difficulties are admittedly great, sometimes insurmountable, and 
though the disappointments still are many, another generation of neurological 
surgeons will unquestionably see them largely overcome.” 
 




After nearly one century, neurosurgery has overcome many of the 
insurmountable challenges that Cushing described. Today, clinicians better 
understand the natural history and aetiology of meningioma (2, 3). The 
development of neuroimaging has made it possible to visualise and identify 
these tumours without operating (4). Surgery is safer than before, and measures 
exist to excise a tumour while preserving neurological tissue and function (5). 
Furthermore, techniques of non-surgically treating these tumours continue to 
emerge (6).  
 
Nevertheless, further questions still exist. What are the molecular mechanisms 
that underpin the development of meningiomas? How can clinicians 
personalise management for patients? Is it possible to accurately predict 




As we learn more about meningioma, the attention is turning to the personal 
impact they can have on those are afflicted by them. Meningiomas have been 
long-considered a benign tumour, but increasing reports suggest that patients 
have long-term and complex health needs. There is an increasing consensus 
within the neurosurgical community to integrate medical, psychological and 
social considerations within patient care. Therefore, it is paramount to 
understand what patients perceive and experience to improve their wellbeing.  
 
The modern-day demands of healthcare give clinicians only limited time with 
their patients. Follow-up appointments are brief and necessitate a focus on 
tumour progression and worsening objective deficits. A thorough 
understanding of patient wellbeing is difficult to ascertain. A patient may never 
convey their concerns and struggles to a healthcare professional.  
 
Collecting Patient-Reported Outcomes (PROs) is one method to empower 
patients to express their view. Standardised collection and analysis methods 
permit quick and objective assessment of a patient’s subjective experiences. 
PROs have the potential to facilitate clinician-patient communication, holistic 
evaluation of therapies and assessment of healthcare delivery from a patient’s 
perspective. However, routine use of PROs in meningioma care and research is 
limited. 
 
This thesis explores PROs in the context of meningioma. Firstly, the reader is 
introduced to the topic of meningioma, PROs and their measurement. Chapter 
2 describes a systematic review to identify all PROs and their measurement tools 
in the meningioma literature. Chapter 3 details the methods and results of the 
‘QUALMS study’ which evaluates health-related quality of life (HRQoL) PROs 
of meningioma. The results of this thesis will contribute to the aim of the 
Liverpool Neuro-Oncology Group to routinely collect and utilise PROs to 
enhance patient care.  
 
  
1.2 Aims and objectives 
 
1.2.1 Research question 
 
• What are the patient-reported and quality of life outcomes in 




1. To summarise the current knowledge regarding intracranial 
meningiomas  
2. To describe the concept of patient-reported outcomes (PROs) and their 
measurement (PROM) tools 
3. To systematically identify PROMs currently used in meningioma 
patients 
4. To systematically review the current literature and quality of reporting 
of PROs in patients with intracranial meningioma 
5. To describe the methods and results of a pilot study assessing the 
HRQoL of patients with either an incidental or operated meningioma.  
6. To highlight the applications of the thesis results to future areas for PRO 














Figure 1.1: Thesis overview 
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 24  
1.3 Nomenclature 
 
The earliest description of meningioma comes from the Swiss physician Felix 
Plater who in 1614 described a ‘round fleshy tumor like an acorn … covered with 
its own membrane and … free of all connection with the matter of the brain.’ (7) 
These tumours have been known by a variety of names including fungoid 
tumour, epithelioma and dural sarcoma (8-11).   
 
However, in 1922, Professor Harvey Cushing first proposed the term 
meningioma (10). This term was chosen because it simplistically summarised 
that these tumours grew from the meninges which surround the brain. The 
term meningioma gained favour within the neurosurgical community and has 




Meningiomas are the most common primary intracranial tumour. They account 
for over a third of all central nervous system (CNS) neoplasms and over half of 
all benign tumours. The incidence rate of meningioma is 8.58 per 100,000 
person-years. More than 30,000 patients will be diagnosed with meningioma 
this year in the USA (1). 
 
The incidence of meningioma increases with age. Meningiomas are rare in 
children, with an incidence rate of 0.2 per 100,000 between the ages of 0 and 19.  
The incidence rate increases to 10.2 per 100,000 between the ages of 45 and 54 
and 53.4 per 100,000 for those aged 85 and above (1).  
 
Women develop meningiomas with twice the frequency of men (12). 
Furthermore, the incidence of meningiomas is significantly higher in black 





1.5 Anatomical location of meningiomas 
 
Intracranial meningiomas can originate from skull base and non-skull base 
locations. Skull base meningiomas arise from the anterior, middle or posterior 
cranial fossa. The most common skull base locations are the medial sphenoid 
wing, olfactory groove and the suprasellar region (13). Common non-skull base 
origins of meningioma are the cerebral convexity, parasagittal and parafalcine 
regions (13). Rarely, meningiomas can arise from within the ventricular system 
of the brain and in the pineal region; these locations are deeper within the brain 
and difficult to access surgically. Meningiomas may be supratentorial or 
infratentorial, which describes their position in relation to the tentorium 
cerebelli. Infratentorial meningiomas arise in proximity to the cerebellum or 
brain stem and can also present surgical challenges.  Table 1.1 shows the 
International Consortium of Meningioma (ICOM) classification of 
meningiomas by location. Figure 1.2 illustrates the anatomical origins of 
meningioma.  
 
Table 1.1: ICOM classification of meningiomas by location  
Main category Subcategories 
convexity anterior 1 posterior 1  
parasagittal anterior 1 posterior 1 falco-tentorial 
parafalcine anterior 1 posterior 1 falco-tentorial 





cribriform plate or 
olfactory groove 2 
planum 
Tuberculum and diaphragma 
sellae 
post fossa - 
midline 
clival petro-clival anterior foramen magnum 4 
post fossa - 
lateral & posterior 
petrous squamous occipital posterior foramen magnum 4 
tentorial supratentorial infratentorial  
intraventricular    
pineal region 5    
 
1 The main attachment is located anterior or posterior, respectively, to the coronal suture 
2 Arising between the crista galli and the fronto-sphenoid suture 
3 Arising between the fronto-sphenoid suture and the limbus sphenoidale 
4 The main attachment is located anterior or posterior, respectively, to the hypoglossal canal 
5 No obvious tentorial attachment 
ACP: anterior clinoid process 


















Figure 1.2: Coronal section of the brain and axial view of skull base showing meningioma locations 





Sporadic meningiomas arise in the absence of a specific underlying cause. They 
are the most common variant of meningioma and the focus of this thesis. 
Neurofibromatosis type 2-associated meningiomas and radiation-induced 
meningiomas have a different natural history compared to sporadic 
meningiomas. For this reason, they are considered different disease entities and 
addressed separately by the meningioma research community. 
 
1.6.1 Neurofibromatosis type 2 
 
Neurofibromatosis type 2 (NF2) is a rare condition with an incidence of 1 in 
30,000 that arises from a mutation of the NF2 tumour suppressor gene (14). It 
has an autosomal dominant inheritance pattern; however, up to 50% of NF2 
patients have no family history and have acquired de novo mutations. NF2 
predisposes patients to develop multiple neoplasias of the nervous system, eyes 
and skin (15).  Development of bilateral vestibular schwannomas is highly 
sensitive of an NF2 diagnosis (16). As many as half of NF2 patients develop 
meningiomas in their lives (16). Frequently these are multiple and occur earlier 
in life compared to patients with sporadic meningioma (17-19). Studies have 




Over recent decades, research has highlighted an association between radiation 
and meningioma. Low-dose radiation previously used to treat childhood tinea 
capitis in the 1950s and 1960s was identified to increase the relative risk of 
developing meningioma nearly 10-fold (21). Furthermore, those who were 
within 2km of the 1945 atomic bomb blast in Hiroshima had an increased 
incidence of meningioma (22). Radiotherapy is an effective treatment modality 
for childhood malignancies such as acute lymphoblastic leukaemia and CNS 
tumours. However, childhood cranial irradiation is also associated with the 
development of meningiomas (23, 24). Meningiomas occurring many years 
 28  
following cranial radiotherapy are known as radiation-induced meningiomas 
(RIMs) (25, 26).  
 
In comparison to sporadic meningiomas, RIMs occur equally in both sexes and 
at a younger age (26). RIMs are more aggressive compared to sporadic 
meningiomas and demonstrate a substantial proportion of atypical or 
malignant features (26-29). Following treatment, approximately 20% of RIMs 
recur (26, 30, 31). Given the strong association between radiation and 
meningiomas, researchers have questioned whether radiation from telephones 
or dental x-rays may also increase tumour risk. However, one case-control study 
showed no increased odds between telephone use and development of 
meningiomas (32). Furthermore, two meta-analyses have concluded that dental 
X-rays do not increase the risk of developing meningiomas (33, 34). 
 
1.6.3 Hormonal factors 
 
Meningiomas occur more commonly in females and grow during pregnancy (35-
37). This observation has prompted researchers to investigate the association 
between meningiomas and hormonal factors. Meningiomas express an 
increased number of progesterone and oestrogen receptors compared to 
healthy meningeal tissue (38, 39). In vitro studies demonstrate that 
progesterone agonists can promote the growth of meningioma cell lines. 
Conversely, progesterone antagonists cause inhibition of meningioma cells in 
vitro (40, 41). However, clinical studies have failed to show the efficacy of the 
progesterone receptor antagonist mifepristone in improving patient survival 
(42, 43).  
 
One recent case-control study found that meningioma patients taking 
progesterone-only contraception pills have shorter progression-free survival 
than those taking oestrogen pills with or without progesterone (44). 
Furthermore, two systematic reviews have identified a significant association 
between Hormone Replacement Therapy (HRT) use and development of 
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meningioma (45, 46). Given that large numbers of women use hormonal 
contraception and HRT, it is vital to demonstrate their safety in women with 
meningioma. Additionally, a number of case studies have reported an 
association between intake of anti-androgen and progestin drugs and 
development of meningioma (47, 48). Some tumours have been reported to 
regress upon discontinuation of hormonal therapy (49). Further prospective 




The meninges are a protective membrane which envelope the brain and spinal 
cord. The meninges contain three layers: the dura, arachnoid and pia mater. 
Meningiomas arise from the arachnoid cap cells found on the outer layer of the 
arachnoid mater (50, 51). Meningiomas usually have a firm consistency which 
may become gritty if they are calcified with psammoma bodies (52). 
Meningiomas have variable vascularity and derive their blood supply from the 
meningeal vessels (52, 53). Meningiomas can grow in size and compress 
underlying structures of the brain and spinal cord to cause symptoms. 
Aggressive meningiomas may invade the brain or metastasise (52, 54). Some 
meningiomas may release substances which promote osteolysis or hyperostosis 
of adjacent bone. Cerebral oedema may surround the tumour, which further 
increases intracranial pressure and risk of symptoms such as seizure (55-57).  
 
The World Health Organisation (WHO) classification of tumours of the central 
nervous system classifies meningioma as Grade I (benign), II (atypical) and III 
(anaplastic/ malignant) (54). Increasing WHO Grade denotes increasing 
aggressiveness of the meningioma and corresponds with worsening prognosis 
(58). Over 80% of meningiomas are WHO grade I (1). Within each WHO grade, 
a variety of histological subtypes exist. WHO Grade is determined by either 
identification of specific histological features or subtypes. Table 1.2 illustrates 
the histological criteria used to determine the WHO Grade of meningiomas. 
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Brain invasion is a histological criterion which has been controversial within 
meningioma research. WHO defines brain invasion as an invasion of the brain 
by a meningioma without an intervening layer of leptomeninges (58). Studies 
have found that the presence of brain invasion conveys a similar recurrence rate 
to atypical meningiomas (59). Accordingly, WHO recently made the presence 
of brain invasion a standalone feature which can define a tumour as a WHO 
grade II meningioma (54). However, one systematic review identified that 
various definitions of brain invasion exist in the literature, and there is a weak 
correlation with prognosis (60). The classification change is significant as WHO 
Grade II meningiomas will be increasingly diagnosed (61).  Since WHO grading 
guides management decisions, the diagnosis of a WHO Grade II meningioma 
may prompt adjuvant treatment and more frequent MRI follow-up, which may 





















Table 1.2: Prevalence and diagnostic criteria of WHO Grade I, II and III meningiomas. 
Modified from Bi et al. 2016 (62)  
 WHO Grade I WHO Grade II WHO Grade III 
Prevalence 
(%) (1) 








Low mitotic rate, <4 
per 10 HPF 
AND 
Absence of brain 
invasion 
 




3/5 of these histologic 
features: 
I. Increased cellularity 
II. High nuclear/cytoplasmic 
ratio 
III. Large and prominent 
nucleoli 
IV. Architectural sheeting 
V. Foci of “spontaneous” or 
geographic necrosis 
OR 





























Atypical by criteria 











1.8 Molecular biology of meningiomas 
 
As biomedical technology and techniques continue to improve, research is 
providing a better understanding of the molecular changes occurring within 
tumour cells. Routine neuro-oncology clinical practice now applies this 
knowledge: molecular features currently contribute to the classification of 
glioma and medulloblastoma (54). Nevertheless, meningioma classification 
remains entirely based on histopathology. The investigation into the molecular 
landscape of meningioma is rapidly expanding, and changes to clinical practice 
are likely to soon reflect this.   
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1.8.1 Copy number variations 
 
Copy number variations (CNVs) are losses, gains or duplications of sections of 
chromosomes (63). While CNVs are present in healthy individuals, some CNVs 
are implicated in disease. Pathological CNVs alter the function of genes 
involved in regulating cell proliferation (64). Loss of the long arm of 
chromosome 22 is a prevalent CNV in meningioma (65, 66). This CNV occurs 
early in meningioma development and increases in prevalence with WHO 
Grade (66, 67). WHO Grade II meningiomas have an increased frequency of 
CNVs on chromosome 1p and 14q (66, 67). Grade III tumours frequently 
demonstrate CNVs on chromosome 4p, 6q, 7p, 10q, 11p and 18q (66). Frequency 
of CNVs is associated with meningioma aggressiveness. WHO Grade I, II and 
III tumours show a median chromosomal arm loss per tumour of 1.0, 3.0 and 
9.5, respectively (66).  
 
1.8.2 Genetic mutations 
 
The NF2 gene is located on the long arm of chromosome 22 and codes for the 
protein neurofibromin 2 (also known as merlin). This cell-membrane bound 
protein interacts with the cytoskeleton and is responsible for contact-
dependent regulation of cellular proliferation (68). Germline or de novo NF2 
mutations lead to neurofibromatosis type 2 (NF2), which is known to increase 
the risk of meningioma (69). However, as many as 50% of sporadic meningioma 
cells also have an NF2 mutation (70-72). Specific mutations correspond to WHO 
Grade and clinical phenotypes. For example, TRAF7, AKT1 and KLF4 mutations 
are more frequent in WHO grade I meningioma (73). Mutations of the SMO 
gene are exclusively associated with WHO grade I meningiomas (73-75).  
However, mutations of the proto-oncogene TERT and tumour suppressor gene 







Imbalances of DNA methylation patterns are involved in meningioma 
development (76). In healthy cells, DNA methylation of CpG islands (cytosine-
guanine dinucleotide repeats) regulates gene expression. The promoter regions 
of genes contain CpG islands, and their function is to regulate gene 
transcription (77). When unmethylated, CpG islands allow transcription of 
genes (77). However, DNA methyltransferase (DNMTs) enzymes can methylate 
the CpG islands and cause downstream gene silencing (78). Pathological 
hypermethylation of CpG islands near tumour suppressor genes such as THBS1, 
MGMT, TIMP-3, p16INK4a, p14ARF and p73 causes gene silencing and contributes 
to tumorigenesis (76). 
 
Conversely, widespread hypomethylation may increase transcription of genes 
involved in carcinogenesis, tumour invasion and metastasis (79). Genome-wide 
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1.9 Clinical features  
 
Meningiomas give rise to both generic and location-specific symptoms; many 
are slow-growing, and symptom onset can be insidious (81). Moreover, 
meningiomas may be asymptomatic and identified by neuroimaging completed 
for unrelated reasons.  
 
1.9.1 General features 
 
One of the earliest features of a meningioma may be the onset of epilepsy (82). 
Approximately 25% of meningioma patients will experience seizures, 
particularly those with supratentorial tumours (56, 57, 83). The aetiology of 
tumour-induced epilepsy is unclear. Hypotheses suggest a role of biochemical 
abnormalities, dysfunctional NMDA receptors and altered immunological 
activity (82). Several studies purport an association between peritumoral 
oedema and seizures (56, 83). Generalised seizures involve the whole brain and 
patients may present with tonic-clonic seizures. Alternatively, focal seizures 
may present with auras such as a ‘rising epigastric’ sensation or the déjà vu 
phenomenon.  
 
Headache is considered by many as the archetypal symptom of a brain tumour. 
However, as an isolated symptom, it has a low positive predictive value for brain 
tumours in adult patients (84). No headache type or syndrome is pathognomic 
for meningioma. However, a change in a pre-existing headache phenotype or a 
headache associated with red flags (such as abnormal neurological examination 
or a headache which causes awakening from sleep) may prompt clinicians to 
further investigate for the presence of a brain tumour (85). The main factors 
thought to induce headaches from brain tumours are related to distortion and 
displacement of pain-sensitive structures within the blood vessels, cranial 
nerves, dura mater and periosteum (85, 86). 
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Other clinical features include the development of cognitive impairment such 
as deficits of memory, attention and executive function (87). Meningiomas that 
increase intracranial pressure (ICP) can present with reduced consciousness or 
papilledema (88). Occasionally, symptoms mimicking a mental health disorder 
may be the only presenting feature of meningioma (89).  Frontal lobe 
meningiomas can cause psychosis, delirium, depression, apathy, mania and 
change in personality (90).  
 
1.9.2 Focal features 
 
Patients may present with a variety of focal symptoms arising as local neuronal 
structures are distorted and compressed. Left hemisphere meningiomas in the 
perisylvian region may cause an expressive, receptive or mixed dysphasia. A 
paresis or apraxia can arise from meningioma overlying the motor cortices. 
Involvement of the parietal lobe may lead to somatosensory disturbances. 
Occipital lobe meningiomas can result in visual field defects or agnosia. Skull 
base meningiomas frequently compress the cranial nerves (91, 92). Olfactory 
groove meningiomas distorting cranial nerve I may lead to a loss of smell and 
anterior skull base lesions may compress the optic nerve or chiasm leading to a 
visual deficit. Cavernous sinus meningiomas can involve cranial nerves III, IV, 
V and VI manifesting as visual loss, diplopia and facial numbness. 
Cerebellopontine angle meningiomas affecting cranial nerve VII or VIII can 
produce facial pain, sensory disturbance, sensorineural hearing loss and vertigo. 
Meningiomas of the clivus and foramen magnum can manifest as a complex 









1.10 Incidental meningiomas 
 
Small, asymptomatic meningiomas are common and may occur in up to 1% of 
the population (93). These clinically indolent meningiomas may go unnoticed 
through an individual’s life or get identified by chance through neuroimaging 
performed for unrelated reasons. The diagnosis of these so-called ‘incidental 
meningiomas’ is increasing due to the widespread use of neuroimaging in 
clinical practice and research (94). Over 90% of these meningiomas are WHO 
Grade I (95). Consensus guidelines suggest that incidental meningiomas should 
be managed by observation, although variation exists in practice (96, 97).  
 
Three critical questions concerning incidental meningiomas include:  
1. Is long-term follow-up necessary to monitor the growth of incidental 
meningiomas? 
2. Do patients with incidental meningiomas experience neurocognitive 
deficits? 
3. Does a diagnosis and follow-up of incidental meningioma affect a 
patient’s quality of life? 
 
Approximately 10% of incidental meningioma patients develop symptoms 
during follow-up, and 20% demonstrate radiological progression (95). The 
majority of patients who have clinical or radiological progression do so within 
five years of diagnosis (95). Larger size and peri-tumoural oedema are variables 
associated with progression of incidental meningiomas (95). These radiological 
factors can be combined with clinical information to develop personalised 
incidental meningioma monitoring regimes (98).  
 
There is a paucity of research regarding neurocognitive outcomes of patients 
with an incidental meningioma. One study has identified that patients with 
incidental meningioma have similar neurocognition to matched controls (99). 
However, another has found that patients have lower psychomotor speed and 
working memory (100). Regarding the quality of life outcomes, patients report 
 38  
lower vitality and self-perceived general health (100). A diagnosis of a brain 
tumour and follow-up may lead to anxiety for patients. Quality of life outcomes 




The confirmation of a meningioma diagnosis is by histological analysis of tissue 
obtained during surgery. However, neuroimaging is accurate in predicting 
meningioma in the majority of cases. Consensus guidelines recommend a 
Magnetic Resonance Imaging (MRI) scan as the initial investigation for 
diagnosis (96). However, complex meningiomas may require the use of 




Magnetic Resonance Imaging (MRI) scans of meningioma typically reveal a 
well-circumscribed and extra-axial lesion (81). Meningiomas are isointense or 
hypointense to adjacent grey matter on T1-weighted MRI sequences. They are 
isointense or hyperintense on T2-weighted sequences. Following injection of 
gadolinium contrast, a meningioma demonstrates homogenous enhancement. 
MRI may identify a dural tail which represents thickening of dura extending 
peripherally from the meningioma. MRI may also reveal the CSF cleft sign, 
which refers to a high signal intensity between the meningioma and the brain 
parenchyma. Oedema can surround a meningioma, and this is best visible on 
T2 and T2 FLAIR sequences (81). Magnetic Resonance Spectroscopy (MRS) 
utilises magnetic fields to identify metabolic activity in tissues (101). MRS of 
meningioma shows increased choline and alanine peaks and decreased peaks of 








Computed Tomography (CT) scans are regularly requested for assessment of 
headaches, head injury and suspected stroke (103). Therefore, CT frequently 
identifies incidental meningiomas. Similar to MRI, CT reveals an extra-axial, 
hyperdense and well-circumscribed lesions (104). CT is ideally suited to 
identifying calcification and bony changes such as osteolysis and hyperostosis 





Angiography involves injecting contrast into arteries and taking radiographs. 
Meningiomas may be highly vascularised by meningeal arteries. Therefore, 
angiography demonstrates a ‘tumour blush’ and delayed ‘washout’ as the 
contrast is taken up and leaves the meningioma (104-106). Angiography is not 
required for diagnosing meningioma but may be used to understand the arterial 
supply of complex tumours (96).  
 
1.11.4 Somatostatin analogue 
 
Meningiomas show increased expression of somatostatin receptor 2 (SSR2) 
(107). DOTATE and DOTATOC are ligands which bind with high affinity to 
meningioma SSR2 (108). These ligands are marked with radioisotopes such as 
Gallium-68 which allows their detection using Positron Emission Tomography 
(PET) scans.  This PET tracing discriminates between tumour and healthy 
tissue, makes their use valuable for diagnosis and treatment planning of 
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1.11.5 Differential diagnosis 
 
No further investigation or biopsy is necessary for tumours which show typical 
imaging characteristics of meningioma. However, clinicians should be aware of 
potential mimics of meningioma (96). Primary lesions that may mimic 
meningioma include solitary fibrous tumours, hemangiopericytomas and 
schwannomas (112-114). Dural metastases, usually originating from breast or 
lung carcinomas, are an important differential diagnosis to exclude with further 






Surgery represents a safe and effective method to reduce tumour burden for a 
majority of patients. Surgery may be curative in WHO Grade I meningiomas 
and can reduce tumour burden. It is an established first-line therapy for 
symptomatic or growing meningiomas. However, not all patients may be 
suitable for surgery. Factors which influence the decision to operate include 
patient’s general health, functional status and presence of comorbidities. Some 
tumours, such as petroclival or foramen magnum meningiomas, are surgically 
challenging to access and preclude resection. 
 
The goal of surgery is maximal safe resection of the meningioma to obtain a 
diagnosis, reduce ICP and relieve symptoms. Intra-operatively, surgeons can 
estimate the extent of resection using the Simpson grading system (118). This is 
confirmed by MRI postoperatively. Modern interpretation favours that Simpson 
Grade 1-3 denotes gross total resection (GTR) and grades 4 and 5 are a subtotal 
resection (STR). The extent of resection is considered a prognostic indicator and 
influences decisions about further management such as whether to offer 
adjuvant therapy. The surgical gold-standard is to achieve a Simpson Grade 1 
resection which is complete resection of the tumour, dural attachment and 
abnormal bone (118).   
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Grade 1 Macroscopic complete removal of the tumour and excision of its dural 
attachment and any abnormal bones. If a tumour arises from the wall of a 
dural venous sinus, a Grade I resection involves excision of the sinus.  
Grade 2 Macroscopic complete removal of the tumour and its visible extensions, 
with endothermy coagulation (to the point of charring) of dural attachment. 
Grade 3 Macroscopic complete removal of the intradural tumour without resection 
or coagulation of its dural attachment or extradural extensions, e.g. invaded 
sinus or hyperostotic bone. 
Grade 4 Partial removal of the tumour, leaving intradural tumour in situ. 
Grade 5 Decompression of tumour with or without biopsy. 
 
However, surgical resection of meningioma is not without risk of long-term 
complications. Convexity meningioma resection can lead to hemiparesis, 
hemisensory loss and dysphasia. Skull-base surgery may cause CSF leak or 
meningitis. Cranial nerve damage can occur, causing loss of sensation (smell, 
vision, hearing and taste) and motor control (facial paresis, mastication, speech 
and swallowing). Previously seizure-naïve patients can develop epilepsy 
postoperatively (56). Cognitive decline may follow, leading to difficulty with 
concentration and memory (87). In this regard, surgery can sometimes induce 
the deficits it attempts to relieve.   
 
1.12.2 Radiation therapy 
 
A variety of techniques exist to deliver radiation to meningiomas, such as 
external beam radiotherapy (EBRT) and stereotactic radiosurgery. EBRT is the 
name given to conventional external radiation delivery techniques. EBRT is 
favourable for larger tumours or those adjacent to critical neurovascular 
structures. Examples of EBRT include 3D conformal radiotherapy (3D-CRT), 
Intensity-modulated radiotherapy (IMRT), Volumetric Modulated Arc Therapy 
(VMAT) and Proton beam therapy (119-121). Stereotactic radiosurgery (SRS) and 
fractionated stereotactic radiotherapy (SRT) both use steep dose gradients to 
spare radiation toxicity to healthy tissue (122). Examples of SRS include Linear 
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Accelerator (LINAC) and Gamma Knife techniques. SRS is useful for controlling 
the growth of small or incompletely resected meningiomas (123).  
 
Radiotherapy is a largely safe and effective treatment option which can be used 
as primary or adjuvant therapy. Radiation therapy can be used to treat residual 
or recurring meningiomas. Complication rates from EBRT are low but can 
include radiation necrosis, visual deficit and osteomyelitis (124).  SRS is a day-
case procedure and usually well tolerated by patients (6). However, 
complications of treatment include new cranial nerve dysfunction, visual loss 
and worsening headache (125). SRT has shown reduced symptom burden in 
comparison to SRS, particularly from symptomatic radiation-induced oedema 
(126-128).  
 
Other radiation-based treatments may have value for high-grade or recurring 
meningiomas where alternative treatment options are exhausted or unsuitable. 
Brachytherapy involves surgically placing a radioactive source in close 
proximity to meningioma tissue (129). Radionuclide therapy involves 
administering analogues which bind to meningioma-specific SSR2 receptors 
and deliver radiation to meningioma cells (130). Further prospective studies are 
required to evaluate the efficacy of these treatments for managing 
meningiomas.  
 
1.12.3 Systemic therapy 
 
A variety of chemotherapy, hormone receptor antagonist and SSR2 receptor 
analogue therapies have been assessed for efficacy in clinical studies and shown 
sub-optimal treatment benefits (6, 131). However, studies investigating the 
efficacy of systemic therapies are currently on-going. Immunotherapy using 
pembrolizumab and nivolumab is currently being investigated for patients with 
high-grade meningioma (NCT03279692, NCT02648997). Furthermore, 
molecular therapies targeting the NF2, AKT and Hedgehog pathways are being 
developed (6, 96). Medical management of meningioma is an evolving area of 
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research and currently remains reserved for when surgical and radiotherapy 
options have been exhausted.  
 
1.12.4 Active monitoring 
 
Active monitoring through neuroimaging assists clinicians in deciding when to 
treat a patient and also to assess the objective response from treatment. 
Consensus guidelines recommend that both incidental and symptomatic WHO 
Grade I meningiomas are followed-up with a yearly MRI scan. Patients with 
WHO Grade II and III meningiomas have an increased risk of recurrence and 
should have an MRI biannually or quarterly (96). Active monitoring can identify 
tumour recurrence in patients who have had a complete resection of their 
meningioma. Furthermore, active monitoring may reveal tumour progression 
in patients with incompletely resected or incidental meningiomas.   
 
1.13 Guidelines for the management of meningiomas 
 
1.13.1 WHO Grade I 
 
For symptomatic meningiomas or those causing mass-effect, the primary 
treatment option is surgical resection. Incompletely resected meningiomas may 
undergo active surveillance or be treated with adjuvant stereotactic 
radiosurgery or fractionated radiotherapy (96). Some skull base meningiomas 
are intentionally incompletely resected to spare damage to critical 
neurovascular structures such as the cranial nerves. The residual tumour is 
treated with adjuvant stereotactic radiosurgery (96). For patients who are not 
fit for surgery, stereotactic or fractionated radiotherapy techniques can be used 
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1.13.2 WHO Grade II 
 
Completely resected WHO Grade II meningiomas can be treated with either 
upfront adjuvant radiotherapy or observation using MRI scans (96). At present, 
there is a paucity of high-quality, prospective studies showing the superiority of 
either approach following surgery. This clinical equipoise forms the basis for the 
on-going ROAM/EORTC 1308 (ISRCTN71502099) clinical trial (132).  For 
incompletely resected WHO Grade II meningiomas, adjuvant radiotherapy is 
given to improve tumour control and reduce the risk of recurrence (96). 
Consensus guidelines recommend fractionated radiotherapy over SRS in these 
cases (96).  
 
1.13.3 WHO Grade III 
 
Anaplastic meningiomas should be treated with surgery and adjuvant 
fractionated radiotherapy (96). In the event of tumour recurrence and 
exhaustion of surgical and radiation treatment options, experimental 
pharmacotherapy may be offered (96).   
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Figure 1.4: EANO recommendations for the treatment of WHO Grade I, II and III meningiomas (96) 
 
Figure 1.5: An infographic to summarise the clinical features, investigations and 
management of intracranial meningioma 
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1.14 Prognosis 
 
A comprehensive discussion of the prognostic factors influencing meningioma 
outcome is beyond the scope of this thesis. Combining clinical, 
histopathological and molecular factors is necessary to improve classification 
and prognostication (133). An integrated clinical model can help to develop 
personalised meningioma management algorithms.  
 
The life expectancy of meningioma patients remains lower than the general 
population (134, 135). Overall survival of meningioma decreases with increasing 
WHO Grade. The overall 5-year and 10-year UK survival rates for WHO Grade I 
meningioma is 90% and 81%, for WHO Grade II it is 80% and 63% and for WHO 
Grade III it is 30% and 15% (136).  
 
WHO grading also determines the risk of meningioma recurrence. The risk of 
recurrence for WHO Grade I, II and III meningiomas is 7-25%, 29-52% and 50-
94%, respectively (58). Histological parameters that are associated with an 
increased risk of recurrence include an increasing number of mitotic figures and 
the presence of focal necrosis (137). Furthermore, the risk of recurrence 
increases with Simpson grades of meningioma resection. In Simpson’s original 
study, the meningioma recurrence rate was 9%, 19%, 29%, 44% and 100% for 
Simpson grades 1–5, respectively (118). Similar recurrence trends are evident in 
modern series (138-141) and Simpson grades 4 and 5 are also associated with 
decreased overall survival (141).  
 
The value of molecular markers for prognostication of meningioma is 
increasing. One study has suggested that ‘TRAKLS’ (TRAF7, AKT1 and KLF4) 
mutations generally confer a better prognosis genotype (73, 142). Moreover, 
mutations of the transcription factor FOXM1 are a marker for aggressive 
meningioma and poor clinical outcomes (143). More recently, methylation data 
has been combined with clinical factors to develop a nomogram which 
accurately predicts meningioma recurrence (144, 145).  
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Survival and recurrence represent one aspect of meningioma prognosis. 
Morbidity is also high, and patients experience a variety of physical, cognitive 
and emotional difficulties which impair quality of life (87, 146). Chapter 2 of this 
thesis will highlight this in further detail.  
 
1.15 Patient-Reported Outcomes 
 
The World Health Organisation defines health as ‘a state of complete physical, 
mental, and social wellbeing not merely the absence of disease or infirmity’ 
(147). Therefore, an evaluation of a person’s health must include a holistic 
review of wellbeing in addition to an investigation of the morbidity from 
disease. Traditionally, researchers have assessed health by using objective 
measures of morbidity and mortality and patient wellbeing was considered of 
secondary importance. However, in the last two decades, healthcare and 
research have appropriately become patient-centred with increasing 
importance given to the subjective experiences of patients.  
 
Healthcare in economically developed countries is increasingly focussing on 
long-term management of chronic diseases. The goal of clinicians is often to 
reduce symptom burden and disability from disease and treatment. Modern 
healthcare places emphasis on increasing the functioning and participation of a 
patient in activities of daily living. Thorough measurement of these outcomes 
requires an assessment of a patient’s own perspective (148).  
 
Patient-Reported Outcomes (PROs) are a patient’s expression of their 
subjective perceptions and experiences. The European Medicines Agency 
(EMA) and the US Food and Drug Administration (FDA) define a PRO as an 
outcome directly from a patient about the status of their health condition or 
perception of a disease and its treatment (149, 150). A PRO must be without 
amendment or interpretation of the patient’s response by anyone else (150). 
PRO is an umbrella term encompassing measurement of quality of life, health 
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status, symptom burden, adherence to and satisfaction with treatment (149, 
151).  
 
1.15.1 Quality of Life 
 
Quality of life (QoL) is a specific type of PRO that concerns a person’s state of 
wellbeing. In many ways, it is an abstract term that carries a different meaning 
to each person. Campbell et al. described Quality of Life as a ‘vague and ethereal 
entity, something that many people talk about, but which nobody knows very 
clearly what to do about.’ (152)   
 
However, some aspects of QoL are generally agreed. Firstly, QoL is subjective 
and understood only from an individual’s perspective. Secondly, QoL is 
multidimensional and influenced by a variety of factors. Subjectivity and 
multidimensionality form the foundations of understanding QoL (153).  WHO 
defines QoL as ‘an individual’s perception of their position in life in the context 
of the culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns.’ (154) 
 
Health-related quality of life (HRQoL) refers to ‘the extent to which one’s usual 
or expected physical, emotional, and social wellbeing are affected by a medical 
condition or its treatment.’ (155) This definition highlights that HRQoL is not 
merely a measure of wellbeing, but how this aligns with a patient’s subjective 
expectations (156).   
 
1.16 Application of PROs  
 
1.16.1 Clinical research 
 
Within clinical research, PROs allow assessment of net clinical benefit of a 
treatment. Integration of PRO data with traditional endpoints within clinical 
trials and studies provides a holistic overview of disease burden and efficacy of 
an intervention (157, 158). The US FDA states that Clinical Outcome Assessment 
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(COA) of drug development should encompass both objective clinical evidence 
of benefit and subjective experiences reported by patients (150).  
 
In clinical trials, PROs may be a primary outcome used to differentiate therapies 
in non-inferiority studies. For example, a patient’s subjective experiences can 
be a primary outcome used to compare two palliative therapies (159). 
Alternatively, clinical trials may use PROs as a secondary outcome. Traditional 
endpoints such as survival describe only the physical benefit of treatment; PROs 
add a patient perspective which contributes to a holistic assessment (148, 151). 
For example, the ROAM clinical trial is assessing the clinical benefit of radiation 
treatment compared to observation alone for atypical meningiomas (132). The 
primary outcome of the trial is progression-free survival, and HRQoL is a 
secondary outcome. The trial may identify that radiotherapy confers a modest 
survival advantage but at the expense of decreasing HRQoL. In this case, the 
PROs would provide an additional lens to assess the value of radiotherapy 
against observation. Such information would be necessary for future patients 
and clinicians when making management decisions.    
 
The increasing use of PROs in clinical effectiveness research is reflected by the 
PRO extensions to the CONSORT and SPIRIT checklists for reporting clinical 
trials and their protocols (160, 161). The Response Assessment in Neuro-
Oncology (RANO) working group is currently producing guidelines for the use 
of PROs in neuro-oncology (162).   
 
However, there are some challenges to using PROs in clinical research. Firstly, 
the PRO instrument must be appropriate (valid) for use within the population 
being assessed. This is a particular issue for meningioma research; one review 
found that only three of thirteen quality of life tools used in meningioma 
research were validated for use (146). Using unvalidated tools may cast doubt 
on the study findings. Furthermore, systematic reviews have found 
shortcomings in reporting of PRO results which may hamper the interpretation 
of results (163, 164). Common issues include not reporting method of collecting 
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PROs or not detailing the extent of missing data. Such reporting omissions 
reduce the confidence of stakeholders in using the PRO data to make clinical 
decisions (165).  
 
1.16.2 Clinical practice 
 
PROs can maximise the clinician-patient interaction by providing items for 
discussion. Sometimes, patient issues are not acknowledged or addressed by 
clinicians in a consultation (166-169). In clinic appointments (where there is 
often limited time), discussion about the objective measures of meningioma 
may predominate, and issues that are distressing to the patient may not be 
offered for discussion by the patient or asked about by the clinician. One 
solution to this is for patients to complete a PRO assessment before the clinic 
appointment, and the results are made available for the patient and clinician to 
discuss. PROs quantify the experiences of patients across a range of domains. 
In this way, domains that are low-scoring can be used as discussion points to 
enhance clinician-patient communication (170). PRO alerts, which are 
‘concerning levels of psychological distress or physical symptoms that may 
require an immediate response’ (171), can be used to notify clinicians to issues 
that the patient may not volunteer during the clinic consultation. Additionally, 
serial measurements during long-term follow-up may identify trends in PROs 
that the patient has not noticed. Healthcare professionals can address the 
identified issues during clinic appointments. In this way, PROs can be used as 
an objective measurement of wellbeing and as an adjunct in monitoring a 
patient’s condition.  
 
1.16.3 Healthcare delivery 
 
Healthcare delivery can be assessed using PROs. In Sweden, National Quality 
Registers collect PRO data alongside information about medical interventions 
and outcomes (172). This amalgamation of clinical and PRO data allows 
policymakers to make comparisons of outcomes from different hospitals. 
Swedish quality registers are publicly available, and patients can use this 
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information to choose where they would like to receive elective treatment (173). 
Furthermore, the quality registries allow for population-based data which can 
be used for research and quality improvement of existing services (172, 174).   
 
Since 2009, NHS England has collected PRO data from patients undergoing two 
elective surgical procedures (175). All patients undergoing hip or knee repair are 
invited to complete a generic and disease-specific PROM preoperatively and 
three months postoperatively. The data assesses health gains and cost-
effectiveness of treatment. Like the Swedish National Quality Registries, the 
PRO data can allow for comparisons of the performance and variability of NHS 
funded care providers (176).  
 
1.17 Patient-Reported Outcome Measures 
 
A Patient-Reported Outcome Measure (PROM) is an instrument or tool used to 
measure a PRO (150, 151). PROMs are typically paper-based or electronic 
questionnaires that ask a variety of questions (items) to record a patient’s 
subjective perceptions and experiences. PROMs typically capture PRO data 
through rating scales or counts of events rather than free-text responses (150).  
 
PROMs may be generic or disease-specific (148). Generic PROMs measure 
aspects which are common to a variety of conditions. These PROMS allow for 
comparisons between different medical conditions (151). Generic PROMs such 
as the EQ-5D tool also allow for cost-utility analysis to assess the cost of an 
intervention and the benefit it confers. However, generic PROMs may not cover 
essential issues which are experienced by patients with specific medical 
conditions.  
 
Disease-specific PROMs concern aspects of a particular medical condition and 
their impact on patient’s wellbeing (151). Examples of disease-specific PROMs 
are the EORTC QLQ-C30 and FACT-G for cancer. Disease-specific PROMs 
include items which are more relevant to patients than generic PROMs and 
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therefore have greater face validity (151). However, it is not typically possible to 
use disease-specific PROMs to make comparisons between medical conditions 
(151).   
 
1.17.1 Method of PROM administration 
 
PRO data collection can yield varying results depending on the mode of 
administration (177). Some studies have found that patients report higher 
HRQoL scores when completing a PROM through telephone interview 
compared with mailed responses (178, 179). PROM scores may be higher 
because patients are more reluctant to express their quality of life difficulties to 
an interviewer.  
 
Additionally, the mode of administration may influence the response rate. One 
study found that PROM response rates were higher when by mail (88%) or 
telephone (79%) compared to e-mail (33%) (180). Telephone administration has 
the advantages of reduced missing data and cost when compared to 
administering postal questionnaires (181, 182).  
 
Response-rate is important, and studies with a high response rate have greater 
power and precision. A low response rate may increase the risk of bias if non-
responses are associated with health status. Previous studies mailing 
questionnaires to surgical patients postoperatively or surveying hospitalised in-
patients have found an association between non-responses and poorer health, 
social deprivation, substance abuse, cognitive limitations and sight deficiency; 
all of which may reduce a patient’s perceived health outcome (183, 184). 
Furthermore, non-response may be associated with demographic variables such 
as age, gender and ethnicity, which may hamper generalisability of the findings 
(184, 185).  
 
A variety of strategies can improve PRO questionnaire response rates (186). If 
the PROM is to be completed in the clinic, then the research staff can explain 
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the purpose of the PROM and clarify how to answer the questions (187). PROMs 
should contain straightforward instructions for use (188), postal PROMs should 
provide, a pre-paid, self-addressed return envelopes (189) and electronic or 
telephone reminders may be sent (190, 191). Where possible, the research team 
should minimise the number of PROMs each person is asked to complete and 
the time required of the person (192). Statistical methods may be used to 
account for lower response rates (193).  
 
1.17.2 Patient, Clinician and Observer Responses 
 
It is important to consider who should make assessments about a patient’s 
subjective experiences and perceptions. Studies have found only moderate 
concordance between the outcomes reported by patients and clinicians (194-
197). Similarly, HRQoL reports completed by observers such as carers vary from 
the patients (198-201). Clinicians and observers cannot predict a patient’s views 
with certainty; thus, outcome assessment should always include patients. 
However, clinician reports do remain of value, particularly when evaluating 
more easily observable patient outcomes such as toxicity (202, 203). Likewise, 
observer reports such as from carers can be of value when patients are not able 
to express themselves. Observer reports are particularly relevant for the 
paediatric population and those who may be cognitively impaired. Outcome 
reporting from the perspective of the patient (PRO), observer (ObsRO) and 
clinician (ClinRO) are essential in the holistic evaluation of a patient’s health 
status (150).  
 
 
1.17.3 PROM theoretical background 
 
A PROM will contain several items (questions) which assess a patient’s 
subjective experience or perception. One example of an item in the EORTC 
QLQ-C30 questionnaire is ‘have you vomited?’. The response for this item can 
be graded on a 4-point scale (not at all - very much) (204). This single-item 
provides valuable information about an aspect of vomiting. However, this single 
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item does not capture the severity or duration of vomiting, which may be items 
of interest. Therefore, multiple items can be added together to produce a multi-
item vomiting scale. PROMs typically contain both single and multi-item scales. 
Both single and multi-item scales can be scored to quantify the response. (205) 
 
Multi-item scales are used to measure factors (also known as latent traits). 
Examples of factors include physical functioning, emotional functioning and 
social functioning. Multiple items (such as pain, fatigue and nausea) may be 
combined to represent a factor (physical functioning) (205). 
 
One or more factors can represent an overarching construct (also known as 
latent variables). Constructs are unobservable and theoretical concepts and can 
only be measured by theorising their relationship with factors.  For example, 
HRQoL is a theoretical construct which is believed to be related to measurable 
factors such as physical functioning, emotional functioning and social 
functioning. HRQoL is multidimensional since it is a construct with multiple 
underlying factors. Unidimensional constructs have only one underlying factor. 
(205) 
 




PROMs must be reliable and measure in a consistent, repeatable and 
reproducible manner. If a patient’s HRQoL remains stable, a repeated PROM 
administration over time should obtain a similar score. However, each patient 
may display variability in their responses to individual items. Multi-item scales 
account for inter-respondent variation by averaging the score of multiple items 




Since there will be variability between respondents, there is a margin for error 
in responses. Reliable instruments are able to distinguish between respondents 
despite the presence of error (206).  
 
Furthermore, reliable multi-item scales of PROMs should demonstrate high 
internal consistency. Internal consistency refers to the extent to which 
individual items correlate in their measurement of a factor (207). For example, 
patients who indicate that they strongly agree with the item ‘I always feel tired’ 
should strongly disagree with the item ‘I never feel tired’. The internal 
consistency of a multi-item scale can be statistically measured using Cronbach’s 
coefficient alpha (α). Cronbach’s α between 0.70 and 0.95 are considered to 
represent satisfactory internal consistency of multi-item scales (208). 
 
Precision is an aspect of PROM reliability and indicates the reliability of a scale 
to discriminate between responders. A single-item scale which asks a patient to 
rate their subjective importance of vomiting on a 5-point scale (not at all 
important, slightly important, moderately important, very important, 
extremely important) can discriminate between respondents better than a 2-
point scale (not important and important). However, increasing response 
categories can sometimes lead to difficulty interpreting the difference between 
adjacent options. For example, it is easier for a patient to score their pain on an 
11-point scale (0 - 10) than a 101-point scale (0 - 100). The difference between 





The validity of a PROM refers to whether it can measure what it intends to, and 
there are several types. Content validity refers to whether patients and clinicians 
consider the content (items) of a PROM to be relevant to the condition (206). 
A PROM designed to assess anxiety which includes items related to 
concentration, restlessness and irritability will show higher content validity 
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than a PROM which includes items related to vomiting. The former items are 
of greater relevance to a patient with anxiety. Face validity is a type of content 
validity referring to the extent to which patients and clinicians perceive that a 
scale is measuring what it intends to (209). Construct validity refers to how well 
a PROM measures the underlying construct it intends to (209).  For example, a 
PROM designed to measure the construct anxiety will have a high construct 




Meningioma is a common intracranial tumour which can present with a variety 
of clinical features. Surgery and radiotherapy form the mainstay of therapy for 
symptomatic meningiomas, and both can cause morbidity for patients. For 
incidental meningiomas, long-term follow-up with MRI may cause anxiety for 
patients. The long-term survival of meningioma patients is good. Therefore, it 
is important to consider how meningiomas and their management affect 
patient-reported outcomes and quality of life. The next chapter details a 
systematic review performed to identify PROs and PROMs included in 



















































































































Chapter 2: A systematic review of Patient-Reported Outcomes 
in intracranial meningiomas 
 
2.1 Chapter overview 
 
Patient-Reported Outcomes (PROs) and their measurement tools (PROMs) are 
recognised as an important asset to clinical effectiveness research, healthcare 
organisation and individual patient care. Over the last decade, there has been 
an increase in the number of studies examining the PROs of meningioma.  
 
A majority of studies assessing PROs investigate Health-Related Quality of Life 
(HRQoL). However, meningioma and its treatment may have effects on 
domains that are not captured by HRQoL. Furthermore, HRQoL assessments 
cover a breadth of issues and may not evaluate particular domains (such as 
symptom burden, fatigue or employment) in depth. As meningioma-specific 
HRQoL tools are still being validated (210), current HRQoL studies may omit 
matters which are relevant to patients. A holistic evaluation of all PROs of 
meningioma is required.  
 
This systematic review identifies all studies of meningioma patients which 
report PROs. The PROs of meningioma studies are summarised qualitatively. 
The quality of reporting and risk of bias of each study is evaluated. This chapter 
concludes by providing recommendations for future PRO research.  To date, no 
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2.2 Scoping search 
 
An umbrella review was conducted to identify all systematic reviews of 
meningioma. This identified two systematic reviews of HRQoL in meningioma 
patients published between 2015 and 2017 (146, 211). Tanti et al. reviewed four 
studies and concluded that epilepsy in meningioma patients has an adverse 
effect on quality of life (211). Zamanipoor et al. reviewed 19 studies and 
concluded that patients with meningioma have impaired HRQoL (146). The 
results of that review were used by Zamanipoor et al. to interview meningioma 
patients and the healthcare professionals (HCPs) involved in their care (212). 
The interviewers first asked the patients and HCPs to identify issues that 
meningioma patients experience, and then asked patients and HCPs to assess 
the relevance of the issues identified from both the HRQoL tools and the 
interview. This study concluded that the 14 included HRQoL tools contain a 
number of issues which are not relevant to meningioma patients, and there are 
additional issues which are not captured by existing tools (212). Both systematic 
reviews focused on HRQoL, and none examined PROs of meningioma patients 
in their entirety. 
 
A scoping search on MEDLINE (Ovid) was undertaken to identify additional 
HRQoL studies of meningioma which were not included in previous systematic 
reviews. Additionally, systematic reviews examining reporting standards of 
PROs within neuro-oncology and other surgical specialities were identified 
(164, 213-215). No studies qualitatively summarising PROs were found, and this 










2.3 Research question and objectives 
 
2.3.1 Research question 
 
• What are the PROs reported in primary studies of adult patients with an 
intracranial meningioma examined before or after intervention (such as 





• To identify all published studies with PROs in meningioma  
• To identify the PROMs used to assess PROs  
• To qualitatively summarise the current literature of PROs in 
meningioma 
• To assess the quality of reporting and risk of bias of the identified studies  




The review protocol was registered on PROSPERO (CRD42020191947). The 
systematic review has been reported according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (216).  
 
2.4.1 Inclusion and exclusion criteria 
 
Table 2.1 details the inclusion and exclusion criteria of this systematic review. 
The focus of this systematic review is the PROs of adults with sporadic, 
intracranial meningioma. Studies including spinal meningiomas were excluded 
as they are anatomically distinct to intracranial meningioma and have different 
presenting features, surgical outcomes and morbidity. Studies of 
neurofibromatosis type 2 (NF2)-associated meningioma and radiation-induced 
meningioma (RIM) were excluded as they are considered a different biological 
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entity to sporadic meningioma and patients often have other associated 
comorbidities and history of previous medical treatment. Finally, studies 
including other brain tumours such as glioma were excluded as the study 
authors wanted to identify PROM tools used specifically in the cohort of 
meningioma patients.  
 
Table 2.1: A PICOS table of inclusion and exclusion criteria 
 Include Exclude 
Population • Patients aged 18 years and 
above 
• Patients aged below 18 years 
• Animal studies 




• Medical therapy 
• Active monitoring 
• Combinations of the above 
• N/A 
Condition • Intracranial meningioma: 
WHO Grade I, II or III 
• Spinal meningioma 
• NF2-associated meningioma 
• RIM 
• Studies with mixed pathology 
(i.e. meningioma and other 
tumours) 
Comparator None 
Outcome • PRO such as HRQoL as a 
primary or secondary 
outcome 
 
Study design • Primary research 
• Retrospective, cross-sectional 
or prospective study 
• English language 
• Full text available 
• Studies including ten or more 
patients 
• Any year of publication 
• Reviews, systematic review 
and meta-analysis 
• Studies not making clear 
reference within abstract to 
obtaining a PRO 
• Studies including only one 
PRO item (question), e.g. 
subjective pain rating scale 










2.4.2 Article identification 
 
2.4.2.1 Electronic database searches 
 
Electronic databases were searched using a search string based on terms 
identified from two previous systematic reviews of PROs (164, 213). The search 
string was adapted for meningiomas, and a number of modifications were made 
to increase the sensitivity of the search. The final search string included a 
combination of free text and MeSH terms related to meningiomas, outcome 
assessment, PRO, quality of life, symptoms and PROM tools. The search string 
was adapted to the syntax requirements of each electronic database. The 
EMBASE search string is included in appendix 1. 
 
Electronic databases searches were conducted between 29th April and 1st May 
2020. No restriction was placed on the date of publication. However, only 
publications in the English language were eligible for inclusion. The following 




• Cochrane Central Register of Controlled Trials (CENTRAL) via The 
Cochrane Library 
• Cochrane Database of Systematic Reviews (CDSR) via The Cochrane 
Library 
• CINAHL via EBSCO 
• PsycInfo via EBSCO 
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2.4.2.2 Removal of duplicates 
 
Articles from online databases were imported into Endnote X9.3.3 and de-
duplicated. De-duplicated articles were transferred onto the online systematic 
review management platform Rayyan (217).  
 
2.4.2.3 Article screening 
 
Two reviewers (SMK and CPM1) used Rayyan to independently screen the title 
and abstract of articles in accordance with the pre-determined inclusion 
criteria2.  
 
2.4.3 Full-text analysis 
 
Full texts were obtained for articles included at the end of the screening process. 
These full-texts were read and evaluated against the inclusion criteria. Reasons 
for exclusion of articles were recorded.  
 
2.4.4 Additional methods of study identification 
 
The reference lists of all included articles were searched for further relevant 
studies. The two systematic reviews identified from the umbrella review were 
also screened to identify studies not identified by the search (146, 211).  
 
2.4.5 Data extraction 
 
Each article was read by one of three authors (SMK, CPM or AII3) and data were 
extracted and independently entered into a spreadsheet in Microsoft Excel 
(v16.34, Microsoft, Washington DC, USA). Table 2.2 lists the extracted data 
fields. The spreadsheet was not pre-piloted before data extraction started. 
 
 
1 Mr Christopher P. Millward 
2 See study limitations for description of an error during study screening process 
3 Dr Abdurrahman Islim 
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Table 2.2: A PICOS table of extracted study data 
Field Description 
Study details Author, title, year of publication, study location, study type, study objective, 
inclusion and exclusion criteria 
Population Number of meningioma participants, participation rate, number of controls, age 
of meningioma participants, sex, WHO Grade, tumour location, tumour 
laterality, functional status, previous treatment 
Intervention Type of intervention, extent of surgical resection, dose of radiation treatment  
Outcome Name of PROM, PROM used in entirety or part, method of administration, time 
point of measurement, description of article PRO findings 
 
2.4.6 Qualitative synthesis 
 
Each included study was categorised according to the domain of PRO it 
reported: ‘HRQoL’, ‘Patient-Reported Symptoms’, ‘Patient-Reported 
Functioning’, ‘Patient-Reported Feelings’ or ‘Other PROs’. These categories 
were chosen on the basis of previous publications categorising the domains of 
PRO (218-220). Since HRQoL tools incorporate Symptoms and Functioning 
assessment, a study was only categorised as encompassing Symptoms or 
Functioning if these were measured or reported separately to the HRQoL 
assessment. For example, a study may measure HRQoL using the SF-36 tool and 
Anxiety and Depression using the HADS tool. This study would be categorised 
as measuring both HRQoL and Symptoms. The Patient-Reported Outcome 
Measure (PROM) tools used in the studies were summarised. The descriptions 
of PROs were qualitatively summarised.  
 
2.4.7 Quality of reporting assessment 
 
Each article was assessed for quality of reporting according to the International 
Society for Quality of Life Research (ISOQOL) reporting standards (221). These 
standards are recommendations for high-quality PRO reporting of RCTs and 
were developed following a process of systematic review and consensus 
discussions. The ISOQOL standards have informed the development of the 
Consolidated Standards of Reporting Trials (CONSORT) PRO extension (222, 
223). Whilst originally designed for use in randomised controlled trials (RCTs), 
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the ISOQOL standards have been implemented in systematic reviews which 
include a variety of study types (146, 224). The original ISOQOL standards 
contain 17 recommendations for any study which reports PROs. A further 11 
recommendations are provided for studies where PRO is a primary outcome. 
Dirven et al. applied these standards to neuro-oncology RCTs and added four 
new items and split one item (164).  
 
Therefore, the final standards used in this study contained 22 recommendations 
for all PRO studies and 11 additional recommendations where PRO is a primary 
outcome. 
 
Each study was evaluated against the ISOQOL recommendations. As these 
recommendations were developed for RCTs, not all recommendations were 
applicable to other study types. Appendix 2 shows the ISOQOL 
recommendations with the modifications made by the review authors. To judge 
the reporting quality of studies, a total reporting score was calculated as the 
percentage of applicable and original ISOQOL recommendations met by the 
study. In line with previous systematic reviews, studies meeting 66% of 
recommendations were deemed as having satisfactory reporting quality (225).  
 
2.4.8 Quality assessment 
 
Methodological quality assessment was completed last so that the review 
authors would not be biased during the data extraction stage or reporting 
quality assessment stages. Quality assessment was completed at the study level 
of included articles. Quality assessment did not influence the data synthesis 
presented in this chapter. Since both cross-sectional and prospective cohort 
studies were included within this review, two different tools were used to assess 
the risk of bias according to study type (appendices 3 & 4). The Joanna Briggs 
Institute (JBI) checklist for analytical cross-sectional studies assesses the 
methodological quality and extent of bias (226). The JBI critical appraisal tool 
has been developed following an extensive peer-review process. The Newcastle-
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Ottawa Scale (NOS) for cohort studies uses a ‘star system’ to assess the 
methodological quality of non-randomised studies (227). The NOS tool was 
created by the University of Newcastle, Australia and the University of Ottawa, 




No meta-analyses were completed due to heterogeneity of the included studies. 
Studies varied in patient characteristics, type of intervention, PROM tool used 




2.5.1 Study identification 
 
Figure 2.1 summarises the study identification process. A total of 9,898 articles 
were identified from searching the electronic databases. One additional article 
was identified from hand-searching included studies. After removing 
duplicates, 7,489 articles were screened, and 54 full-texts were then examined 
for eligibility. Thirty-three articles met the inclusion criteria for this systematic 
review.  
 
2.5.2 Study and patient characteristics 
 
Table 2.3 details the study and patient characteristics. The majority of studies 
were completed in European hospitals (n=23), although studies from America 
(n=5), Canada (2), Australia (n=2) and Brazil (1) were also identified. The 
number of meningioma patients included per study ranged from 14 to 1722. Six 
studies included a control group of participants; in the remaining studies, PRO 
results were compared to the normative general population, brain tumour 
patient data or not compared at all. The participation rate of studies ranged 
from 13% to 100%. The average age of meningioma patients was between 50 and 
60 years for most studies (median of means= 57.2, range of means= 52.0 - 67.3). 
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All studies had a high proportion of female participants (median of proportion 
female= 76.5, range= 59.0 – 100.0).  
 
 








Table 2.3: Study and patient characteristics 
Author (year) Location Patients and 
controls 











Australia Meningioma: 70 Unspecified Mean: 57.2 
Range 36-87.5 




United Kingdom • Meningioma 
alone: 109  






33 Mean: 59.9 81 I: 100 Surgery 
Krupp 
(2009)(230) 
Germany Meningioma: 91 
 
77 Mean: 56 
Range: 31-75 
66 I: 100 Surgery 
van Nieuwenhuizen 
(2019)(231) 
The Netherlands Meningioma: 21 
Controls: 21 
75 Mean: 55.3 
Range: 35-72 




Australia Meningioma: 70 
 









United States of 
America 
Meningioma 121 Not applicable Median: 44 years 
 






van der Vossen 
(2014) 
(234) 
The Netherlands Meningioma: 136 76 Mean: 59.1 
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Table 2.3: Study and patient characteristics (continued) 
Author (year) Location Patients and 
controls 














The Netherlands Meningioma: 36 
Controls: 18 
40 Mean: 
RT -ve: 63 
RT +ve: 63  
RT -ve: 88 
RT +ve: 89 





Sweden Meningioma: 16 80 Mean: 53.5 
Range: 27-74 
69 Unspecified Surgery 
Pintea 
(2018)(238) 
Germany Meningioma: 54 69 Mean: 57 
Range: 31-82 
78 Unspecified Surgery 
Jones 
(2016)(239) 
United States of 
America 









The Netherlands Meningioma: 89 
Controls: 89 




Germany Meningioma: 133 52 Mean: 67.3 
Range: 55-84 






The Netherlands Meningioma: 21 
Controls: 21 









publication by Lang 
et al. (above). 
United Kingdom 
 




Table 2.3: Study and patient characteristics (continued) 
Author (year) Location Patients and 
controls 





















Van der Linden 
(2020) 
(247) 
The Netherlands Meningioma: 
• Pre-op: 65  
• Post-op: 53  
Not applicable Mean 
• Pre-op: 56.2 
• Post-op: 54.8 
Pre-op: 74 
Post-op: 76 





Germany Meningioma: 58 100 Mean: 56.6 
Range: 29-75 





Germany Meningioma: 52 67 Median: 57 
Range: 40-81 











67 Mean: 57.6 
Range: 20-79 




United States of 
America 






• Pre-op: 78 
• Post-op: 71 










Switzerland 249 61 Unspecified 74 I: 88 
II/III: 12 
Surgery 
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Table 2.3: Study and patient characteristics (continued) 
Author (year) Location Patients and 
controls 

















The Netherlands Meningioma: 242  Not applicable Mean: 57.2  
Range: 23-82  





United States of 
America 
225 88 Unspecified Unspecified Unspecified  Unspecified 
dos Santos 
(2011)(258) 




Canada 291 100 Mean age: 
• Cohort 1: 60 
• Cohort 2: 59 
• Cohort 3: 59 
• Cohort 4: 55 










2.5.3 PRO characteristics of studies 
 
Table 2.4 summarises the PRO assessment characteristics of the included 
studies. There were 24 cross-sectional and eight prospective cohort studies. 
HRQoL was evaluated by 25 studies. The Patient-Reported Symptom and 
Functioning outcomes were reported by nine and eight studies, respectively. 
Health Status, Patient-Reported Feelings and Other PROs were each reported 
by two studies. Most studies used self-administered PROMs (n=21), though 
some studies administered PROMs by telephone (n=6) or interview (n=4). 
There was heterogeneity in reporting of the time point of PRO assessments; 
studies provided time since surgery (n=21), others since diagnosis (n=3) and 
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Table 2.4: PRO characteristics of studies 
Author (year) PRO domains reported PRO collection tool/ interview Method of PROM 
administration 
Study type regarding PRO 
collection 















Unclear Cross-sectional Since diagnosis: 








Self-administered Cross-sectional Postoperative: 
Median: 3.9 years 










• Structured interview  
• FKV 









HRQoL • SF-36 Unclear Cross-sectional Since histological diagnosis 












Self-administered Cross-sectional Since diagnosis (mean) 
• Early group: 11.3 
months 






Feelings • Study-specific survey Self-administered Cross-sectional Unspecified 
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Table 2.4: PRO characteristics of studies (continued) 
Author (year) PRO domains reported PRO collection tool/ interview Method of PROM 
administration 
Study type regarding PRO 
collection 
Timepoint of assessment 
(meningioma patients) 








Self-administered Cross-sectional Postoperative: 











HRQoL • SF-36 
• BCM-20 
Self-administered Cross-sectional Mean time since diagnosis 
• RT -ve group: 3.0 years 

















HRQoL • ASBQ 
• SNOT-22 
Self-administered Cross-sectional 
& Prospective cohort for a 
subsample 
Postoperative: 
Median: 2 years 


















Prospective cohort • Preoperative: 1-3 days 
before surgery 
• Early assessment: median 
47 days postoperatively 
• Late assessment: median 
33 months postoperatively 
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Table 2.4: PRO characteristics of studies (continued) 
Author (year) PRO domains reported PRO collection tool/ interview Method of PROM 
administration 
Study type regarding PRO 
collection 





HRQoL • SF-36 Self-administered Cross-sectional Mean 
• From diagnosis: 4.2 years 


















HRQoL • SF-36 Self-administered Cross-sectional Unspecified 
Lang 
(1999)(243) 





publication by Lang 
et al. (above). 
HRQoL 
 







• EORTC QLQ-C30 
• EORTC BN20 
• HADS 




Functioning • USER-P 
• CFQ 
• HADS 
Self-administered Cross-sectional Postoperative: 
Mean: 32.6 months 











Prospective cohort • One day preoperatively 
• One year postoperatively 
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Table 2.4: PRO characteristics of studies (continued) 
Author (year) PRO domains reported PRO collection tool/ interview Method of PROM 
administration 
Study type regarding PRO 
collection 








• EORTC QLQ-C30 
• HADS 
Self-administered Prospective cohort • One day preoperatively 
• 3-5 months postoperatively 





HRQoL • SF-36 Self-administered Prospective cohort • Before initiation of SRT 
• At the last day of SRT 





HRQoL • SF-36 Telephone-
administered 
Cross-sectional Postoperative: 

























• STAI-T & STAI-S  
• PTSS-10 






Prospective cohort • Preoperatively 







HRQoL • Study-specific 
questionnaire 
Self-administered Cross-sectional Unspecified 
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Table 2.4: PRO characteristics of studies (continued) 
Author (year) PRO domains reported PRO collection tool/ interview Method of PROM 
administration 
Study type regarding PRO 
collection 










• EORTC QLQ-C30 
• EORTC BN20 
• MDASI-BT 
Self-administered Cross-sectional Unspecified 
Honeybul 
(2001) (255) 








Self-administered Prospective cohort • One day preoperatively 
• Three months 
postoperatively 






















Prospective cohort • Preoperatively 
• Three months 
postoperatively 
• Six months postoperatively 




HRQoL • EORTC QLQ-C30 Interview-
administered 




2.5.4 Patient-Reported Outcome Measures 
 
Table 2.5 describes all PROMs identified in meningioma studies (n=27) 
(excluding measures developed by the study authors themselves, e.g. the PROM 
used by Owens et al. (233)). In total, ten generic or disease-specific HRQoL 
PROMs were found to have been used across the studies. The SF-36 was most 
commonly used HRQoL PROM (n=15). Two brain cancer-specific HRQoL tools 
(EORTC BCM20/BN20 and FACT-BR) were used in three studies each. An 
additional brain cancer and location-specific questionnaire (ASBQ) was used in 
one study. No meningioma-specific tool has been used in any study to date.  
 
Ten Symptom PROMs were identified, of which seven assessed emotional 
symptoms. HADS was the most frequently used Symptom PROM (n=6). Three 
tools were Functioning PROMs, of which the CFQ was most used (n=4). The 
only Health Status PROM identified was EQ-5D. BFS was the only Feelings 
PROM. Three tools (Freiburg Questionnaire on Coping with Illness, MSPSS, 
EPICES) could not be categorised as HRQoL, Symptom, Function, Health Status 
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 Table 2.5: Summary of PRO tools used in meningioma studies 
PROM PRO domain and subdomain Description # studies using 
this PROM (n) 
Medical Outcomes Study 







• Physical Activities, Social Activities, Role- Physical, Role-Emotional, 
Bodily Pain, Vitality (energy and fatigue), General Health perceptions, 
General Mental Health 
• Subscales added to form Physical Component Score (PCS) and Mental 
Component Score (MCS) 
Items: 36 
15 






• Part I: Pain, Physical Mobility, Emotional Reactions, Energy, Social 
Isolation, Sleep.  
• Part II: additional questions related to daily living 
Items: 45 (Part 1 [38] & 2 [7]) 
1 
Questions on life satisfaction 






• Health, Income/ Financial Security, Leisure Time/Hobbies, Physical 
Condition/Fitness, Sexuality, Friends/Acquaintances, Housing/Living 
Conditions, Occupation/Work, Marriage, Family Life/Children 
Items: 70 
1 
The Functional Assessment of 






• Physical, Functional, Social, and Emotional wellbeing 





EORTC Quality of Life 
Questionnaire Cancer 30 (QLQ 




• Function (Physical, Role, Cognitive, Emotional and Social), Symptom 
(Fatigue, Pain, Nausea and Vomiting), Global Health, Quality of Life  





Table 2.5: Summary of PRO tools used in meningioma studies (continued) 
PROM PRO domain and subdomain Description # studies using 
this PROM (n) 
The Functional Assessment of 




• Brain cancer-specific 
Subscale: 1 
• Subscale is specific for patients with a brain tumour. When combined 
with FACT-G, it is known as FACT-BR.  
Items: 23 
3 




• Brain cancer-specific 
Subscales: 4 
• Future Uncertainty, Visual Disorder, Motor Dysfunction, 
Communication Deficit 
Additional single items: 7 
Items: 20  
3 
















• Disease-specific:  
Chronic Rhinosinusitis 
Domains: 
• Physical Problems, Functional Limitations, Emotional Consequences 
Items: 22 
1 







• Communication, Physical Condition, Autonomic Function, 
Independence, Psychological Condition, Social Isolation 
Items: 38 
1 







• EQ-5D-3L: previous version: 3 Levels of severity assessment 
• EQ-5D-5L: new version: 5 Levels of severity assessment 
Domains: 5 
• Mobility, Self-Care, Usual Activities, Pain/Discomfort, 
Anxiety/Depression 
• Visual Analogue Scale  
Items: EQ-5D-3L (15), EQ-5D-5L (25) 
2 
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Table 2.5: Summary of PRO tools used in meningioma studies (continued) 
PROM PRO domain and subdomain Description # studies using 
this PROM (n) 
Hospital Anxiety and 





• Anxiety, Depression 
Items: 14 
6 







• Intrusions (repeated thought about traumatic experience), Avoidance 











• Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor, Fatigue, 
Confusion-Bewilderment 
Items:  65 
(228) 
2 






This is a modified version of the Centre for Epidemiological Studies - 









• Trait Anxiety (STAI-T), State Anxiety (STAI-S) 








Assesses: Post-Traumatic Stress Syndrome 
Items: 10 
1 













Table 2.5: Summary of PRO tools used in meningioma studies (continued) 
PROM PRO domain and subdomain Description # studies using 
this PROM (n) 
M.D. Anderson Symptom 






This brain tumour module is combined with core items from MDASI tool to 
make then MDASI-BT 
Domains: 
• Generalized Neurologic Symptoms, Focal Neurologic Symptoms, 
Treatment-related Symptoms. 








• General Fatigue, Physical Fatigue, Mental Fatigue, Reduced 








• Toxicity from AEDs 
Subscale: 1 











• Subjective Cognitive 
Functioning 
Domains: 




Instrumental of Activities of 




• Activities of Daily Living 
Domains: 8 
• Telephoning, Shopping, Food Preparation, Housekeeping, Laundering, 
Use of Transportation, Use of Medicine, Financial Behaviour 
Items: 8 
1 








• Frequency, Restrictions, Satisfaction 
Items: 31 
1 
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Table 2.5: Summary of PRO tools used in meningioma studies (continued) 
PROM PRO domain and subdomain Description # studies using 
this PROM (n) 
Benefit Finding Scale (BFS) 
(283, 284) 
Feelings 
• Benefit finding 
Domains:  
• accepting life circumstances, awareness of the role of others in life, 
developing a sense of purpose 
Items: 17 
1 
Freiburg Questionnaire on 





• Depressive Coping, Active Problem-Oriented Coping, Distractions, 
Spirituality, Minimizing Importance 
Items: 35 
1 
The Multidimensional Scale of 




• Support  
Domains: 
• Support from Significant Other, Friends, Family 
Items: 12 
1 
Evaluation of Deprivation and 
Inequalities in Health 





• Marital Status, Health Insurance Status, Economic Status, Family 











2.5.5.1 Surgery: prospective assessment 
 
Four studies provided a longitudinal assessment of HRQoL in patients with 
surgically treated meningioma (235, 248, 252, 258). All four studies reported 
some improvement in HRQoL postoperatively. This improvement was 
identified by studies using the EORTC QLQ-C30 (total score), SF-36 (Mental 
Component Score - MCS) and NHP (pain, emotional reaction, sleepiness, 
physical abilities) and IHD-NS (communication, physical condition, 
independence, psychological). However, one study found increased SF-36 MCS 
scores but decreased SF-36 Physical Component Score (PCS) upon follow-up of 
71 patients (252). Furthermore, in a study comparing outcomes of 37 patients 
with ‘simple’ or ‘complex’ skull base tumours, patients with complex skull base 
tumours had reduced SF-36 total scores postoperatively but the ‘simple’ tumour 
group improved (235). One study included an analysis of a subset of patients 
who had completed both preoperative and postoperative HRQoL assessments 
following endoscopic endonasal resection and found that ASBQ scores 
remained stable (239).  
 
2.5.5.2 Early postoperative HRQoL outcomes 
 
Five cross-sectional studies assessed HRQoL in meningioma patients on 
average within two years of surgery (median of mean= 1.125 years, range of 
mean= 0.5 - 1.3 years) (230, 231, 243, 245, 250). One study evaluated HRQoL six 
months postoperatively using the EORTC QLQ-C30 (245). Meningioma 
patients reported significantly lower Functional domain scores compared to 
normative values, yet Symptom domain scores were not different. Another 
study assessed HRQoL one year postoperatively using SF-36; meningioma 
patients reported significantly lower SF-36 scores in all domains except Body 
Pain in comparison to healthy controls (250). Patients had clinically significant 
lower scores in the domains of Vitality, Physical Functioning, Social 
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Functioning, Role Emotional and Role Physical. Furthermore, a different study 
assessed HRQOL one year after histological diagnosis in 21 patients with WHO 
Grade I meningioma and found no significant differences between scores of 
meningioma patients and healthy controls (231).  
 
2.5.5.3 Late postoperative HRQoL outcomes 
 
Eight studies assessed HRQoL in meningioma patients on average two years or 
more after surgery (median of mean= 4.2 years, range of mean= 3.8 – 4.3 
years)(229, 236, 238-242, 251). One study of 165 patients used SF-36, FACT-G and 
FACT-BR at a median time of 3.9 years postoperatively (229). Meningioma 
patients had worse SF-36 MCS summary scores compared to normative values. 
In another study using SF-36 at a mean time of 3.4 years since last treatment 
meningioma patients scored similar to healthy controls in all domains but 
reported worse scores in the domain of Role Physical (241). In a study of skull 
base meningiomas (petroclival and posterior petrous) using SF-36; patients had 
significantly reduced values of Physical Functioning, Role Physical, General 
Health, Vitality and Social Functioning scores in comparison to normative 
values (238). In a large study of 291 patients assessed cross-sectionally with 
EORTC QLQ-C30 at different timepoints, overall HRQoL was impaired at 12, 
48, 108, and 120 months postoperatively compared to normative values (259).  
By contrast, in a study of 133 patient 3.8 years postoperatively, similar scores 
were identified between patients and the normative values of SF-36, with 
improved patient scores reported in domains of Physical Role Functioning and 
Bodily Pain (242). 
 
2.5.5.4 Postoperative variables associated with HRQoL  
 
One study reported that age had no association with HRQoL scores (248). 
However, another study assessing HRQoL following endonasal endoscopic 
resection of skull base meningiomas found that younger patients reported 
better ASBQ and SNOT-22 scores (239). In a study specifically assessing HRQoL 
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in elderly patients, younger patients generally reported higher SF-36 scores 
which decreased with age (242). By contrast, a study which assessed HRQoL by 
qualitative interview found that younger patients were more likely to report 
lower self-esteem, inability to accept disease, and dissatisfaction with life (230). 
Another study reported that younger patients were more likely to give a 
negative response to the question ‘are you content with quality of life right now?’ 
(251).  
 
Meningioma patients with epilepsy report worse HRQoL outcomes (229). Two 
studies report that patients taking anti-epileptic drugs (AEDs) have inferior 
HRQoL irrespective of seizure frequency (229, 241). Unemployment, lower 
subjective work ability, impaired cognitive functioning and elevated depression 
and PTSS scores are also associated with inferior HRQoL outcome (228, 229, 
241, 254).  No association has been identified between HRQoL and tumour size, 
preoperative tumour volume or preoperative presence of peri-tumoural oedema 
(231, 248).  
 
2.5.5.5 Stereotactic radiotherapy (SRT) 
 
Three studies reported HRQoL outcomes in patients who received stereotactic 
radiotherapy (SRT) (249, 251, 253). Two of these studies give outcomes of SRT 
and radiotherapy combined (251, 253). One study prospectively evaluated 
HRQoL using SF-36 in 52 patients undergoing SRT (249). Pre-treatment HRQoL 
scores were lower in all eight domains of SF-36 compared to normative values. 
At the end of SRT, HRQoL scores decreased further in six domains, most 
prominently in the domains Role Physical, Role Emotional, and Pain. At six 
months post-treatment HRQoL scores improved, and at 12 months post-
treatment HRQoL began to return to initial values. Patients who had prior 
surgery had significantly improved MCS scores compared to patients with 
primary SRT. 
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2.5.5.6 Fractionated radiotherapy 
 
Five studies provided HRQoL outcomes in patients who received fractionated 
radiotherapy (228, 236, 250, 251, 253). In a study of 1722 patients assessed by SF-
36 0.53 years postoperatively, HRQoL scores were lower in the domains of 
Vitality, Role Physical and Social Functioning for patients who received 
radiotherapy compared to patients who had surgery only (250). However, in a 
study assessing late HRQoL outcomes in 36 patients, no significant differences 
were identified between SF-36 and EORTC BCM20 scores in patients treated 
with adjuvant radiotherapy compared with surgery only (236).  
 
2.5.5.7 Incidental meningiomas 
 
One study investigated HRQoL outcomes of incidental meningioma (100). The 
21 included patients reported significantly lower scores on the SF-36 domains of 
General Health and Vitality compared to healthy controls.  
 
2.5.6 Health status 
 
Two studies report Health Status of patients; both were prospective and used 
the EQ-5D tool (240, 252). In a study evaluating health status changes from 
preoperatively to one year postoperatively, the EQ-5D-5L remained stable (252). 
Anxiety, depression and PTSS scores negatively correlated with EQ-5D-5L 
values. Anxiety, depression and PTSS scores negatively correlated with EQ-5D-
5L values.  In a study of 54 patients, clinically meaningful improvement 
occurred in 49% and worsening in 20% of patients at late assessment. The 
domains of EQ-5D which improved were pain/discomfort, anxiety/depression, 









2.5.7.1 Symptom burden 
 
Symptom burden was reported specifically as an outcome by two studies (254, 
257). One study used MDASI-BT to compare symptom burden preoperatively 
and one year postoperatively of 249 patients (254). Improvement was identified 
in the domains of Total Symptom Severity, General Symptoms, Focal 
Neurological Symptoms, GI Symptoms, Affective Symptoms, Symptom 
Interference with Mood, Symptom Interference with Activity and Symptom 
Interference with Daily Function. However, no MDASI-BT subdomain showed 
clinically meaningful improvement. There was postoperative worsening of the 
Cognitive Symptom domain, but this was not significant.  Akagami et al. 
assessed symptom severity postoperatively in patients with skull base 
meningioma and found the prevalence of no, minor, some and severe symptoms 
to be 32, 34, 30 and 4% respectively (257).   
 
2.5.7.2 Emotional symptoms 
 
Emotional symptoms were specifically reported by six studies (228, 232, 234, 
245, 248, 252). In a study assessing psychological wellbeing of 78 meningioma 
patients, 68% of patients had abnormal anxiety scores preoperatively. 
Abnormal anxiety decreased to 57% at three months and 39% at 12 months 
postoperatively (252). Another study showed that six months postoperatively 
anxiety and depression scores were not significantly different from normative 
values (245). Two studies identified that anxiety is significantly higher early 
after surgery compared to late (228, 252).  However, one study showed that 
anxiety scores remain stable (248).  
 
Patient-reported depression scores are similar to normative values at six 
months postoperatively (245). Two cohort studies report that depression scores 
remain stable upon follow-up (248, 252). One study reported depression scores 
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were higher early after surgery compared to late, but this difference was not 
significant (232). Variables associated with higher depression scores include 
unemployment due to health problems, presence of epilepsy and lower 
Karnofsky Performance Status (KPS) scores (234, 245).  
 
Three studies reported on emotional symptoms other than anxiety and 
depression (228, 232, 252). One study identified that post-traumatic stress 
syndrome (PTSS) scores significantly decreases between preoperative and 
postoperative assessment (252). However, meningioma associated PTSS is still 
reported by 16% of patients on longer-term follow-up (228). This group of 
patients were increasingly likely to seek support services due to feeling of 
distress or fear of tumour progression and recurrence. Furthermore, 
meningioma patients reported significantly higher anger/hostility scores on 




One study specifically assessed patient’s fatigue using MFI preoperatively and 
one year postoperatively (247). High fatigue scores in one or more subscales 
were reported by 68% preoperatively and 57% postoperatively. Compared to 
normative values, meningioma patients reported significantly higher fatigue 
scores in all domains (General Fatigue, Physical Fatigue, Mental Fatigue, 
Reduced Activity, Reduced Motivation) both preoperatively and 
postoperatively. One year postoperatively, General Fatigue, Physical Fatigue 
and Mental Fatigue scores remained unchanged, but improvements occurred in 
the domains of Reduced Activity and Reduced Motivation. Fatigue was 







2.5.7.4 Toxicity from AEDs 
 
One study assessed symptoms of AED toxicity using LAEP (229). Meningioma 





2.5.8.1 Subjective cognitive functioning 
 
Subjective cognitive functioning (SCF) was reported by three studies (230, 234, 
256). In a study of 136 patients assessing using CFQ at a mean time of 32.6 
months postoperatively, 23% reported subjective cognitive complaints (234). 
However, SCF was identified as similar or marginally better in meningioma 
patients compared to normative values. Similarly, in a study of 242 patients 
assessed prospectively, SCF was significantly higher preoperatively and three 
months postoperatively compared to normative values (256). However, SCF 
significantly decreased one year postoperatively and became similar to the 
normative group.  
 
Factors influencing SCF include country of birth, anxiety and depression or 
burn out in medical history (234, 256). SCF was not associated with objective 
cognitive functioning assessment scores, sociodemographic or clinical 
characteristics (256).  
 
Another study assessed patient perceptions of cognition using qualitative 
interview (230). This study identified that older meningioma patients 
considered cognitive deficit a general problem of ageing. However, younger 
patients were more doubtful of their cognitive functioning than older patients. 
These doubts caused patients to feel mentally disabled and socially isolated; 
some reported that they had retreated from their social life. 
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2.5.8.2 Employment 
 
Five studies discuss the employment outcomes of patients with meningioma 
(230, 246, 251, 254, 257). In a cross-sectional study of 136 patients, 32.9% of those 
in work preoperatively did not resume paid employment postoperatively (246). 
Similarly, in a study specifically assessing socioeconomic outcomes of 249 
patients, 20% of participants did not resume work one year postoperatively; 10% 
had retired due to age, 5% were unemployed and 5% were disabled (254). 
Significantly fewer patients were employed full-time postoperatively compared 
to preoperatively. Three other studies report postoperative impaired work 




Five studies comment on participation in activities by patients with 
meningioma (230, 242, 246, 251, 257), with up to 51% of patients reporting 
participation restrictions (246). Restrictions were most frequently reported in 
the items ‘household duties’ (41.5%), ‘paid work, unpaid work and education’ 
(41.1%) and ‘sports or other physical exercise’ (40.4%). Dissatisfaction with 
participation was most frequently reported in the items ‘sports or other physical 
exercise’ (43.4%), ‘going out’ (41.0%) and ‘day trips and other outdoor activities’ 
(36.8%). Anxiety or depression were related to inferior participation scores on 
all three scales.   
 
By contrast, another study reported that 87% of patients consider themselves 
‘quite a bit’ or ‘very much’ independent (251). Furthermore, a study of 225 skull 
base meningioma patients found that 83% of patients can complete activities 
either ‘normally’ or ‘with effort’ (257). In a study of 133 patients, 85% scored 7 or 







2.5.9.1 Benefit finding 
 
Benefit finding (BF) was assessed in a cross-sectional study of 70 patients with 
benign meningioma (232). BF was defined as ‘positive changes that result from 
a trauma experience’. Moderate BF (total BFS score >2) was reported by 63% of 
participants. The items ‘having had a meningioma (brain tumor) has taught me 
how to adjust to things I cannot change’ and ‘… helped me to take things as they 
come’ were scored as ‘quite a bit’ or ‘extremely’ by 61% of patients. Elevated 
depression scores were significantly associated with greater benefit finding in 
patients diagnosed with meningioma for two years or less.  
 
2.5.9.2 Birth desires 
 
One study reported on birth desires of female meningioma patients living in 
America (233). Patients in the age group 25-44 were significantly more likely to 
indicate that they would like to have a baby compared to normative values of 
women. Factors which influenced birth desires in patients aged 25-44 include 
‘risk of meningioma returning & need for more treatment’ (62%), ‘risk of lasting 
symptoms or impairments’ (44%), ‘fear of dying’ (34%), ‘medical advice against 
getting pregnant’ (31%).  
 




Patient-reported support requirements are described by three studies (228, 254, 
257). In one study,  support services were sought by 67% of patients following 
the diagnosis of meningioma (228). Another study found that 10% more patients 
required professional care following surgery (254).  In a study of skull base 
meningioma patients, occasional assistance was required by 20% of patients and 
considerable assistance or specialist care by 5% (257).  
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2.5.10.2 Deprivation 
 
One study retrospectively assessed deprivation before surgery and at one year 
postoperatively by using the EPICES tool (254). Social deprivation was not 
found to change significantly from preoperatively to one year postoperatively.  
 
2.5.11 PRO reporting across studies 
 
2.5.11.1 ISOQOL core recommendations 
 
Table 2.6 describes adherence to ISOQOL core recommendations across all of 
the included studies (n=33). All studies identified PRO within the abstract (n= 
33, 100%). Most specified the mode of PROM administration (n=26, 79%), 
identified PRO as a primary or secondary outcome (n=29, 88%) and provided 
baseline participant characteristics and PROs (n=31, 94%). The majority of 
studies did not provide a rationale for the choice of PRO instrument (n= 21, 
64%) or report the clinical significance of PRO findings (n= 24, 73%). 
 
2.5.11.2 ISOQOL additional recommendations  
 
Table 2.7 describes adherence to ISOQOL additional recommendations across 
all of the studies in which PRO was a primary outcome (n=27). Most studies 
summarised the PRO research relevant to the study (n= 26, 96%) and provided 
results for all domains of PROM (n= 26, 96%). The majority of studies did not 
make clear reference to PRO in the study title (n= 25, 93%) or specify and justify 
windows for valid PRO responses (n= 19, 70%).  
 
2.5.11.3 Total score 
 
In studies where PRO was a primary outcome (n=27), the mean ISOQOL 
reporting score was 73% (range 28-89%). The number of studies with 
satisfactory reporting quality (total ISOQOL score >66%) was 24 (89%). 
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In studies where PRO was a secondary outcome (n=6), the mean ISOQOL 
reporting score was 54% (range 36%-80%). The number of studies with 
satisfactory reporting quality was 2 (33%). 
Table 2.6: The level of Patient-Reported Outcome (PRO) reporting in included studies 
ISOQOL core recommendations for all studies reporting PRO Option Total: 33 
n (%) 
Title and abstract 
1. The PRO should be identified as an outcome in the abstract Yes 33 (100) 
No 0 (0) 
Introduction, background and objectives 
2. The PRO hypothesis should be stated and should specify the 
relevant PRO domain(s) if applicable 
 
Yes 6 (18) 
No 0 (0) 
N/A 27 (82) 
Methods 
3. The mode of administration of the PRO tool and the methods of 
collecting data (e.g., telephone, other) should be described 
Yes 26 (79) 
No 7 (21) 
4. Electronic modes of distribution? a Yes 1 (3) 
No 32 (97) 
5. The rationale for choice of the PRO instrument used should be 
provided 
Yes 11 (33) 
No 21 (64) 
N/A 1 (3) 
6. Evidence of PRO instrument validity and reliability should be 
provided or cited 
Yes 21 (64) 
No 10 (30) 
N/A 2 (6) 
7. The intended HRQL data collection schedule should be provided Yes 9 (27) 
No 2 (6) 
N/A 22 (67) 
8. PROs should be identified in the trial protocol; post hoc analyses 
should be identified 
Yes 9 (27) 
No 0 (0) 
N/A 24 (73) 
9. The status of PRO as either a primary or secondary outcome 
should be stated c 
Yes 29 (88) 
No 4 (12) 
10. There should be evidence of appropriate statistical analysis and 
tests of statistical significance for each PRO hypothesis tested 
Yes 8 (24) 
No 0 (0) 
N/A 25 (76) 
11. Extent of missing data should be stated b, c Yes 25 (76) 
No 8 (24) 
12. Statistical approaches for dealing with missing data should be 
explicitly stated b 
Yes 3 (9) 
N/A 30 (91) 
Results 
 
13. A flow diagram or a description of the allocation of participants 
and those lost to follow-up should be provided for PROs 
specifically 
Yes 5 (15) 
No 3 (9) 
N/A 25 (76) 
14. The reasons for missing data should be explained Yes 20 (61) 
No 6 (18) 
N/A 7 (21) 
15. The study patients’ characteristics should be described, including 
baseline PRO scores. 
Yes 31 (94) 
No 2 (6) 
16. Are PRO outcomes also reported in a graphical format? a Yes 12 (36) 
No 21 (64) 
17. The limitations of the PRO components of the trial should be 
explicitly discussed 
Yes 26 (79) 
No 7 (21) 
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18. Generalizability issues uniquely related to the PRO results should 
be discussed, if applicable 
Yes 16 (49) 
No 9 (27) 
N/A 8 (24) 
19. Are PRO interpreted? (not only restated) a Yes 31 (94) 
No 2 (6) 
Table 2.6: The level of Patient-Reported Outcome (PRO) reporting in included studies 
(continued) 
ISOQOL core recommendations for all studies reporting PRO Option Total: 33 
n (%) 
Discussion 
20. The clinical significance of the PRO findings should be discussed d Yes 8 (24) 
No 24 (73) 
N/A 1 (3) 
21. Methodology used to assess clinical significance (in case this was 
addressed) a 
Distribution 7 (21) 
Anchor 1 (3) 
N/A 25 (76) 
22. The PRO results should be discussed in the context of the other 
clinical trial (study) outcomes 
Yes 13 (39) 
No 0 (0) 
N/A 20 (61) 
 
a These items are not part of original ISOQOL recommended standards (221) but were added by Dirven 
et al. (164) to provide a wider outlook on the level of reporting. These do not form part of the final 
reporting score. b These items were originally combined in the ISOQOL recommended standards (221) 
but were split by Dirven et al. (164) to better investigate possible discrepancies between 
documentation of PRO missing data. c These items have been misapplied in the ISOQOL assessment 
of studies – please see limitations. d Any description of clinical significance (statistically calculated or 
qualitatively summarised) was considered acceptable. 
 
 
Table 2.6: The level of Patient-Reported Outcome (PRO) reporting in included studies 
ISOQOL additional recommendations for all studies where PRO is 
primary outcome 
Option Total: 27 
n (%) 
Title and abstract 
1. The title of the paper should be explicit as to the RCT including a 
PRO 
Yes 2 (7) 
No 25 (93) 
Introduction, background and objectives 
2. The introduction should contain a summary of PRO research that is 
relevant to the RCT 
Yes 26 (96) 
No 1 (4) 
3. Additional details regarding the hypothesis should be provided, 
including the rationale for the selected domain(s), the expected 
direction(s) of change, and the time points for assessment 
Yes 6 (22) 
N/A 21 (78) 
Methods 
4. A citation for the original development of the PRO instrument 
should be provided 
Yes 15 (56) 
No 10 (37) 
N/A 2 (7) 
5. Windows for valid PRO responses should be specified and justified 
as being appropriate for the clinical context 
Yes 8 (30) 
No 19 (70) 
6. There should be a power/sample size calculation  
relevant to the PRO based on a clinical rationale (e.g., anticipated 
effect size) 
N/A 27 (100) 
7. The manner in which multiple comparisons have been addressed 
should be provided 
Yes 5 (19) 
N/A 22 (81) 
Results 
8. The analysis of PRO data should account for survival differences 
between treatment groups if relevant 
N/A 27 (100) 
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Table 2.7: The level of Patient-Reported Outcome (PRO) reporting in included studies 
(continued) 
ISOQOL additional recommendations for all studies where PRO is 
primary outcome 
Option Total: 27 
n (%) 
Results (continued) 
9. Results should be reported for all PRO domains (if multi-
dimensional) and items identified by the reference instrument (i.e., 
not just those that are statistically significant) 
Yes 26 (96) 
No 1 (4) 
10. The proportion of patients achieving pre- defined responder 
definitions should be provided where relevant 
N/A 27 (100) 
11. A copy of the instrument should be included if it has not been 
published previously 
Yes 3 (11) 
N/A 24 (89) 
 
2.5.12 Quality assessment of studies 
 
Table 2.8 and 2.9 summarise the results of the quality assessment of the 
included cross-sectional studies and prospective cohort studies, respectively. 
One cross-sectional study provided a prospective analysis on a subgroup of 
participants and so was assessed by both the JBI and NOS appraisal tools (239). 
 
From the JBI tool, question 3 (was the exposure measured in a valid and reliable 
way?) was omitted because the exposure was often the condition and therefore 
assessed in question 4 (were objective, standard criteria used for measurement of 
the condition?). Question 7 (were the outcomes measured in a valid and reliable 
way?) was also omitted. This is because valid PRO measurement requires that 
PROM tools are validated for use in patients with the disease. A majority of 
PROMs are not validated for use in meningioma patients, so this question could 
not discriminate reporting quality between studies. However, the analysis of the 
validity of PROMs constitutes a separate piece of work and is not included 
within this review.  
 
From the NOS tool, question 1 of the Outcome section (Assessment of outcome- 
independent blind assessment, record linkage, self-report, no description) was 
omitted. This is because PROs by definition are self-reported and so no study 
could not receive a star for this question.  
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Table 2.8: Risk of bias in cross-sectional studies 
 Joanna Briggs Institute Critical Appraisal Checklist 
Author (year) Q1 Q2 Q4 Q5 Q6 Q8 
Kangas (2012)(228) YES YES YES YES YES YES 
Tanti (2017)(229) YES YES YES YES UNCLEAR YES 
Krupp (2009)(230) YES YES YES N/A N/A YES 
van Nieuwenhuizen 
(2019)(231) YES YES YES YES YES YES 
Kangas (2011)(232) YES YES UNCLEAR YES N/A YES 
Owens (2015)(233) YES YES NO YES YES YES 
van der Vossen (2014)(234) YES YES YES YES YES YES 
van Nieuwenhuizen 
(2007)(236) YES YES YES YES YES YES 
Mathiesen (2007)(237) YES YES YES YES NO YES 
Pintea (2018)(238) YES YES YES YES NO YES 
Jones (2016)(239) YES YES YES NO N/A YES 
Waagemans (2011)(241) YES YES YES YES YES YES 
Timmer (2019)(242) YES YES YES UNCLEAR UNCLEAR YES 
Van Nieuwenhuizen 
(2013)(100) YES YES YES YES YES YES 
Lang (1999)(243) YES UNCLEAR YES NO N/A NO 
Neil-Dwyer (2000)(244) YES UNCLEAR YES NO NO NO 
Konglund (2012)(245) YES UNCLEAR YES UNCLEAR UNCLEAR YES 
Schepers (2018)(246) YES YES YES YES N/A YES 
Benz (2017)(250) YES YES YES YES YES YES 
Kalkanis (2000)(251) YES YES YES YES NO YES 
Combs (2013)(253) YES NO YES NO NO YES 
Wirsching (2020)(254) YES YES YES YES NO YES 
Honeybul (2001)(255) NO NO YES NO N/A N/A 
Akagami (2002)(257) YES NO UNCLEAR NO N/A YES 
Nassiri (2019)(145) YES YES YES YES UNCLEAR YES 
 
Table 2.9: Risk of bias in prospective cohort studies 
 Newcastle-Ottawa Scale for Cohort Studies 
Selection Comparability Outcome 
Author (year) Q1 Q2 Q3 Q4 Q1 Q2 Q3 
Makarenko 
(2016)(235) 1 star N/A 1 Star 1 Star 2 Stars 1 Star 0 Star 
Jones (2016)(239) 1 Star N/A 1 Star 1 Star N/A 1 Star 1 Star 
Jakola (2012)(240) 1 Star N/A 1 Star 1 Star N/A 1 Star 1 Star 
Van der Linden 
(2020)(247) 1 Star N/A 1 Star 1 Star N/A 1 Star 0 Star 
Zweckberger 
(2017)(248) 1 Star N/A 1 Star 1 Star N/A 1 Star 1 Star 
Henzel (2013)(249) 1 Star N/A 1 Star 1 Star N/A 1 Star 1 Star 
Wagner (2019)(252) 1 Star N/A 1 Star 1 Star N/A 1 Star 1 Star 
van Lonkhuizen 
(2019)(256) 1 Star N/A 1 Star 1 Star N/A 1 Star 1 Star 






The aim of this review was to identify all studies which assessed PROs of 
meningioma patients. In total, 33 studies were identified. They measured a 
range of PRO domains including HRQoL, Health Status, Symptoms, 
Functioning and Feelings. Of the 27 PROMs used, only nine were HRQoL tools. 
This highlights that PROs extend beyond the HRQoL.  
 
The most frequently used PROM was SF-36. Whilst it is a popular generic 
HRQoL instrument, this tool remains unvalidated for use in intracranial 
meningioma, and it is uncertain whether the issues covered in the SF-36 are 
relevant to these patients. Patients may have unique issues arising from their 
meningioma which affect HRQoL and that are not assessed within the SF-36. 
To date, the only meningioma-specific PROM that has been developed is the 
FACT-MNG (210). However, this tool has not been validated in an independent 
meningioma patient cohort and has not used in a published clinical study to 
date. Given the importance of PROs in clinical effectiveness research, there is 
an urgent requirement for the validation of existing tools for the meningioma 
population.  
 
HRQoL covers attitudes towards one’s quality of life alongside an assessment of 
the impact of symptoms and functional limitations. Therefore, one advantage 
of HRQoL PROMs is that they have a breadth of coverage and can highlight 
issues which can be explored further. However, HRQoL tools do not assess all 
issues in depth; for example, the FACT-G only includes one item related to 
fatigue (‘I have a lack of energy’). Symptom and Functioning-specific PROMs are 
necessary to evaluate specific issues in detail; for example, the MFI explores 
fatigue using 20 items encompassing five different domains. Alongside using 
validated HRQoL PROMs to capture a breadth of issues, it is important to have 
validated Symptom and Functioning PROMs which investigate specific issues 
in depth. However, the majority of current studies focus on HRQoL. 
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Moreover, this review identified PROs which are not typically assessed within 
the scope of existing HRQoL studies, for instance, in studies reporting feelings 
of benefit finding and the birth desires of women. This highlights that the 
diagnosis of meningioma and its treatment has effects on aspects of life beyond 
HRQoL, Symptoms and Functioning. Research into other domains of PRO 
research such as Feelings is welcomed in order to better understand patient’s 
perspectives and experiences.  
 
2.6.1 Summary of clinical outcomes 
 
Most studies assessed PROs through self-administered reports, but ten studies 
used telephone or interview-based reporting. Telephone and interview methods 
of data collection have advantages such as reduced missing data, but patients 
may report better outcomes using these methods than through self-assessments 
(178, 179, 181, 182). Future studies should consider this when collecting data, 
particularly when comparing outcomes collected by mixed methods as some 
meningioma studies did. Additionally, there was heterogeneity in the reporting 
of timepoint of data collection as some studies reported measurements from 
the time of surgery and others from the point of diagnosis. As a result of the 
lack of standardisation in the timing of assessing PROs, it is not possible to 
conduct a meta-analysis. Future studies should measure PROs at defined time 
points, for example, at initial diagnosis, postoperatively, post-radiotherapy (if 
given), at recurrence (if it occurs) and longer-term (e.g. five years).  
 
Prospective studies reported overall improvement of HRQoL scores 
postoperatively. This suggests that surgery does have a beneficial effect on 
patient wellbeing. However, studies reporting early outcomes within one year 
of surgery suggest that HRQoL remains impaired in comparison to normative 
patient values and healthy controls. In studies assessing late HRQoL outcomes 
postoperatively, most report at least one impaired domain of HRQoL. However, 
there are conflicting results regarding this, and further studies are required to 
verify late HRQoL of patients. Furthermore, studies suggest that HRQoL is low 
 
 101 
in the months following radiotherapy treatment, but not different from that of 
those treated with surgery alone in the longer-term. There are very few studies 
investigating HRQoL after stereotactic radiotherapy and in patients diagnosed 
with incidental meningiomas.  
 
Patients with meningioma-associated epilepsy and those using anti-epileptic 
drugs (AEDs) after being diagnosed with a meningioma reported worse HRQoL 
outcomes and the studies in this review indicate that HRQoL is lower in patients 
taking AEDs irrespective of seizure frequency (229, 241). In the absence of 
objective clinical benefit and in light of inferior HRQoL outcomes, the routine 
use of AEDs in meningioma patients is questionable. Globally, seizure 
prophylaxis with AEDs is common practice. However, there is a paucity of 
evidence supporting their routine use (287, 288). Clinical trials such as Surgical 
Trial Of Prophylaxis for Epilepsy in Meningioma (STOP ‘EM) are planned to 
provide high-quality, prospectively-collected evidence of their objective clinical 
benefit for patients (289).  
 
The symptom burden of meningioma patients appears to reduce following 
surgery; psychological symptoms, anxiety and PTSS scores are high before 
surgery and decrease postoperatively. This is likely to be due to patients 
adjusting to their diagnosis and treatment. However, one study highlighted that 
in the long-term, nearly a sixth of patients reported abnormal PTSS scores. 
Clinicians should be aware of the long-term psychological impact patients may 
experience and screen for emotional wellbeing as part of routine clinical follow-
up. 
 
After surgery, nearly 20% of patients report impaired work ability. The reason 
for this and the specific challenges patients face requires exploring in further 
detail. Employment is important for financial wellbeing but also because it can 
cultivate a sense of purpose and facilitate reintegration into society (220, 290). 
Unemployment is associated with higher anxiety and depression scores, and 
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further qualitative research investigating patient perceptions of work 
restrictions and challenges in resuming employment would be beneficial.  
 
2.6.2 Quality of studies 
 
Overall, studies in which PRO was a primary outcome had a high quality of 
reporting. For studies in which PRO was a secondary outcome, the quality of 
reporting was low. For studies which report PROs, the review authors would 
encourage reporting study results according to the ISOQOL recommendations; 
this would improve the clarity of research findings.  
 
Studies which report a PRO as a primary outcome should make specific 
reference within the title as to outcomes being patient-reported as this is not 
always implied. Whilst it is commonly accepted that domains such health-
related quality of life are patient-reported, studies do exist which assess HRQoL 
by means of clinician reports. Furthermore, this review identified that most 
studies did not justify their use of particular PROMs. This is particularly 
important in meningioma as no meningioma-specific PROM is validated and a 
range of tools are available for use. 
 
2.6.3 Comparison to previous reviews 
 
Previous systematic reviews of meningioma have only assessed outcomes and 
quality of reporting of HRQoL studies (146, 211). 
 
2.6.4 Recommendations for future research 
 
1. The most commonly used PROMs in meningioma research should be 
validated. This includes generic HRQoL (SF-36), cancer-specific HRQoL 




2. HRQoL studies of meningioma should focus on outcomes following 
stereotactic radiosurgery and the diagnosis of incidental meningioma. 
Validated tools should be used for assessment.  
3. Future studies should provide in-depth outcomes of specific symptoms 
(anxiety, depression, fatigue) and functional limitations (subjective 
cognitive functioning and employment) of meningioma patients. 
4. Researchers and healthcare professionals should collaborate to produce 
large-scale, multicentre PRO research. This will improve the generalisability 
of PRO results. Furthermore, this will increase the confidence of 
policymakers to translate the results of PRO research into interventions to 
improve patient care. 
5. PRO results should be reported in accordance with ISOQOL criteria to 
improve the clarity of study findings. 
 
 
2.6.5 Strengths and limitations 
 
 
One of the strengths of this study is that an extensive search strategy was used. 
The search was based on searches used in previous systematic reviews, and 
modifications were made to further increase the sensitivity of the search. 
Accordingly, 7,489 unique articles were identified. However, it was not feasible 
to search the full manuscript of all studies to be screened. Therefore, the review 
authors screened abstracts for reference to a PRO. It is possible that some 
studies have assessed PROs (e.g. as a secondary outcome) and not described 
this in the abstract. These studies would not have been identified as part of the 
screening process; however, we assume that the PRO component of these study 
were likely to be limited and/or of low quality.  
 
Furthermore, only English language articles were screened, which may be a 
reason as to why most identified articles are from Europe and North America. 
Additionally, the grey literature (e.g. conference abstracts) was not included 
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because the review authors wanted to assess PRO reporting quality which 
required full manuscripts.  
 
Screening of unique articles, data extraction and quality assessment was 
performed by only one reviewer. This raises the potential for error and 
introduction of rater bias. This limitation may affect how studies were 
categorised, e.g. as ‘HRQoL’, ‘Health Status’, ‘Symptoms’, ‘Functioning’ or 
‘Other’. The systematic review manuscript for publication will utilise an 
alternative method of classification (Dodd et al. (291)) to reduce the potential 
for ambiguity in classifying outcomes.   
 
The screening process was initially incomplete and not robust at the time of 
writing this chapter. The PRISMA diagram included in this chapter is not 
reflective of the complete article identification process. At least 11 additional 
articles of relevance were identified from the search after this chapter was 
written. These articles are included in Appendix 9. These additional articles 
identify PROs of relevance to meningioma patients, and further highlight the 
heterogeneity of PRO assessment. Therefore, the additional articles are not 
considered to significantly change the conclusions of this chapter. However, the 
newly identified articles will be incorporated into the systematic review 
manuscript for publication. A second reviewer will screen a proportion of 
unique articles prior to submission of the manuscript for publication. The 
second reviewer will re-read all included articles and confirm data extraction 
and ISOQOL and study quality assessment decisions. This will reduce the 
likelihood of a similar error in the published manuscript. 
 
In the ISOQOL assessment of studies assessing PRO, items 9 (PRO as primary 
or secondary outcome) and 11 (extent of missing data) were misapplied. Readers 
should be aware of this when interpreting the results. The final manuscript for 




Finally, we did not assess whether the PROs included in this study are valid for 
use in meningioma patients. This constitutes an additional piece of work to 
assess the methodological quality of PROMs and develop of a holistic PROM 




This systematic review is the first to identify and summarise studies reporting 
PROs of patients with intracranial, sporadic meningioma. PRO studies can be 
categorised as assessing ‘HRQoL’, ‘Health Status’, ‘Symptoms’, ‘Functioning’, 
‘Feelings’ or ‘Other PROs’. HRQoL is the most frequently reported PRO domain, 
and SF-36 is the most commonly used PRO tool. The diagnosis of meningioma 
has an impact on each of the PRO domains. Studies suggest HRQoL is impaired 
in meningioma patients, but there is a shortage of studies investigating 
outcomes following SRT and in incidental meningiomas. The reporting quality 
of studies is good for studies in which PRO is a primary outcome. Future work 
should reflect all domains of PRO to comprehensively evaluate outcomes from 
a patient’s perspective. 
 
  
















































Chapter 3: Patient-Reported Health-Related Quality of Life 




The care for patients with meningiomas has steadily improved over the past 
three decades due to a combination of a better understanding of the natural 
history and disease biology of meningioma, advances in surgical frameworks 
and increasing adjuvant and salvage therapy options. Survival rates and 
neurological outcomes have consequently improved (292, 293). Traditionally, 
neurosurgical outcomes have been reported in terms of morbidity, mortality 
and disability. However, these standard metrics are by themselves insufficient, 
and the metrics for measuring treatment outcomes are appropriately shifting to 
become increasingly patient-centred. 
 
As identified in Chapter 2, Patient-Reported Outcomes (PROs) can focus on 
‘Health-Related Quality of Life’ (HRQoL), ‘Patient-Reported Health Status’, 
‘Patient-Reported Symptoms’, ‘Patient-Reported Functioning’, ‘Patient-
Reported Feelings’ or ‘Other PROs’. Most studies investigating PROs of patients 
with meningiomas focus on HRQoL. However, few studies have assessed the 
long-term HRQoL of patients. Furthermore, only one study has reported 
HRQoL outcomes of radiologically suspected meningiomas, and no studies 
have specifically evaluated long-term HRQoL in patients with incidental 
meningiomas (100).  
 
This chapter describes an exploratory analysis of initial findings from ‘the 
QUALMS study’ (Quality of Life outcomes in patients with Incidental and 
Operated Meningiomas). The chapter compares the HRQoL outcomes of the 
cohort to normative population values. Furthermore, patients are stratified into 
distinct, clinically relevant groups and their HRQoL outcomes compared.  
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3.1.1 Study reporting 
 
This study has been reported in accordance with ISOQOL standards for 
reporting Patient-Reported Outcomes (221, 294).  
 
3.2 Aims and objectives 
 
3.2.1 Research question  
 
• In patients with incidental and/or operated intracranial meningioma, 
what are the physical, cognitive and psychosocial quality of life 
outcomes? 
 
3.2.2 Primary objective 
 
• To determine the prevalence of physical, cognitive and psychosocial 
problems in patients with either incidental meningioma and/or operated 
meningioma 
 
3.2.3 Secondary objectives 
 
• Determine the difference in the HRQoL between patients with 
incidental and non-incidental meningioma 
• Determine the difference in the HRQoL between patients with 
meningioma receiving intervention compared to active monitoring 
alone 
• Determine the difference in the HRQoL between patients with 
meningioma stratified tumour locations of skull base versus non-skull 
base 
• Determine the difference in HRQoL of patients with meningioma who 
completed assessments during the Coronavirus disease 2019 (COVID-19) 
lockdown compared to before the lockdown.  
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As this is an exploratory analysis, there is no hypothesis as to whether HRQoL 
will be affected in patients. Patient-reported HRQoL was the primary outcome 




3.3.1 Research team 
 
Professor Michael D Jenkinson was the Chief Investigator for the study. Sumirat 
M Keshwara was the Primary Investigator.  
 
3.3.2 Study sponsorship and ethical approval  
 
The QUALMS study protocol is included in appendix 5. The University of 
Liverpool was the study sponsor. The QUALMS study received Health Research 
Authority (HRA) approval and was accepted onto the National Institute for 
Health Research (NIHR) Clinical Research Network portfolio in December 2019.  
 
3.3.3 Study design 
 
3.3.3.1 Design and setting 
 
A cross-sectional study was completed at The Walton Centre NHS Foundation 
Trust (The Walton Centre), Liverpool, England between December 2019 and 
July 2020.  
 
3.3.3.2 Participant inclusion and exclusion criteria 
 
Table 3.1 lists the participant inclusion and exclusion criteria. The focus of the 
QUALMS study was to identify long-term HRQoL outcomes of adult patients 
with meningioma. Incidental meningiomas were diagnosed on the basis of 
radiological features. Patients with operated meningiomas had a diagnosis 
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confirmed by histology. In the QUALMS study, patients followed-up for a 
minimum of 5 years were eligible to participate.  
 
Table 3.1: The QUALMS study inclusion and exclusion criteria 
 Inclusion Exclusion 
General • Age ≥16 years at the time 
of diagnosis of 
meningioma 
• Communicate effectively 
using the English 
language 
• Aged <16 years at the time of 
diagnosis of meningioma 
• Lacks capacity to consent  
• Identified as having suffered a 
cerebral neurological insult (e.g. 
trauma, meningitis, stroke) prior to 
presenting with meningioma 
• Diagnosed with any congenital or 
neurological disease prior to a 
diagnosis of meningioma (e.g. 
cerebral palsy)  
• Radiation-induced meningioma  
• Neurofibromatosis type II-associated 
meningioma 
• Diagnosed with any condition which 
leads to cognitive decline (e.g. 
dementia, Parkinson’s disease or 
intellectual disabilities), either before 




• Patients with radiological 
diagnosis of meningioma 
and have been followed-
up for a minimum of 5 
years 
• Patients with radiological diagnosis 
of meningioma and have been 
followed-up for less than 5 years 
• Diagnosis of meningioma considered 




• Patients who have had 
surgery for their 
meningioma and have a 
minimum of 5 years 
follow-up 
• Patients who have had surgical 
resection of their meningioma and 
have less than 5 years follow-up 
 
3.3.4 HRQoL assessment tools  
 
Three HRQoL Patient-Reported Outcome Measures (PROMs) were chosen for 
use in this study. In order to assess HRQoL holistically, one general, one cancer-
specific and one brain-tumour specific tool were selected. Although a 
meningioma-specific HRQoL tool exists, this was not chosen as it has not been 
used in a clinical study to date and its validity has not been assessed (210). In 
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addition to the three HRQoL PROMs, patients were asked to complete one 
study-specific questionnaire which asked patients to provide demographic (e.g. 




The RAND 36-item Short Form Health Survey version 1.0 (SF-36) was chosen as 
the general HRQoL tool (260, 295). This tool is identical to the MOS SF-36 but 
differs in its scoring. The SF-36 contains 36 items and assesses eight HRQoL 
domains: Physical Functioning, Bodily Pain, role limitations due to Physical 
ealth problems (Role Physical), role limitations due to personal or emotional 
problems (Role Emotional), Emotional Wellbeing, Social Functioning, Energy/ 
Fatigue, and General Health perceptions. It includes one item asking patients 
to rate their current health compared to one year previously.  Many of the items 
assess HRQoL in the last four weeks. All items are statistically transformed so 
that a higher score represents a more favourable health state. The SF-36 is a 
validated PROM with Cronbach’s α reported to be greater than 0.85 (296).  
 
3.3.4.2 EORTC QLQ-C30 
 
The EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30) was chosen 
as the cancer-specific HRQoL tool (204). The QLQ-C30 contains 30 items and 
assesses five functional scales (Physical, Role, Cognitive, Emotional and Social) 
and three symptom scales (Fatigue, Pain, Nausea and Vomiting) and one Global 
Health Status/ QoL scale. Six single items evaluate specific symptoms 
(Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial 
Difficulties). Many of the items assess HRQoL in the last one week.  
 
A higher functional scale score and Global Health Status score represent higher 
level of functioning and health status, respectively. However, a higher symptom 
scale or item score represents higher symptom burden. It is possible to combine 
the scores of each scale and single items (excluding Global Health Status and 
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Financial Difficulties) to produce a summary score. A higher summary score 
represents a higher overall HRQoL. The QLQ-C30 is a validated PROM with 
Cronbach’s α ≥ 0.7 in all scales except role functioning (204).  
 
3.3.4.3 EORTC QLQ-BN20 
 
The EORTC Quality of Life Questionnaire Brain Cancer Module (EORTC QLQ-
BN20) was chosen as a brain tumour-specific HRQoL tool (265). The QLQ-BN20 
contains 20 items and assesses four symptom scales (Future Uncertainty, Visual 
Disorder, Motor Dysfunction and Communication Deficit). Seven single items 
evaluate specific symptoms (Headaches, Seizures, Drowsiness, Hair Loss, Itchy 
Skin, Weakness of Legs and Bladder Control).  All of the items evaluate HRQoL 
over the last one week. All scales and items are statistically transformed so that 
a higher score represents a higher level of symptom burden. The QLQ-BN20 has 
been internationally validated, and Cronbach’s α reported as ≥ 0.7 in all scales 
(297).  
  
3.3.5 Rationale for assessment schedule 
 
Assessment of HRQoL five or more years after diagnosis (incidental cohort) or 
surgery (operated cohort) was chosen to represent long-term HRQoL 
outcomes. This is because if an incidental meningioma is to progress, it will 
usually do so within five years of diagnosis. Patients with incidental 
meningiomas diagnosed five or more years ago can expect clinical stability (98). 
For operated meningiomas, 5-year survival rates for WHO Grade I and II 
meningiomas are 90% and 80% respectively (136). As a majority of patients are 
alive and clinically stable five years postoperatively, this seemed an appropriate 






3.3.6 Study size 
 
A total of 699 patients were eligible to participate and were contacted by post. 
No sample-size calculation was necessary as the QUALMS study is exploratory 
and therefore does not need to be powered to assess a specific hypothesis. 
Eligible patients attending routine clinic appointments were also identified and 
invited to participate.   
 
3.3.7 Invitation to participation 
 
Eligible patients were identified from three existing databases of meningioma 
patients held at The Walton Centre. Eligible patients included patients 
currently under active follow-up and those who have previously received care 
for their meningioma at The Walton Centre but were subsequently discharged. 
The three databases were combined to form The Walton Meningioma database, 
and deceased patients were removed. Patient contact details were identified 
using the NHS Spine.  Date of the patient’s next clinic appointment at The 
Walton Centre was recorded.  
 
Eligible patients were approached in one of two ways: either when they 
attended routine clinic appointments or by post. Eligible patients that attended 
routine clinic appointments at The Walton Centre between December 2019 and 
March 2020 were approached by the Primary Investigator and invited to 
participate. Patients were informed of the study purpose, given the study 
invitation letter and the Patient Information Sheet (appendices 6, 7 and 8) and 
offered an opportunity to ask questions. Patients who were willing to participate 
signed the study consent form (appendix 8) and completed the study 
questionnaires individually or with the person that they attended the clinic 
appointment with.  
 
In March 2020, all eligible patients identified through The Walton Meningioma 
database were contacted by post. Patients were sent a cover letter explaining 
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the study purpose, the Patient Information Sheet and a study consent form. A 
pre-paid return envelope was provided for patients to return the study consent 
form. Patients who returned the consent form were mailed the study 
questionnaires alongside another pre-paid return envelope. After four weeks, 
the patients who had not responded to the initial invitation to participate letter 
were re-sent the cover letter, Patient Information Sheet, consent form and a 
pre-paid return envelope.   
 
3.3.8 Mode of PROM administration 
 
The study questionnaires were self-administered whether the patient was 
invited to participate by post or during clinic appointments.  
 
3.3.9 Study data 
 
HRQoL outcomes and responses from the study-specific questionnaire were 
entered into The Walton Meningioma database. Patient demographic, 
diagnosis and treatment data were extracted from digital case-notes and from 
the study-specific questionnaire. The digital case notes only provide data after 
2007. Therefore, some data recorded before 2007 were not available to access. 
A manual case-note review was not possible to complete at the time of writing 
this chapter. Table 3.2 shows the information extracted from the case-notes and 
the study-specific questionnaire.  
 
Table 3.2: Study data obtained from case-note review or from the study-specific questionnaire 
Variables Description 
Patient  Age at the completion of questionnaire*†, time since diagnosis*†, sex†, highest 
education level*, employment status*, driving status* 
Clinical  Presenting features†, preoperative performance status (ECOG)†, medical 
conditions*† (to calculate Age-adjusted Charlson Comorbidity Index - ACCI), 
number of medications*, number of AEDs* 
Tumour  WHO Grade†, tumour location†, tumour laterality† 
Intervention  Initial management†, subsequent management†, the extent of surgical 
resection† 
Outcome Progression since diagnosis (defined as either regrowth or recurrence)† 
 
ECOG: Eastern Cooperative Oncology Group. AEDs: Anti-epileptic drugs 
* Obtained or calculated from the study-specific questionnaire. † Obtained or calculated from case-
note review.  
 
 115 
3.3.10 Quantitative variables 
 
HRQoL scores obtained from patient questionnaires were transformed into the 
scale and single item scores as per their scoring manuals (295, 298). No scoring 
manual is available for the QLQ-BN20. Therefore, the QLQ-BN20 scales were 
constructed using information about the domains and their corresponding 
items that can be obtained from the development and validation studies (265, 
297). The QLQ-BN20 scales were computed and transformed using the QLQ-
C30 manual (298), which is the same methodology as was used in the QLQ-
BN20 development study (265). Table 3.3 shows all variables assessed in this 
exploratory analysis. 
 
Table 3.3: Variables used in the QUALMS study analysis  
Variable type Variable name 
Continuous Age at the completion of questionnaires, time since the initial diagnosis, 
number of medications, number of AEDs, HRQoL outcomes (quasi-
continuous) 
Ordinal Performance status (ECOG) at diagnosis, ACCI, highest education level 
Nominal Tumour location, tumour laterality, employment status, presenting features 
Dichotomous Sex, WHO Grade, skull-base tumour, multiple meningioma, incidental 
meningioma, initial management, intervention, subsequent surgery, 
subsequent SRS, subsequent FRT, extent of resection, progression since 
diagnosis, current driving status, currently taking AEDs, response during 
COVID-19 lockdown 
SRS: stereotactic radiosurgery, FRT: fractionated radiotherapy 
 
3.3.11 Statistical analysis 
 
Statistical analysis was completed using IBM SPSS Statistics (IBM Corp. 
Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM 
Corp.). The exception to this is the comparison of the HRQoL scores of the total 
meningioma cohort to normative populations values, which was completed 
using the two-sample test on a statistical calculator website (www.select-
statistics.co.uk)(299). Continuous variables with normal distributions were 
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described with means and standard deviations. Continuous variables which 
were not normally distributed were described with medians. Ordinal, nominal 
and dichotomous data were described by counts and percentages.  
 
For all significance testing, a statistically significant result was defined as 
p<0.05. The independent samples t-test was used to compare means between 
HRQoL and normative population data. This test assumes normality of data, 
absence of outliers and equality of variances. Where these assumptions were 
not met, between-groups comparisons of continuous outcomes were completed 
using Mann-Whitney-U (Wilcoxon rank-sum test) and reported with the 
Mann-Whitney-U (U) statistic, the standard test statistic (Z) and significance 
values (p). Medians could be directly compared when HRQoL scores were 
considered equally distributed (as assessed by visual inspection). Mean ranks 
are additionally reported where HRQoL scores were not considered equally 
distributed.   
 
Between groups comparisons of dichotomous or multinomial dependent 
variables was completed using the chi-square test (test of two proportions). This 
test assumes independence of observations, random sampling of two 
populations and expected frequency values of 5 or more.  Where an expected 
frequency was identified as being less than 5, Fisher’s exact test was used. 
Between groups comparisons of ordinal data were completed using the Mann-
Whitney-U test.  
 
Internal consistency of questionnaires was calculated using Cronbach’s α (300). 
This test is used to measure how much individual items measure within a scale 
measure the same dimension. A satisfactory internal consistency was pre-
defined as an alpha value between 0.700-0.950 (301).  
 
A multivariate linear regression model was not performed due to limited sample 
size, presence of outliers and no linear relationship between dependent and 
independent variables. As this is an exploratory analysis, the p values were not 
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adjusted to account for multiple comparisons. This was to reduce the risk of 
making a type 2 error and obtaining a false negative result (302).  
 
3.3.11.1 HRQoL missing data analysis 
 
The RAND SF-36 manual states that missing responses to items within a scale 
did not preclude a patient from inclusion in the study. The items that have been 
answered can be used to compute an average score for the scale (295). If no 
items of the scale are answered it is not possible to produce a scale score. For 
the EORTC QLQ-C30 and QLQ-BN20, if 50% or more of items that form a scale 
are answered, those responses can be used to compute a scale score. If less than 
50% of items for a scale are answered, a scale score should not be computed 
(298). Little’s test was used to assess whether missingness occurred completely 




3.4.1 Sample characteristics 
 
Table 3.4 describes the patient demographic, clinical and treatment 
characteristics. A total of 699 patients were contacted by post, of which 31 
patients had responded and subsequently had their responses recorded at the 
point that this analysis was undertaken. The postal response rate was therefore 
4.4%. An additional 23 patients were identified at outpatient clinic 
appointments, and their questionnaire responses were also analysed. Therefore, 
a total of 54 patients were included in this initial exploratory analysis.  
 
The mean age of participants was 66.2, and 80% were female. Of those with 
histological diagnosis, 89% of patients had WHO Grade I meningiomas. 
Patient’s meningiomas were equally distributed between right (41%) and left 
(43%) hemispheres, and 16% were located in the midline. Approximately half 
(48%) of patients had skull base meningiomas. Cerebral convexity (33%), 
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anterior midline (22%) and sphenoid wing (16%) were the commonest tumour 
locations. Incidental meningiomas were diagnosed in 41% of the cohort. Twenty 
nine patients (54%) had an operation to remove their meningioma as initial 
management. The mode highest education level was GCSE (41%), and a majority 
of participants were retired (59%). Ten patients (19%) reported they were taking 
anti-epileptic drugs. Thirty-one patients (57%) in this analysis completed the 




Table 3.4: QUALMS study responder 
characteristics 
Characteristic Value  
Sample size  54 (100) 
Mean age (years) at completion 
of questionnaires (standard 
deviation) 
66.2 (11.6) 




Female 43 (80) 
Male 11 (20) 
WHO Grade (where histology available) * 
I 31 (89) 
II 4 (11) 
III 0 (0) 
Tumour location (ICOM) † 
Convexity 17 (33) 
Anterior midline 11 (22) 
Sphenoid wing 8 (16) 
Parasagittal 5 (10) 
Posterior fossa- lateral 
and posterior 
4 (8) 
Parafalcine 3 (6) 
Posterior fossa- midline 1 (2) 
Pineal 1 (2) 
Tentorial 1 (2) 
Skull base tumour ‡ 25 (48) 
Tumour laterality § 
Right 21 (41) 
Left 22 (43) 
Midline 8 (16) 
Table 3.4: QUALMS study responder 
characteristics (continued) 
Characteristic Value 
Performance Status at diagnosis (ECOG) 
¶ 
0 17 (34) 
1 22 (44) 
2 10 (20) 
3 1 (2) 
ACCI  
0 2 (4) 
1 5 (9) 
2 12 (22) 
3 14 (26) 
4 9 (17) 
5 4 (7) 
6 5 (9) 
7 3 (6) 
Intervention  






Surgery 29 (54) 
Further management 




SRS 2 (4) 
Extent of resection (if operated) # 
GTR 22 (61) 






Table 3.5: QUALMS study responder 
characteristics (continued) 
Characteristic Value 
Multiple meningioma 4 (7) 
Presenting features 
Seizure 8 (15) 
Headache 7 (13) 
Nausea 1 (2) 
Vomiting 0 (0) 
Motor weakness 6 (11) 
Sensory deficit 10 (19) 
Language deficit 2 (4) 




Altered GCS score 0 (0) 
Incidental finding 22 (41) 
Mean number of medications 
(standard deviation) 
3.3 (2.7) 
Currently taking AEDs 10 (19) 
 
* The meningioma WHO Grade of two patients is 
unknown. 
† Three patients have multiple meningiomas in 
different cerebral locations. Therefore, these 
patients have been omitted from analyses of ICOM 
location and are not presented here. 
‡ Two patients have multiple meningiomas in skull 
base and non-skull base locations. They have been 
omitted from analyses of skull base and are not 
presented here. 
§ Three patients have multiple meningiomas in 
both right and left hemispheres. Therefore, these 
patients have been omitted from analyses of 
tumour laterality and are not presented here.  
Table 3.6: QUALMS study responder 
characteristics (continued) 
Characteristic Value 
Highest education level 
No education 9 (17) 
GCSE 22 (41) 
A Levels  13 (24) 












Self-employed 4 (7) 
Unable to work 
due to health 
4 (7) 
Homemaker 1 (2) 
Current driving status 31 (57) 
COVID-19 response 31 (57) 
 
¶ Performance status of four patients is 
unknown 
# The Extent of Resection of one patient is 
unknown. 
 
All results in Table 3.4 are reported as frequency 
and percentages: n (%) unless stated otherwise. 
 
 
3.4.2 Missing data 
 
Table 3.5 shows the items with missing responses from patient questionnaires. 
Of the cohort, 13 patients (24%) had missing data in their returned 
questionnaires. Eight of these patients (62%) had only one missing item. Eleven 
patients (85%) had missing data from SF-36. Little’s MCAR (Missing Completely 
at Random) test revealed p=0.000, suggesting missingness was not completely 
random across the three questionnaires.  
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Table 3.6 shows a description of items which were missing in more than one 
patient. Notably, SF-36 Item 23 (did you feel full of pep?) was missing in five 
patients. Additionally, SF-36 Item 32 (physical health interference in social 
activities) was missing in four patients, and SF-36 Item 3 (limitations in vigorous 
activities) was missing in three patients.  
 
No multiple imputation method was necessary for the analysis of HRQoL data.  
 
Table 3.7: Missing items from responses 
Patient 
number 
Method of contact Missing items 
SF-36 QLQ-C30 QLQ-BN20 
1 Postal 32 - - 
2 Postal 23 - - 
17 Postal 3, 4, 32 - - 
18 Postal 32 - - 
22 Postal 3, 33, 34, 36 - - 
32 Postal 3, 7, 10, 11 - - 
38 Clinic - 12 - 
40 Clinic 23, 24, 25, 26, 27, 
28, 29, 30, 31, 32, 
33, 34, 35, 36 
- - 
45 Clinic 6 - - 
58 Clinic 23 - - 
60 Clinic 13, 14, 15, 16, 17, 
18, 19, 23, 25, 26, 
28, 30 
10 - 
62 Clinic 23 - - 




Table 3.8: Frequency and description of missing items  
Questionnaire name Item 
number 
Verbatim item summarised  Domain Frequency 
missing 
SF-36 3 ‘Does your health now limit you in… vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports’ 
Physical functioning 3 
SF-36 23 ‘Did you feel full of pep?’ Energy/ Fatigue 5 
SF-36 25 ‘Have you felt so down in the dumps that nothing could cheer you up?’ Emotional wellbeing 2 
SF-36 26 ‘Have you felt calm and peaceful?’  Emotional wellbeing 2 
SF-36 28 ‘Have you felt downhearted and blue?’ Emotional wellbeing 2 
SF-36 30 ‘Have you been a happy person?’ Emotional wellbeing 2 
SF-36 32 ‘How much of the time has your physical health or emotional problems interfered 
with your social activities (like visiting with friends, relatives, etc.)?’ 
Social functioning 4 
SF-36 33 ‘I seem to get sick a little easier than other people’ General health 2 
SF-36 34 ‘I am as healthy as anybody I know’ General health 2 
SF-36 36 ‘My health is excellent’ General health 2 
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3.4.3 Internal consistency 
 
Table 3.7 shows the internal consistency of individual scales. Across all scales, 
alpha ranged between 0.518 and 0.950. Of the 21 individual scales, 19 scales 
(90%) scored above the pre-defined satisfactory score of 0.700. The QLQ-C30 
Nausea and Vomiting and QLQ-BN20 Motor Dysfunction scale scored 0.646 
and 0.518, respectively.  
 
Table 3.9: Internal consistency of the HRQoL tools 
Questionnaire Scale Items Cronbach’s 
α 
SF-36 Physical functioning 3 4 5 6 7 8 9 10 11 12 0.946 
SF-36 Role limitations due to physical 
health 
13 14 15 16 0.908 
SF-36 Role limitations due to 
emotional problems 
17 18 19 0.950 
SF-36 Energy/ Fatigue 23 27 29 31 0.919 
SF-36 Emotional well-being 24 25 26 28 30 0.812 
SF-36 Social functioning 20 32 0.827 
SF-36 Pain 21 22 0.908 
SF-36 General health 1 33 34 35 36 0.870 
QLQ-C30 Global health status/ QoL 29, 30 0.950 
QLQ-C30 Physical functioning 1, 2, 3, 4, 5 0.844 
QLQ-C30 Role functioning 6, 7 0.896 
QLQ-C30 Emotional functioning 21, 22, 23, 24 0.934 
QLQ-C30 Cognitive functioning 20, 25 0.819 
QLQ-C30 Social functioning 26, 27 0.871 
QLQ-C30 Fatigue 10, 12, 18 0.836 
QLQ-C30 Nausea and Vomiting 14, 15 0.646 
QLQ-C30 Pain 9, 19 0.912 
QLQ-BN20 Future Uncertainty 31, 32, 33, 35 0.858 
QLQ-BN20 Visual Disorder 36, 37, 38 0.852 
QLQ-BN20 Motor Dysfunction 40, 45, 49 0.518 




3.4.4 HRQoL of the entire cohort 
 
3.4.4.1 Normative values 
 
Table 3.8 shows the HRQoL scores of the 54 participants and compares their 
scores to normative population values (303, 304). The SF-36 normative values 
were obtained from surveying the general population of Wales 5. The QLQ-C30 
normative values were obtained from surveying patients across Europe. 
Normative general population values for the QLQ-BN20 were unavailable.  
 
3.4.4.2 Justification for comparison 
 
HRQoL scores were not normally distributed as assessed by with Shapiro-Wilk 
test (p values <0.05). QLQ-BN20 scores and QLQ-C30 symptom scores were 
generally positively skewed, QLQ-C30 functional scale and SF-36 scores were 
negatively skewed. This is similar to previously reported studies  (303, 305). 
Some domains contained outliers as assessed by inspection of box plots, but 
these were considered to be true patient values and not data collection or data 
entry errors. There was no justification for removing outliers from the analysis. 
As previous studies have compared means of sample data to normative 
population values by independent samples t-test, it seemed appropriate to do 
this for this exploratory analysis. This was justified as the independent samples 
t-test is considered stable against assumptions of non-normality. It was not 
possible to test homogeneity of variances or use the non-parametric Mann-
Whitney-U test as raw normative population values were not available (306). 
The purpose of this analysis was to identify domains reported as impaired in 






5 See limitations section  
 124  
Table 3.10: HRQoL scores for the entire cohort and comparison with normative population 
values 
Domain Sample Normative Sig 
median IQR mean SD 95% CI  mean SD p 
SF-36 Physical 
Functioning 
85.0 53.8 68.6 30.4 60.2-77.1 77.8 30.0 0.031 
SF-36 Role Physical 
 
100.0 75.0 63.5 42.4 51.6-75.3 78.3 32.3 0.014 
SF-36 Role Emotional 100.0 58.3 76.3 40.9 64.9-87.7 87.0 26.0 0.063 
SF-36 Energy/ 
Fatigue 
60.0 45.0 57.1 26.8 49.6-64.5 57.2 22.3 0.978 
SF-36 Emotional 
Wellbeing 
80.0 27.0 75.1 19.3 69.7-80.5 74.0 18.9 0.680 
SF-36 Social 
Functioning 
93.8 46.9 75.7 31.4 67.0-84.5 80.2 28.1 0.298 
SF-36 Pain 
 
68.8 45.0 66.2 28.0 58.4-74.0 70.1 28.9 0.312 
SF-36 General Health 57.5 37.5 58.8 24.1 52.1-65.6 66.2 24.0 0.028 
QLQ-C30 Summary 
Score 
88.3 20.0 81.8 16.8 77.1-86.5 - - - 
QLQ-C30 Physical 
Functioning 
86.7 40.0 79.2 22.3 73.0-85.4 85.1 18.9 0.058 
QLQ-C30 Role 
Functioning 
100.0 33.3 81.1 28.8 73.1-89.1 84.3 24.6 0.419 
QLQ-C30 Emotional 
Functioning 
83.3 33.3 76.9 25.0 70.0-83.9 74.2 24.7 0.432 
QLQ-C30 Cognitive 
Functioning 
83.3 50.0 72.1 27.2 64.6-79.7 84.8 21.3 0.001 
QLQ-C30 Social 
Functioning 
100.0 33.3 79.8 29.2 71.7-87.9 86.2 24.1 0.114 
QLQ-C30 Fatigue 
 
22.2 38.9 27.0 26.2 19.8-34.3 29.5 25.5 0.487 
QLQ-C30 Nausea & 
Vomiting 
0.0 0.0 4.8 12.1 1.5-8.2 5.9 16.0 0.509 
QLQ-C30 Pain 
 
16.7 45.8 28.2 30.5 19.7-36.7 23.5 27.1 0.263 
QLQ-C30 Dyspnoea 
 
0.0 0.0 9.6 23.2 3.2-16.1 15.9 24.6 0.052 
QLQ-C30 Insomnia 
 
33.3 58.3 32.7 34.6 23.1-42.3 26.6 30.3 0.202 
QLQ-C30 Appetite 
Loss 




0.0 25.0 9.0 16.3 4.4-13.5 12.5 23.3 0.122 
QLQ-C30 Diarrhoea 
 




0.0 0.0 5.8 18.3 0.7-10.9 10.6 23.6 0.060 
QLQ-C30 Global Health 
Status/QoL 
 
75.0 22.9 70.8 22.6 64.5-77.1 66.1 21.7 0.133 
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Table 3.8: HRQoL scores for the entire cohort and comparison with normative population 
values (continued) 
Domain Sample Normative Sig 
median IQR mean SD 95% CI  mean SD p 
QLQ-BN20 Future 
Uncertainty 
16.7 41.7 22.4 22.8 16.1-
28.8 
- - - 
QLQ-BN20 Visual 
Disorder 
0.0 22.2 14.5 23.3 8.0-21.0 - - - 
QLQ-BN20 Motor 
Dysfunction 
11.1 22.2 13.9 17.4 9.0-18.7 - - - 
QLQ-BN20 
Communication Deficit 
0.0 22.2 11.5 16.8 6.9-16.2 - - - 
QLQ-BN20 Headaches 0.0 33.3 22.4 30.8 13.9-
31.0 
- - - 
QLQ-BN20 Seizures 
 
0.0 0.0 1.3 6.5 0.0-3.1 - - - 
QLQ-BN20 Drowsiness 0.0 33.3 23.7 29.8 15.4-
32.0 
- - - 
QLQ-BN20 Hair Loss 
 
0.0 0.0 6.4 18.7 1.2-11.6 - - - 
QLQ-BN20 Itchy Skin 
 
0.0 0.0 8.3 20.7 2.6-14.1 - - - 
QLQ-BN20 Weakness of 
Legs 
0.0 0.0 9.6 21.2 3.7-15.5 - - - 
QLQ-BN20 Bladder 
Control 
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3.4.4.3 HRQoL 
 
Three domains of the SF-36 were significantly impaired in meningioma patients 
compared to normative population values. Physical Functioning (mean 68.6 vs 
77.8, p=0.031), Role Physical (mean 63.5 vs 78.3, p=0.014)  and General Health 
scores (58.8 vs 66.2, p=0.028) were significantly lower. Role Emotional scores 
were also lower (mean 76.3 vs 87.0), but this was not statistically significant 
(p=0.063). 
 
In the QLQ-C30, Cognitive Functioning scores were lower in the meningioma 
patients compared to the general population (mean 72.1 vs 84.8, p=0.001). 
Meningioma patients reported better HRQoL scores for Diarrhoea (3.8 vs 9.5, 
p=0.002), Dyspnoea (mean 9.6 vs 15.9, p=0.052) and Financial Difficulties (mean 
5.8 vs 10.6, p=0.060).
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3.4.5 Incidental meningioma  
 
HRQoL scores were compared between patients whose meningioma was 
diagnosed incidentally compared with non-incidentally. HRQoL scores in the 
groups were not normally distributed as assessed by the Shapiro-Wilk test (p 
values < 0.05). Individual group sizes were small. A number of domains had 
outliers. The most appropriate test for comparing the HRQoL scores of the 
groups was the non-parametric Mann-Whitney-U test.  
 
3.4.5.1 Group characteristics 
 
Table 3.9 shows the group characteristics of patients with incidental and non-
incidental meningioma. The two groups differed in their site of tumour location 
(p=0.020), and patients with incidental meningioma had significantly lower 
baseline ECOG performance status (p=0.004)6. Patients with incidental 
meningioma were significantly less likely to receive treatment interventions 
(23% vs 100%, p=0.000) or to experience progression of their tumour (0% vs 















6 A lower ECOG performance status score indicates a better level of functioning 
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Table 3.11: Comparison of demographic, clinical and treatment variables between patients 
diagnosed with an incidental and non-incidental meningioma 
Variable Incidental Non-incidental p 
Sample size (n=54) 22 32 n/a 
Median age at 
completion of 
questionnaires 
67.8 (27.9*) 67.9 (27.2*) 0.874 
Median years since 
diagnosis 
7.7 (21.9*) 10.4 (26.7*) 0.238 
Female   19 (86)  24 (75) 0.493† 
WHO Grade  I: 5 (100) 
II: 0 (0) 
I: 26 (87) 
II: 4 (13) 
1.000† 
Tumour location  Convexity: 10 (48) 
Anterior midline: 6 (29) 
Sphenoid wing: 1 (5) 
Parasagittal: 0 (0) 
Posterior fossa- lateral and 
posterior: 1 (5) 
Parafalcine: 3 (14) 
Posterior fossa- midline: 0 (0) 
Pineal: 0 (0) 
Tentorial: 0 (0) 
Convexity: 7 (23) 
Anterior midline: 5 (17) 
Sphenoid wing: 7 (23) 
Parasagittal: 5 (17) 
Posterior fossa- lateral and 
posterior: 3 (10) 
Parafalcine: 0 (0) 
Posterior fossa- midline: 1 
(3) 
Pineal: 1 (3) 
Tentorial: 1 (3) 
0.020† 
Skull base tumour 
 
8 (38) 17 (55) 0.236 
Tumour laterality  Right: 8 (40) 
Left: 10 (50) 
Midline: 2 (10) 
Right: 13 (42) 
Left: 12 (39) 
Midline: 6 (19) 
0.641† 
Multiple meningiomas  2 (9) 2 (6) 1.00† 
Median number of 
medications  
3.0 (27.6*) 2.5 (27.4*) 0.965 
Median number of 
AEDs 
0.0 0.0 0.124 
Baseline Performance 
Status (ECOG)  
0: 12 (55) 
1: 8 (36) 
2: 2 (9) 
3: 0 (0) 
0: 5 (18) 
1: 14 (50) 
2: 8 (29) 
3: 1 (4) 
0.004 
ACCI  0: 0 (0) 
1: 2 (9) 
2: 5 (23) 
3: 7 (32) 
4: 2 (9) 
5: 3 (14) 
6: 2 (9) 
7: 1 (5) 
0: 2 (6) 
1: 3 (9) 
2: 7 (22) 
3: 7 (22) 
4: 7 (22) 
5: 1 (3) 
6: 3 (9) 




Active monitoring: 21 (95) 
Surgery: 1 (5) 
 
Active monitoring: 4 (12.5) 




Table 3.9: Comparison of demographic, clinical and treatment variables between patients 
diagnosed with an incidental and non-incidental meningioma (continued) 
Variable Incidental Non-incidental p 
Intervention  5 (23) 32 (100) 0.000 
If operated, GTR 
 








No education: 1 (5) 
GCSE: 10 (45) 
A-Levels: 6 (27)  
Undergraduate: 3 (14) 
Master’s degrees: 2 (9) 
No education: 8 (25) 
GCSE: 12 (38) 
A-Levels: 7 (22) 
Undergraduate: 2 (6) 




Retired: 15 (68) 
Part-time employment: 4 (18) 
Full-time employment: 2 (9) 
Self-employed: 1 (5) 
Unable to work due to health: 
0 (0) 
Homemaker: 0 (0) 
Retired: 17 (53) 
Part-time employment: 3 (9) 
Full-time employment: 4 
(13) 
Self-employed: 3 (9) 
Unable to work due to 
health: 4 (13) 
Homemaker: 1 (3) 
0.446† 
Current driving status  14 (64) 17 (53) 0.443 
COVID-19 response  15 (68) 16 (50) 0.184 
* Mean rank 
† Fisher’s Exact Test  
All results in Table 3.9 are reported as frequency and percentages: n (%) unless stated otherwise.  
3.4.5.2 HRQoL 
 
Table 3.10 shows the comparison of HRQoL scores between patients with 
incidental and non-incidental meningiomas. HRQoL scores were similar 
between patients with incidental and non-incidental meningioma. The only 
statistically significant finding was lower QLQ-BN20 Communication Deficit 
scores, indicating less communication deficit, in patients with incidental 
meningioma (0.0 vs 11.1, U= 465.0 Z= 2.17 p=0.030). QLQ-C30 summary scores 
were higher, implying higher overall HRQoL, in patients with incidental 
meningioma compared to non-incidental meningioma (mean rank 32.5 vs 24.1, 
U= 243.0 Z= -1.91 p=0.055). QLQ-C30 Cognitive Functioning scores were higher 
in patients with incidental meningioma (91.7 vs 75.0, U= 256.5 Z= -1.72 p=0.085). 
Finally, QLQ-C30 Fatigue scores were lower in the incidental meningioma 
cohort (16.7 vs 27.8, U= 455.5 Z=1.85 p=0.065). 
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Table 3.12: Comparison of HRQoL scores between incidental and treated meningioma 
Domains Incidental  
(median) 
 




n = 32 
U Z p 
SF-36 Physical Functioning 85.0 85.0 348.5 -0.62 0.950 
SF-36 Role Physical 100.0 50.0 281.0 -1.18 0.238 
SF-36 Role Emotional 100.0 100.0 294.5 -1.09 0.276 
SF-36 Energy/ Fatigue 70.0 60.0 255.0 -1.56 0.119 
SF-36 Emotional Wellbeing 84.0 76.0 269.0 -1.30 0.192 
SF-36 Social Functioning 100.0 81.3 296.0 -1.06 0.291 
SF-36 Pain 77.5 67.5 312.5 -0.70 0.483 
SF-36 General Health 57.5 (26.1*) 52.5 (28.5*) 383.0 0.55 0.584 
QLQ-C30 Summary Score 91.9 (32.5*) 81.6 (24.1*) 243.0 -1.91 0.055 
QLQ-C30 Physical Functioning 93.3 86.7 303.5 -0.87 0.385 
QLQ-C30 Role Functioning 100.0 100.0 322.5 -0.58 0.563 
QLQ-C30 Emotional Functioning 91.7 75.0 276.5 -1.35 0.177 
QLQ-C30 Cognitive Functioning 91.7 75.0 256.5 -1.72 0.085 
QLQ-C30 Social Functioning 100.0 91.7 297.5 -1.07 0.286 
QLQ-C30 Fatigue 16.7 27.8 455.5 1.85 0.065 
QLQ-C30 Nausea & Vomiting 0.0 0.0 294.0 -1.51 0.131 
QLQ-C30 Pain 8.3 25.0 423.5 1.30 0.194 
QLQ-C30 Dyspnoea 0.0 0.0 354.5 0.07 0.948 
QLQ-C30 Insomnia 16.7 33.3 409.0 1.06 0.288 
QLQ-C30 Appetite Loss 0.0 0.0 379.5 0.715 0.474 
QLQ-C30 Constipation 0.0 0.0 340.0 -0.28 0.781 
QLQ-C30 Diarrhoea 0.0 0.0 378.0 0.91 0.362 
QLQ-C30 Financial Difficulties 0.0 0.0 348.5 -0.106 0.916 
QLQ-C30 Global Health Status 66.7 79.2 377.5 0.46 0.647 
BN20 Future Uncertainty 12.5 16.7 390.0 0.68 0.497 
BN20 Visual Disorder 0.0 0.0 338.0 -0.274 0.784 
BN20 Motor Dysfunction 0.0 (24.2*) 11.1 (29.8*) 424.0 1.35 0.179 
BN20 Communication Deficit 0.0 11.1 465.0 2.17 0.030 
BN20 Headaches 0.0 0.0 334.0 -0.354 0.723 
BN20 Seizures 0.0 0.0 385.0 1.46 0.143 
BN20 Drowsiness 0.0 33.3 418.0 1.27 0.205 
BN20 Hair Loss 0.0 0.0 373.0 0.63 0.526 
BN20 Itchy Skin 0.0 0.0 377.0 0.65 0.515 
BN20 Weakness of Legs 0.0 0.0 404.5 1.27 0.203 
BN20 Bladder Control 0.0 0.0 393.0 0.90 0.369 
* Mean rank 
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3.4.6 Intervention versus Active monitoring 
 
HRQoL scores of patients who have had an intervention for their meningioma 
(surgery, fractionated radiotherapy, SRS) were compared with patients who 
have been followed-up with active monitoring only. HRQoL scores in the 
groups were not normally distributed as assessed by the Shapiro-Wilk test (p 
values < 0.05). Individual group sizes were small. A number of domains had 
outliers. The most appropriate test for comparing the HRQoL scores of the 
groups was by using the non-parametric Mann-Whitney-U test.  
 
3.4.6.1 Group demographics 
 
Table 3.11 shows the characteristics of patients treated with an intervention 
compared to active monitoring alone. Patients treated with intervention had a 
longer median follow-up time (10.6 years vs 7.5 years, mean rank 27.7 vs 18.7, 
p=0.032) and were more likely to have a higher baseline ECOG performance 
status (p=0.042)7. Patients treated with an intervention were more likely to have 
experienced progression than the group managed with active monitoring (24% 














7 A higher ECOG performance status score indicates a lower level of functioning 
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Table 3.13: Comparison of demographic, clinical and treatment variables between patients 
treated with an intervention compared to followed with active monitoring alone 
Variable Intervention Active monitoring p 
Sample size (n=54) 37 17 n/a 
Median age at 
completion of 
questionnaires 
66.58 (26.1*) 68.34 (30.7*) 0.319 
Median years since 
diagnosis 
10.6 (27.7*) 7.5 (18.7*) 0.032 
Female  28 (76) 15 (88) 0.470† 
WHO Grade  I: 31 (89) 




Tumour location Convexity: 11 (31) 
Anterior midline: 6 (17) 
Sphenoid wing: 7 (20) 
Parasagittal: 5 (14) 
Posterior fossa- lateral and 
posterior: 3 (9) 
Parafalcine: 0 (0) 
Posterior fossa- midline: 1 (3) 
Pineal: 1 (3) 
Tentorial: 1 (3) 
Convexity: 6 (38) 
Anterior midline: 5 (31) 
Sphenoid wing: 1 (6) 
Parasagittal: 0 (0) 
Posterior fossa- lateral and 
posterior: 1 (6) 
Parafalcine: 3 (19) 
Posterior fossa- midline: 0 
(0) 
Pineal: 0 (0) 
Tentorial: 0 (0) 
0.109† 
Skull base tumour 18 (50) 7 (44) 0.677 
Tumour laterality Right: 15 (42) 
Left: 15 (42) 
Midline: 6 (17) 
Right: 6 (40) 
Left: 7 (47) 
Midline: 2 (13) 
1.000† 
Multiple meningiomas 2 (5) 2 (12) 0.582† 
Incidental 
meningioma 
5 (14) 17 (100) 0.000 
Number of 
medications (median) 
3.0 (27.6*) 3.0 (27.3*) 0.955 
Current AEDs 
(median) 
0.0 (29.1*) 0.0 (24.0*) 0.101 
Baseline Performance 
Status (ECOG) 
0: 8 (24) 
1: 16 (48) 
2: 8 (24) 
3: 1 (3) 
0: 9 (53) 
1: 6 (35) 
2: 2 (12) 
3: 0 (0) 
0.042 
ACCI 0: 2 (5) 
1: 4 (11) 
2: 9 (24) 
3: 8 (22) 
4: 8 (22) 
5: 1 (3) 
6: 3 (8) 
7: 2 (5) 
0: 0 (0) 
1: 1 (6) 
2: 3 (18) 
3: 6 (35) 
4: 1 (6) 
5: 3 (18) 
6: 2 (12) 
7: 1 (6) 
0.259 
Initial management Active monitoring: 8 (22) 
Surgery: 29 (78) 
Active monitoring: 17 (100) 




Table 3.11: Comparison of demographic, clinical and treatment variables between patients 
treated with an intervention compared to followed with active monitoring alone (continued) 
Variable Intervention Active monitoring p 
Progression since 
diagnosis 
9 (24) 0 (0) 0.044† 
Highest education 
level 
No education: 8 (22) 
GCSE: 13 (35) 
A-Levels: 10 (27) 
Undergraduate: 2 (5) 
Master’s degrees: 4 (11) 
No education: 1 (6) 
GCSE: 9 (53) 
A-Levels: 3 (18)  
Undergraduate: 3 (18) 
Master’s degrees: 1 (6) 
0.572 
Employment status Retired: 19 (51) 
Part-time employment: 5 (14) 
Full-time employment: 4 (11) 
Self-employed: 4 (11) 
Unable to work due to health: 
4 (11) 
Homemaker: 1 (3) 
Retired: 13 (76) 
Part-time employment: 2 
(12) 
Full-time employment: 2 
(12) 
Self-employed: 0 (0) 
Unable to work due to 
health: 0 (0) 
Homemaker: 0 (0) 
0.482† 
Current driving status 22 (59) 9 (53) 0.653 
COVID-19 response 20 (54) 11 (65) 0.462 
* Mean rank 
† Fisher’s Exact Test 
All results in Table 3.11 are reported as frequency and percentages: n (%) unless stated otherwise. 
 
3.4.6.2 HRQoL  
 
Table 3.12 shows the comparison of HRQoL scores between meningioma 
patients treated with intervention or followed-up with active monitoring alone. 
A number of domains across SF-36, QLQ-C30 and QLQ-BN20 were impaired in 
patients treated with intervention. Patients receiving intervention scored lower, 
indicating impairment, in the following SF-36 domains: Role Physical (mean 
rank 23.6 vs 34.3, U=429.5 Z= 2.57 p=0.010), Energy and Fatigue (mean rank 23.4 
vs 34.6, U=435.0 Z=2.47 p=0.014), Emotional Wellbeing, (mean rank 24.5 vs 32.3, 
U=396.5 Z=1.73 p=0.083), Social Functioning (75.0 vs 100.0, U=418.0 Z=2.06 
p=0.039) and Pain (mean rank 24.6 vs 33.8, U=422.0 Z=2.02 p=0.043). 
 
Patients receiving intervention had impaired scores compared to those followed 
with active monitoring alone in the following QLQ-C30 domains: Summary 
Score (80.7 vs 92.1, U=436.0 Z=2.26 p=0.024), Social Functioning (83.3 vs 100.0, 
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U=411.0 Z= 2.00 p=0.045), Fatigue (33.3 vs 11.1, U=199.5 Z=-2.173 p=0.030), 
Cognitive Functioning (mean rank 25.0 vs 33.0, U= 407.5 Z= 1.78 p=0.076) and 
Pain (mean rank 30.5 vs 20.9, U=203.0 Z=-2.15 p=0.032). In the QLQ-BN20, 
impairments were identified in the domains of Communication Deficit (11.1 vs 
0.0, U=212.0 Z=-2.09 p=0.037) and Drowsiness (mean rank 30.6 vs 20.8, U= 




Table 3.14: Comparison of HRQoL scores between patients receiving an intervention or active 








n = 17 
U Z p 
SF-36 Physical Functioning 85.0 85.0 331.5 0.32 0.750 
SF-36 Role Physical 50.0 (23.6*) 100.0 (34.3*) 429.5 2.57 0.010 
SF-36 Role Emotional 100.0 100.0 368.0 1.53 0.126 
SF-36 Energy/ Fatigue 52.5 (23.4*) 70.0 (34.6*) 435.0 2.47 0.014 
SF-36 Emotional Wellbeing 76.0 (24.5*) 84.0 (32.3*) 396.5 1.73 0.083 
SF-36 Social Functioning 75.0 100.0 418.0 2.06 0.039 
SF-36 Pain 67.5 (24.6*) 80.0 (33.8*) 422.0 2.02 0.043 
SF-36 General Health 50.0 65.0 358.5 0.82 0.411 
QLQ-C30 Summary Score 80.7 92.1 436.0 2.26 0.024 
QLQ-C30 Physical Functioning 86.7 93.3 359.5 0.85 0.393 
QLQ-C30 Role Functioning 100.0 100.0 363.0 1.01 0.314 
QLQ-C30 Emotional Functioning 75.0 91.7 
400.5 1.63 0.103 
QLQ-C30 Cognitive Functioning 66.7 (25.0*) 100.0 (33.0*) 407.5 1.78 0.076 
QLQ-C30 Social Functioning 83.3 100.0 411.0 2.00 0.045 
QLQ-C30 Fatigue 33.3 11.1 199.5 -2.17 0.030 
QLQ-C30 Nausea & Vomiting 0.0 0.0 372.0 1.58 0.113 
QLQ-C30 Pain 33.0 (30.5*) 0.0 (20.9*) 203.0 -2.15 0.032 
QLQ-C30 Dyspnoea 0.0 0.0 337.0 0.62 0.535 
QLQ-C30 Insomnia 33.3 (29.5*) 0.0 (23.1*) 240.0 -1.47 0.142 
QLQ-C30 Appetite Loss 0.0 (28.2*) 0.0 (25.9*) 287.5 -0.74 0.457 
QLQ-C30 Constipation 0.0 (26.2*) 0.0 (30.3*) 361.5 1.15 0.250 
QLQ-C30 Diarrhoea 0.0 (27.9*) 0.0 (26.7*) 301.0 -0.50 0.617 
QLQ-C30 Financial Difficulties 0.0 0.0 280.5 -1.09 0.278 
QLQ-C30 Global Health Status 75.0 66.7 342.0 0.52 0.602 
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Table 3.15: Comparison of HRQoL scores between patients receiving an intervention or active 








n = 17 
U Z p 
BN20 Future Uncertainty 25.0 8.3 232.5 -1.55 0.121 
BN20 Visual Disorder 0.0 0.0 320.5 0.12 0.901 
BN20 Motor Dysfunction 11.1 0.0 255.0 -1.18 0.240 
BN20 Communication Deficit 11.1 0.0 212.0 -2.09 0.037 
BN20 Headaches 33.3 0.0 249.5 -1.35 0.176 
BN20 Seizures 0.0 (28.2*) 0.0 (26.0*) 289.0 -1.20 0.232 
BN20 Drowsiness 33.3 (30.6*) 0.0 (20.8*) 200.5 -2.32 0.020 
BN20 Hair Loss 0.0 0.0 311.0 -0.11 0.911 
BN20 Itchy Skin 0.0 0.0 260.5 -1.49 0.137 
BN20 Weakness of Legs 0.0 0.0 292.0 -0.58 0.564 
BN20 Bladder Control 0.0 0.0 283.5 -0.72 0.472 
* Mean rank. Statistically significant (p<0.05) results highlighted in bold. 
 
3.4.7 Skull base meningiomas 
 
HRQoL scores of patients who have skull base meningiomas were compared to 
patients who have non-skull base meningiomas. HRQoL scores in the groups 
were not normally distributed as assessed by the Shapiro-Wilk test (p values < 
0.05). Individual group sizes were small. A number of domains had outliers. The 
most appropriate test for comparing the HRQoL scores of the groups was by 
using the non-parametric Mann-Whitney-U test.  
 
3.4.7.1 Group demographics 
 
Table 3.13 shows the characteristics of patients with skull base compared to non-
skull base meningiomas. The two groups had similar characteristics. However, 
the two groups differed in the proportion of WHO Grade I and II meningiomas 
(p=0.039). Skull base meningiomas were less likely to have been completely 
resected (47% vs 78%, p=0.060).  
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Table 3.16: Comparison of demographic, clinical and treatment variables between patients with 
skull base and non-skull base meningioma 
Variable Skull base Non-skull base p 
Sample size* (n=52) 25 27 n/a 
Median age at 
completion of 
questionnaires 
67.6 (24.9*) 68.3 (28.0*) 0.469 
Median years since 
diagnosis 
9.9 (24.0*) 9.3 (23.1*) 0.826 
Female  18 (72) 23 (85) 0.245 
WHO Grade  I: 18 (100) 
II: 0 (0) 
I: 12 (75) 
II: 4 (25) 
0.039† 
Tumour location Convexity: 0 (0) 
Anterior midline: 11 (46) 
Sphenoid wing: 8 (33) 
Parasagittal: 0 (0) 
Posterior fossa- lateral and 
posterior: 4 (17) 
Parafalcine: 0 (0) 
Posterior fossa- midline: 1 (4) 
Pineal: 0 (0) 
Tentorial: 0 (0) 
Convexity: 17 (63) 
Anterior midline: 0 (0) 
Sphenoid wing: 0 (0) 
Parasagittal: 5 (19) 
Posterior fossa- lateral and 
posterior: 0 (0) 
Parafalcine: 3 (11) 
Posterior fossa- midline: 0 (0) 
Pineal: 1 (4) 
Tentorial: 1 (4) 
 
0.000† 
Tumour laterality Right: 8 (32) 
Left: 10 (40) 
Midline: 7 (28) 
Right: 13 (50) 
Left: 12 (46) 
Midline: 1 (4) 
0.057† 
Multiple meningiomas 1 (4) 1 (4) 1.000† 
Incidental 
meningioma 
8 (32) 13 (48) 0.236 
Number of 
medications 
2.0 (27.8*) 3.0 (25.3*) 0.535 
Current AEDs 0.0 (29.2*) 0.0 (24.0*) 0.058 
Baseline Performance 
Status (ECOG) 
0: 9 (39) 
1: 10 (43) 
2: 4 (17) 
3: 0 (0) 
0: 7 (28) 
1: 12 (48) 
2: 5 (20) 
3: 1 (4) 
0.374 
ACCI 0: 1 (4) 
1: 3 (12) 
2: 5 (20) 
3: 7 (28) 
4: 4 (16) 
5: 1 (4) 
6: 3 (12) 
7: 1 (4) 
0: 0 (0) 
1: 2 (7) 
2: 6 (22) 
3: 7 (26)  
4: 5 (19) 
5: 3 (11) 
6: 2 (7) 
7: 2 (7) 
0.461 
Initial management Active monitoring: 11 (44) 
Surgery: 14 (56) 
Active monitoring: 13 (48) 
Surgery: 14 (52) 
0.764 
Intervention 18 (72) 18 (67) 0.677 
If operated, GTR 8 (47) 14 (78) 0.060 
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Table 3.13: Comparison of demographic, clinical and treatment variables between patients with 
skull base and non-skull base meningioma (continued) 
Variable Skull base Non-skull base p 
Progression since 
diagnosis 






No education: 1 (4) 
GCSE: 13 (52) 
A-Levels: 7 (28)  
Undergraduate: 2 (8) 
Master’s degrees: 2 (8) 
No education: 8 (30) 
GCSE: 8 (30)  
A-Levels: 6 (22)   
Undergraduate: 2 (7) 
Master’s degrees: 3 (11) 
0.314 
Employment status Retired: 16 (64) 
Part-time employment: 3 (12) 
Full-time employment: 3 (12) 
Self-employed: 1 (4) 
Unable to work due to health: 
2 (8) 
Homemaker: 0 (0) 
Retired: 16 (59) 
Part-time employment: 3 (11) 
Full-time employment: 3 (11) 
Self-employed: 2 (7) 
Unable to work due to health: 
2 (7) 
Homemaker: 1 (4) 
1.000† 
Current driving status 15 (60) 14 (52) 0.554 
COVID-19 response 14 (56) 16 (59) 0.812 
* Mean rank 
† Fisher’s Exact Test 
All results in Table 3.13 are reported as frequency and percentages: n (%) unless stated otherwise. 
 
3.4.7.2 HRQoL  
 
Table 3.14 shows the comparison of HRQoL scores between patients with skull 
base and non-skull base meningiomas. HRQoL scores between patients with 
skull base and non-skull base meningiomas were similar. However, patients 
with skull base meningiomas were found to have higher SF-36 Role Physical 
scores (mean rank 30.1 vs 22.3, U=225.0 Z=-2.04 p=0.041) and Social Functioning 
scores (100.0 vs 75.0, U=234.5 Z=-2.02 p=0.043). However, patients with skull 
base meningiomas had impaired QLQ-BN20 Visual Disorder domain scores 
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n = 25 
Non-skull-base 
 (median) 
n = 27 
U Z p 
SF-36 Physical 
Functioning 85.0 75.0 
250.0 -1.62 0.106 
SF-36 Role Physical 100.0 (30.1*) 50.0 (22.3*) 225.0 -2.04 0.041 
SF-36 Role Emotional 100.0 100.0 257.5 -1.61 0.108 
SF-36 Energy/ Fatigue 63.3 (27.4*) 55.0 (24.7) 290.0 -0.64 0.520 
SF-36 Emotional 
Wellbeing 80.0 80.0 
300.0 -0.45 0.650 
SF-36 Social Functioning 100.0 75.0 234.5 -2.02 0.043 
SF-36 Pain 77.5 (29.2*) 57.5 (24.0*) 269.5 -1.26 0.209 
SF-36 General Health 55.0 (28.4*) 55.0 (24.8*) 291.0 -0.86 0.393 
QLQ-C30 Summary 
Score 89.7 (28.4*) 84.3 (24.8*) 
290.5 -0.86 0.389 
QLQ-C30 Physical 
Functioning 93.3 (29.5*) 86.7 (23.7*) 
262.5 -1.40 0.162 
QLQ-C30 Role 
Functioning 100.0 100.0 
279.5 -1.19 0.236 
QLQ-C30 Emotional 
Functioning 83.3 83.3 
336.0 -0.03 0.978 
QLQ-C30 Cognitive 
Functioning 83.3 (25.6*) 83.3 (27.4*) 
361.0 0.44 0.659 
QLQ-C30 Social 
Functioning 100.0 100.0 
318.5 -0.39 0.698 
QLQ-C30 Fatigue 22.2 (25.4*) 22.2 (27.5*) 364.0 0.49 0.623 
QLQ-C30 Nausea & 
Vomiting 0.0 0.0 
334.0 -0.09 0.926 
QLQ-C30 Pain 
 16.7 (25.2*) 33.3 (27.7*) 
370.0 0.61 0.539 
QLQ-C30 Dyspnoea 
 0.0 0.0 
383.5 1.23 0.219 
QLQ-C30 Insomnia 
 33.3 (26.7*) 33.3 (26.4*) 
333.5 -0.08 0.938 
QLQ-C30 Appetite Loss 
 0.0 0.0 
352.5 0.40 0.689 
QLQ-C30 Constipation 
 0.0 0.0 
359.5 0.52 0.601 
QLQ-C30 Diarrhoea 
 0.0 0.0 
346.5 0.32 0.747 
QLQ-C30 Financial 
Difficulties 0.0 0.0 
320.5 -0.53 0.599 
QLQ-C30 Global Health 
Status 83.3 66.7 
271.0 -1.24 0.215 
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n = 25 
Non-skull-base 
 (median) 
n = 27 
U Z p 
BN20 Future 
Uncertainty 16.7 25.0.7 
373.0 0.66 0.509 
BN20 Visual Disorder  11.1 (31.2*) 0.0 (22.2*) 220.5 -2.36 0.018 
BN20 Motor 
Dysfunction 11.1  11.1  
332.0 -0.11 0.915 
BN20 Communication 
Deficit  11.1 (27.5*) 0.0 (25.6*) 
313.5 -0.48 0.634 
BN20 Headaches 0.0 0.0 376.5 0.80 0.424 
BN20 Seizures 0.0 0.0 322.5 -0.68 0.497 
BN20 Drowsiness 0.0 0.0 332.0 -0.11 0.912 
BN20 Hair Loss 0.0 0.0 334.0 -0.12 0.908 
BN20 Itchy Skin 0.0 0.0 282.5 -1.47 0.142 
BN20 Weakness of Legs 0.0 0.0 275.5 -1.54 0.123 
BN20 Bladder Control 0.0 0.0 343.5 0.14 0.890 
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3.4.8 COVID-19 
 
A post-hoc analysis was completed to assess the association of COVID-19 with 
HRQoL in patients with meningioma. HRQoL scores of patients who responded 
during the COVID-19 lockdown period were compared to patients had 
responded prior (at clinic appointments). HRQoL scores in the groups were not 
normally distributed as assessed by the Shapiro-Wilk test (p values < 0.05). 
Individual group sizes were small. A number of domains had outliers. The most 
appropriate test for comparing the HRQoL scores of the groups was by using 
the non-parametric Mann-Whitney-U test.  
 
3.4.8.1 Group demographics 
 
Table 3.15 shows the characteristics of patients responding during COVID-19 
compared to before COVID-19. Patients responding during COVID-19 
lockdown were older (median age 72.3 vs 61.4, mean rank 32.9 vs 20.2, p=0.003) 
and had a higher age-adjusted Charlson Comorbidity Index (ACCI) (p=0.005)8. 
The two groups differed in their tumour laterality (p = 0.031) and their initial 
management (p=0.044). COVID-19 respondents were less likely to have 
experienced progression since diagnosis (6% vs 30%, p=0.028). The two groups 












8 A higher ACCI indicates a higher number of comorbid conditions 
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Table 3.19: Comparison of demographic, clinical and treatment variables between patients 






Sample size (n=54) 31 23 n/a 
Median age at 
completion of 
questionnaires 
72.3 (32.9*) 61.4 (20.2*) 0.003 
Median years since 
diagnosis 
9.8 (25.0*) 10.0 (23.7*) 0.760 
Female  27 (87) 16 (70) 0.173† 
WHO Grade  I: 19 (95) 
II: 1 (5) 
I: 12 (80) 
II: 3 (20) 
0.292† 
Tumour location Convexity: 11 (37) 
Anterior midline: 8 (27) 
Sphenoid wing: 5 (17) 
Parasagittal: 3 (10) 
Posterior fossa- lateral and 
posterior: 1 (3) 
Parafalcine: 1 (3) 
Posterior fossa- midline: 0 
(0) 
Pineal: 1 (3) 
Tentorial: 0 (0) 
Convexity: 6 (29) 
Anterior midline: 3 (14) 
Sphenoid wing: 3 (14) 
Parasagittal: 2 (10) 
Posterior fossa- lateral and 
posterior: 3 (14) 
Parafalcine: 2 (10) 
Posterior fossa- midline: 1 
(5) 
Pineal: 0 (0) 
Tentorial: 1 (5) 
0.550† 
Skull base tumour 14 (47) 11 (50) 0.812 
Tumour laterality Right: 16 (55) 
Left: 8 (28) 
Midline: 5 (17) 
Right: 5 (23) 
Left: 14 (64) 
Midline: 3 (14) 
0.031† 
Multiple meningioma 2 (6) 2 (9) 1.000† 
Incidental meningioma 15 (48) 7 (30) 0.184 
Number of medications 3.0 (28.2*) 2.0 (26.5*) 0.684 
Number of AEDs 0.0 (25.8*) 0.0 (29.8*) 0.170 
Baseline Performance 
Status (ECOG) 
0: 12 (39) 
1: 12 (39) 
2: 6 (19) 
3: 1 (3) 
0: 5 (26) 
1: 10 (53) 
2: 4 (21) 
3: 0 (0) 
0.614 
ACCI 0: 1 (3) 
1: 1 (3) 
2: 5 (16) 
3: 8 (26)  
4: 5 (16) 
5: 4 (13) 
6: 4 (13) 
7: 3 (10) 
0: 1 (4)  
1: 4 (17) 
2: 7 (30)  
3: 6 (26)  
4: 4 (17) 
5: 0 (0) 
6: 1 (4)  
7: 0 (0) 
0.005 
Initial management Active monitoring: 18 (58) 
Surgery: 13 (42) 
Active monitoring: 7 (30) 
Surgery: 16 (70) 
0.044 
Intervention 20 (65) 17 (74) 0.462 
If operated, GTR 15 (75) 7 (44) 0.056 
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Table 3.15: Comparison of demographic, clinical and treatment variables between patients 






Progression since diagnosis 2 (6) 7 (30) 0.028† 
Highest education level No education: 6 (19)  
GCSE: 13 (42) 
A-Levels: 6 (19)   
Undergraduate: 3 (10) 
Master’s degrees: 3 
(10) 
No education: 3 (13) 
GCSE: 9 (39) 
A-Levels: 7 (30) 
Undergraduate: 2 (9) 
Master’s degrees: 2 (9) 
0.570 
Employment status Retired: 22 (71) 
Part-time 
employment: 5 (16) 
Full-time 
employment: 1 (3) 
Self-employed: 0 (0) 
Unable to work due to 
health: 2 (6) 
Homemaker: 1 (3) 
Retired: 10 (43) 
Part-time employment: 2 
(9) 
Full-time employment: 5 
(22) 
Self-employed: 4 (17) 
Unable to work due to 
health: 2 (9) 
Homemaker: 0 (0) 
0.015† 
Current driving status 14 (45) 17 (74) 0.035 
* Mean rank 
† Fisher’s Exact Test 
All results in Table 3.15 are reported as frequency and percentages: n (%) unless stated otherwise. 
 
3.4.8.2 HRQoL  
 
SF-36 Physical Functioning scores were significantly lower in patients 
responding during COVID-19 lockdown (mean rank 23.8 vs 32.5, U= 471.0 Z= 2.02 
p=0.044). A similar finding was also observed in the QLQ-C30 Physical 
Functioning scale (86.7 vs 93.3, U=514.5 Z=2.81 p=0.005). All other HRQoL 
















n = 31 
Pre-COVID-19 
(median) 
n = 23 
U Z p 
SF-36 Physical Functioning 75.0 (23.8*) 85.0 (32.5*) 471.0 2.02 0.044 
SF-36 Role Physical 75.0 (25.3*) 100.0 (29.4*) 394.0 1.04 0.297 
SF-36 Role Emotional 100.0 (24.6*) 100.0 (30.4*) 416.0 1.76 0.079 
SF-36 Energy/ Fatigue 60.0 (28.0*) 57.5 (25.6*) 309.0 -0.58 0.562 
SF-36 Emotional Wellbeing 80.0 (27.0*) 78.0 (27.1*) 342.0 0.02 0.986 
SF-36 Social Functioning 100.0 87.5 381.5 0.47 0.640 
SF-36 Pain 67.5 77.5 402.0 0.80 0.422 
SF-36 General Health 55.0 55.0 373.0 0.29 0.772 
QLQ-C30 Summary Score 85.7 88.7 392.5 0.63 0.529 
QLQ-C30 Physical Functioning 86.7 93.3 514.5 2.81 0.005 
QLQ-C30 Role Functioning 100.0 100.0 423.5 1.31 0.192 
QLQ-C30 Emotional Functioning 83.3 (27.1*) 75.0 (28.1*) 369.5 0.231 0.817 
QLQ-C30 Cognitive Functioning 83.3 (29.3*) 66.7 (25.1*) 300.5 -1.01 0.315 
QLQ-C30 Social Functioning 100.0 100.0 372.5 0.31 0.755 
QLQ-C30 Fatigue 22.2 22.2 309.5 -0.83 0.404 
QLQ-C30 Nausea & Vomiting 0.0 0.0 378.0 0.56 0.578 
QLQ-C30 Pain 33.3 (30.2*) 16.7 (23.9*) 272.5 -1.52 0.129 
QLQ-C30 Dyspnoea 0.0 0.0 292.5 -1.66 0.098 
QLQ-C30 Insomnia 33.3 (27.7*) 33.3 (27.2*) 349.0 -0.14 0.890 
QLQ-C30 Appetite Loss 0.0 0.0 353.0 -0.09 0.928 
QLQ-C30 Constipation 0.0 0.0 361.5 0.12 0.909 
QLQ-C30 Diarrhoea 0.0 0.0 352.0 -0.16 0.876 
QLQ-C30 Financial Difficulties 0.0 0.0 388.5 0.96 0.337 
QLQ-C30 Global Health Status 66.7 83.3 428.0 1.28 0.202 
BN20 Future Uncertainty 16.7 16.7 341.0 -0.28 0.783 
BN20 Visual Disorder 0.0 0.0 341.0 -0.30 0.763 
BN20 Motor Dysfunction 11.1 0.0 304.0 -0.97 0.330 
BN20 Communication Deficit 0.0 0.0 381.0 0.47 0.639 
BN20 Headaches 0.0 33.3 437.5 1.58 0.114 
BN20 Seizures 0.0 0.0 376.5 0.88 0.378 
BN20 Drowsiness 0.0 33.3 405.5 0.94 0.349 
BN20 Hair Loss 0.0 0.0 409.0 1.58 0.115 
BN20 Itchy Skin 0.0 0.0 351.5 -0.13 0.897 
BN20 Weakness of Legs 0.0 0.0 298.0 -1.41 0.159 
BN20 Bladder Control 0.0 0.0 286.5 -1.53 0.127 
* Mean rank. Statistically significant (p<0.05) results highlighted in bold. 
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3.5 Discussion 
 
The aim of the QUALMS study was to identify the physical, cognitive and 
psychosocial quality of life outcomes of patients with meningioma. This study 
identified long-term HRQoL outcomes an average of ten years after diagnosis. 
The QUALMS study is the first to specifically assess HRQoL in patients with 
incidental meningioma and compare patients managed with intervention to 
active monitoring alone. A total of 54 patients were included in this exploratory 
analysis.  
 
In comparison to normative population values, meningioma patients reported 
impairments in the domains of Physical Functioning, Role Physical, General 
Health and Cognitive Functioning. Similarly, impairments of Physical 
Functioning, Role Physical and General Health have been reported in two 
previous studies assessing HRQoL of meningioma patients with SF-36 on 
average 3.4 and 4.9 years after treatment (238, 241). 
 
This study highlights that patients have do have long-term HRQoL issues 
persisting many years after initial diagnosis. Issues relating to physical health 
problems are most evident.  However, this study showed that many other 
domains encompassing self-reported emotional wellbeing and social 
functioning were comparable to normative values. Previous studies have 
highlighted that impairments within these domains are prevalent early after 
diagnosis and treatment (245, 250). However, this study found that these issues 
are less reported as the time since diagnosis increases. A potential reason for 
this is the phenomenon of ‘response shift’ which is defined as a change in the 
meaning of one’s self-evaluation of the target construct QOL (307). Initially, 
after diagnosis and treatment, a number of limitations may affect one’s quality 
of life, but over time patients may re-evaluate what they consider normal. 
Therefore, issues which were initially considered problematic become less so 




Overall, patients diagnosed with incidental meningioma reported better 
HRQoL scores in the domains of Communication Deficit, Cognitive 
Functioning and Fatigue compared to patients with a non-incidental 
meningioma. Furthermore, the QLQ-C30 summary scores were higher, 
indicating better HRQoL in patients with incidental meningioma. Patients in 
the incidental meningioma cohort had overall a lower baseline ECOG 
performance status and were less likely to have had an intervention and or 
experienced tumour progression. Previous studies have shown that patients 
treated with surgery experience cognitive deficits and have a high prevalence of 
fatigue (87, 247). Therefore, it may be hypothesised that patients with incidental 
meningioma, who tend to follow a course of active monitoring alone, may have 
better HRQoL scores because they are less likely experience the morbidity 
associated with the treatment of meningioma. 
   
In a comparison of patients treated with intervention and those followed by 
active monitoring alone, the intervention cohort reported impaired HRQoL 
scores. The intervention cohort reported inferior scores in Role Physical, Energy 
and Fatigue, Emotional Wellbeing, Social Functioning, Pain, Cognitive 
Functioning, Communication Deficit and Drowsiness. Specifically, the domains 
relating to Fatigue, Social Functioning and Pain were found to be impaired 
across multiple questionnaires. The QLQ-C30 summary score was lower in 
patients receiving an intervention. These results suggest that patients managed 
with intervention experience lower long-term HRQoL.  
 
However, a causal relationship between intervention and HRQoL scores cannot 
be inferred from this study. Patients receiving intervention are more likely to 
have a health burden which would lower their quality of life. For example, the 
patients in this study who received an intervention were more likely to have a 
higher baseline ECOG performance status, which may have predisposed them 
to inferior long-term HRQoL outcomes. Future analyses could statistically 
adjust for this potential confounding.  
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A post-hoc analysis was completed to investigate the impact of COVID-19 on 
HRQoL in patients with meningioma. Patients responding during COVID-19 
lockdown had similar HRQoL outcomes to those who had responded before the 
COVID-19 lockdown. Lower Physical Functioning scores were reported by 
patients responding during COVID-19 lockdown; however, these patients were 
older and had a higher ACCI. Notably, COVID-19 lockdown was not associated 
with poorer Social Functioning, Emotional Wellbeing of Future Uncertainty 
scale scores. It may be hypothesised that since COVID-19 lockdown placed 
limitations on travel and interaction with others, patients may have felt isolated 
or had increased anxiety. However, early results from the QUALMS study seems 
to indicate that this was not the case, and patients had similar HRQoL during 
COVID-19 compared to before.   
 
3.5.1 Choice of HRQoL tools 
 
SF-36 was chosen as it is the most popular HRQoL tool used in the meningioma 
literature, which allows for the comparison of this study’s results to previous 
studies. Suitable alternatives to SF-36 include the EuroQoL 5-Dimensions 5-
Levels (EQ-5D-5L) survey, Nottingham Health Profile (NHP) and Questions on 
Life Satisfaction Survey. The QLQ-C30 was chosen because it assesses a range 
of domains and items which are relevant to patients diagnosed and treated for 
cancer.  A suitable alternative is the FACT-G; however, the QLQ-C30 was 
chosen because, by comparison, it covers a wider range of issues. Luckett et al. 
have published a decision algorithm to help researchers to decide whether to 
use QLQ-C30 or FACT-G (308). The Anterior Skull Base Questionnaire (ABSQ) 
is another cancer-specific tool but was not chosen as it assesses issues arising 
from anterior skull base tumours only. The QLQ-BN20 was chosen as it assesses 
issues relevant to patients with a brain tumour. The FACT-BR is a suitable 
alternative, however the QLQ-BN20 was considered more appropriate as the 




However, the results of the preliminary analysis of the meningioma cohort 
(Table 3.8) show limited impairments across a number of symptom items (e.g. 
dyspnoea, appetite loss, constipation, hair loss, itchy skin) on the QLQ-C30 and 
BN20. Indeed, items such as these are more relevant to patients with cancer, 
whose disease and treatment may lead to the onset of systemic symptoms. It is 
not expected that many meningioma patients would suffer these particular 
symptoms as a result of their condition or treatment. Therefore, the content 
validity of these particular questionnaires to meningioma patients is uncertain. 
In retrospect, this study could have utilised (and perhaps validated) the FACT-
MNG, therefore presenting items of potentially greater relevance to 
meningioma patients.  
 
3.5.2 Strengths and Limitations 
 
This is the first study to specifically investigate the long-term HRQoL outcomes 
of patients with incidental meningiomas, and to compare outcomes of patients 
who received an intervention with those managed with active monitoring alone. 
A combination of general, cancer-specific and brain tumour-specific tools was 
used to identify issues affecting the lives of patients with meningioma (see 
Discussion – Choice of HRQoL tools).  The inclusion criteria were broad; 
patients with incidental and/or operated meningiomas of any WHO Grade were 
eligible to participate. 
 
However, a meningioma-specific tool was not used to assess patients. This is 
because none have been clinically validated for use. No pre-treatment or 
baseline HRQoL scores are available, and so it is not possible to determine 
causality between variables and HRQoL scores. No healthy controls were 
sampled in this study, and so comparisons to the general population were made 
using normative population values. However, these values are not matched for 
age, sex, geography or education level when making comparisons to patient 
responses in the QUALMS study. It was identified after the completion of this 
chapter that there is a British and American version of the SF-36 questionnaire. 
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The QUALMS study used the American version of the questionnaire, but 
compared results to the Welsh normative population data, which seem to have 
been assessed using the British version of the questionnaire (303). Future 
analyses will attempt to rectify this issue. 
 
As this study is from a single centre in the North-West of England, it is not 
possible to confidently generalise the study findings to all meningioma patients 
in different countries. There is a risk of responder bias, as the participants who 
responded may be more cognitively able and have a higher HRQoL; those who 
are the most unwell are unlikely to participate.   
 
Moreover, patients contacted by post and those attending clinic would be able 
to discuss their responses with friends and family. Therefore, there is a risk that 
some proxy-reported outcomes may have been provided. This is the case for up 
to three patients that completed the questionnaires at clinic appointments. 
However, this is an unavoidable limitation of the sampling strategy. Finally, this 
exploratory analysis contained a small sample size and data was not normally 
distributed. Therefore, it was not possible to adjust for confounders using 
regression analyses and to isolate variables with the greatest effect on HRQoL.   
 
This chapter details a preliminary analysis of the responses to the QUALMS 
study. At the point of analysis, the postal response rate was only 4%. Therefore 
the generalisability of the results to the wider meningioma population is 
questionable. The final analysis of QUALMS responses will incorporate a larger 
number of postal responses, and the response rate is anticipated to be in the 
region of 25-35%. There is also a potential bias in that the patients who were 
approached at clinic appointments may have been more likely to have on-going 
issues relating to their care, which may impact on their HRQoL responses. To 
address this concern, the final analysis of QUALMS will include a comparison 
of clinical and demographic details of the responders and non-responders. This 
will allow readers to make an assessment of the representativeness of the 
responder cohort and therefore the generalisability of the QUALMS study 
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results. If confounders are identified, the final analysis will attempt to adjust for 
these.  
 
A proportion of participants who returned the completed questionnaires during 
COVID-19 interpreted and answered some questions (e.g. related to social 
functioning) in different ways. For example, some patients wrote on their 
questionnaires about how their social functioning was normal usually, but 
currently limited due to the COVID-19 lockdown. Other patients chose to 
answer these questions not considering the impact of COVID-19. Therefore, 
there were differences of interpretation of selected questions due to the effect 
of the COVID-19 lockdown.  
 
Finally, the pre-COVID-19 responder cohort are patients who responded at 
clinic appointments, and the COVID-19 responder cohort are patients who 
responded by post. Therefore, it is to be noted that the methods of collecting 
the HRQoL results for these two cohorts were different. The difference in the 
response collection may impact the HRQoL results. This is a limitation of the 
study. However, the questionnaires were self-administered in both methods of 





The results of this exploratory analysis suggest that patients with meningioma 
experience long-term HRQoL issues many years after diagnosis. However, 
patients with incidental meningiomas and patients who are managed with 
active monitoring alone are more likely to have better HRQoL outcomes. 
Patients are still being recruited to the study, and future analyses will aim to 
further characterise the nature and magnitude of HRQoL impairments in 
patients with meningioma.   
 
 
















































Chapter 4: Conclusion 
 
Meningiomas are a common intracranial tumour, and their management 
constitutes a large proportion of neuro-oncology clinical practice. The majority 
of sporadic meningiomas are diagnosed in women, and their incidence 
increases with age. Incidental meningiomas are usually managed with active 
monitoring using MRI scans, and symptomatic meningiomas are typically 
treated with surgery or radiotherapy. Patients have good five- and ten-year 
survival outcomes. Patient-Reported Outcomes (PROs) allow the burden of 
disease and treatment to be evaluated through a patient’s perspective. PROs can 
be categorised into assessments of health-related quality of life (HRQoL), 
‘Patient-Reported Health Status’, ‘Patient-Reported Symptoms’, ‘Patient-
Reported Functioning’, ‘Patient-Reported Feelings’ or ‘Other PROs’. Over the 
last three decades, little research has been completed to investigate PROs of 
meningioma.  
 
A systematic review was conducted to identify studies assessing PROs of 
meningiomas. In total, thirty-three studies were identified. HRQoL was 
evaluated by 25 studies, which highlighted that patients have impairments 
across a number of physical and psychological domains. Symptoms and 
functioning were specifically assessed by nine and eight studies, respectively. 
Patients have elevated anxiety scores following diagnosis and treatment; 
however, these tend to improve over time. In a subset of patients, long-term 
anxiety and post-traumatic stress may remain. Meningioma patients were 
found to have reduced participation in activities, and employment levels 
decreased postoperatively. Patient-reported feelings were assessed by two 
studies, which showed that meningioma patients have increased benefit finding 
following their experiences. For young, female patients, the diagnosis of 
meningioma can impact birth desires.  
 
The systematic review shows that PROs extend beyond HRQoL, which has been 
the focus of meningioma PRO research in recent decades. Furthermore, the 
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diagnosis and treatment of meningiomas impact a range of PRO domains other 
than HRQoL. At present, no meningioma-specific tool has been validated for 
use in patients. The FACT-MNG tool is meningioma-specific but focusses only 
on HRQoL tool, and is currently unvalidated (210). Given the results of the 
systematic review, the Liverpool Neuro-Oncology Group will consider 
developing a meningioma-specific, holistic PRO assessment tool. The next step 
in developing this tool is to assess the methodological quality of the 27 PROMs 
identified in this study and to extract individual items for further evaluation.  
 
Furthermore, the systematic review highlights that long-term HRQoL of 
patients has not been evaluated thoroughly. Moreover, there is a lack of studies 
assessing the HRQoL of patients with incidental meningiomas or those treated 
with active monitoring alone. A cross-sectional research study (the QUALMS 
study) assessed HRQoL of patients with incidental and/or operated 
meningiomas. An initial exploratory analysis was completed of 54 patients who 
provided HRQoL outcomes on average ten years after diagnosis.  Compared to 
normative population values, meningioma patients reported impaired HRQoL 
scores in the domains of Physical Functioning, Role Physical, General Health 
and Cognitive Functioning. The domains related to emotional and social 
functioning were similar to normative values. Patients with incidental 
meningiomas and those followed-up with active monitoring alone reported 
better scores than patients with non-incidental meningioma or those who 
received treatment, respectively. However, the QUALMS study design 
precludes assessment of causality. The QUALMS study is currently recruiting 
patients, and a larger sample size will allow for adjustment of confounders to 
better evaluate associations. The Liverpool Neuro-Oncology Group is 




In conclusion, this thesis has investigated the patient-reported and quality of 
life outcomes in intracranial meningioma. Future research is being planned to 
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evaluate PROs further and to develop a meningioma-specific, holistic 





























 154  
References  
 
1. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS 
Statistical Report: Primary Brain and Other Central Nervous System Tumors 
Diagnosed in the United States in 2012–2016. Neuro-Oncology. 
2019;21(Supplement_5):v1-v100. 
2. Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, et al. 
Molecular and translational advances in meningiomas. Neuro-Oncology. 
2019;21(Supplement_1):i4-i17. 
3. Preusser M, Brastianos PK, Mawrin C. Advances in meningioma genetics: 
novel therapeutic opportunities. Nat Rev Neurol. 2018;14(2):106-15. 
4. Villanueva-Meyer JE, Mabray MC, Cha S. Current Clinical Brain Tumor 
Imaging. Neurosurgery. 2017;81(3):397-415. 
5. Badie B, Brooks N, Souweidane MM. Endoscopic and Minimally Invasive 
Microsurgical Approaches for Treating Brain Tumor Patients. Journal of Neuro-
Oncology. 2004;69(1):209-19. 
6. Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, et 
al. Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 
2019;21(Suppl 1):i18-i31. 
7. Plater F. Observationum in hominis affectibus plerisque, corpori et animo, 
functionum laesione, dolore, aliave, molestia et vitio incommodantibus, libri tres. 
Ludovici Konig. 1614. 
8. Bright R. Reports of medical cases, symptoms and morbid anatomy: 
Longman; 1831. 
9. Meyer L. Die Epithelsgranulationen der Arachnoidea. Virchows Arch. 
1859;17:209–27. 
10. Cushing H. THE MENINGIOMAS (DURAL ENDOTHELIOMAS): THEIR SOURCE, 
AND FAVOURED SEATS OF ORIGIN1. Brain. 1922;45(2):282-316. 
11. Okonkwo DO, Laws ER. Meningiomas: Historical Perspective. In: Lee JH, 
editor. Meningiomas. London: Springer London; 2009. p. 3-10. 
12. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. 
Journal of neuro-oncology. 2010;99(3):307-14. 
13. Meling TR, Da Broi M, Scheie D, Helseth E. Meningiomas: skull base versus 
non-skull base. Neurosurg Rev. 2019;42(1):163-73. 
14. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, et al. A genetic 
study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation 
rate, fitness, and confirmation of maternal transmission effect on severity. J Med 
Genet. 1992;29(12):841-6. 
15. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, et al. 
Neurofibromatosis type 2. Lancet. 2009;373(9679):1974-86. 
16. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. 
Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and 
clinical evidence for heterogeneity. Am J Med Genet. 1994;52(4):450-61. 
17. Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, et al. 
The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 
1996;38(5):880-5; discussion 5-6. 
 
 155 
18. Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 
neurofibromatosis. Arch Dis Child. 1999;81(6):496-9. 
19. Nunes F, MacCollin M. Neurofibromatosis 2 in the pediatric population. J 
Child Neurol. 2003;18(10):718-24. 
20. Antinheimo J, Haapasalo H, Haltia M, Tatagiba M, Thomas S, Brandis A, et al. 
Proliferation potential and histological features in neurofibromatosis 2-associated 
and sporadic meningiomas. J Neurosurg. 1997;87(4):610-4. 
21. Ron E, Modan B, Boice JD, Jr., Alfandary E, Stovall M, Chetrit A, et al. Tumors 
of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 
1988;319(16):1033-9. 
22. Shintani T, Hayakawa N, Hoshi M, Sumida M, Kurisu K, Oki S, et al. High 
incidence of meningioma among Hiroshima atomic bomb survivors. J Radiat Res. 
1999;40(1):49-57. 
23. Bowers DC, Nathan PC, Constine L, Woodman C, Bhatia S, Keller K, et al. 
Subsequent neoplasms of the CNS among survivors of childhood cancer: a 
systematic review. Lancet Oncol. 2013;14(8):e321-8. 
24. Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, 
et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood 
Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083-95. 
25. Cahan WG, Woodard HQ, et al. Sarcoma arising in irradiated bone; report of 
11 cases. Cancer. 1948;1(1):3-29. 
26. Yamanaka R, Hayano A, Kanayama T. Radiation-Induced Meningiomas: An 
Exhaustive Review of the Literature. World Neurosurg. 2017;97:635-44.e8. 
27. Al-Mefty O, Topsakal C, Pravdenkova S, Sawyer JR, Harrison MJ. Radiation-
induced meningiomas: clinical, pathological, cytokinetic, and cytogenetic 
characteristics. J Neurosurg. 2004;100(6):1002-13. 
28. Morgenstern PF, Shah K, Dunkel IJ, Reiner AS, Khakoo Y, Rosenblum MK, et 
al. Meningioma after radiotherapy for malignancy. J Clin Neurosci. 2016;30:93-7. 
29. Galloway TJ, Indelicato DJ, Amdur RJ, Swanson EL, Morris CG, Marcus RB. 
Favorable outcomes of pediatric patients treated with radiotherapy to the central 
nervous system who develop radiation-induced meningiomas. Int J Radiat Oncol 
Biol Phys. 2011;79(1):117-20. 
30. Sadetzki S, Flint-Richter P, Ben-Tal T, Nass D. Radiation-induced 
meningioma: a descriptive study of 253 cases. J Neurosurg. 2002;97(5):1078-82. 
31. Soffer D, Pittaluga S, Feiner M, Beller AJ. Intracranial meningiomas following 
low-dose irradiation to the head. J Neurosurg. 1983;59(6):1048-53. 
32. Group IS. Brain tumour risk in relation to mobile telephone use: results of 
the INTERPHONE international case-control study. Int J Epidemiol. 2010;39(3):675-
94. 
33. Mupparapu M, Baddam VRR, Lingamaneni KP, Singer SR. Dental x-ray 
exposure is not associated with risk of meningioma: a 2019 meta-analysis. 
Quintessence Int. 2019;50(10):822-9. 
34. Xu P, Luo H, Huang GL, Yin XH, Luo SY, Song JK. Exposure to ionizing 
radiation during dental X-rays is not associated with risk of developing meningioma: 
a meta-analysis based on seven case-control studies. PLoS One. 
2015;10(2):e0113210. 
 156  
35. Bickerstaff ER, Small JM, Guest IA. The relapsing course of certain 
meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg 
Psychiatry. 1958;21(2):89-91. 
36. Kerschbaumer J, Freyschlag CF, Stockhammer G, Taucher S, Maier H, Thomé 
C, et al. Hormone-dependent shrinkage of a sphenoid wing meningioma after 
pregnancy: case report. J Neurosurg. 2016;124(1):137-40. 
37. Michelsen JJ, New PF. Brain tumour and pregnancy. J Neurol Neurosurg 
Psychiatry. 1969;32(4):305-7. 
38. Cahill DW, Bashirelahi N, Solomon LW, Dalton T, Salcman M, Ducker TB. 
Estrogen and progesterone receptors in meningiomas. J Neurosurg. 
1984;60(5):985-93. 
39. Carroll RS, Glowacka D, Dashner K, Black PM. Progesterone receptor 
expression in meningiomas. Cancer Res. 1993;53(6):1312-6. 
40. Olson JJ, Beck DW, Schlechte J, Loh PM. Hormonal manipulation of 
meningiomas in vitro. J Neurosurg. 1986;65(1):99-107. 
41. Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T. Antitumor 
effects of antiprogesterones on human meningioma cells in vitro and in vivo. J 
Neurosurg. 1994;80(3):527-34. 
42. Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, et al. Double-
Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the 
Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol. 
2015;33(34):4093-8. 
43. Sharma R, Garg K, Katiyar V, Tandon V, Agarwal D, Singh M, et al. The role of 
mifepristone in the management of meningiomas: A systematic review of literature. 
Neurol India. 2019;67(3):698-705. 
44. Harland TA, Freeman JL, Davern M, McCracken DJ, Celano EC, Lillehei K, et 
al. Progesterone-only contraception is associated with a shorter progression-free 
survival in premenopausal women with WHO Grade I meningioma. J Neurooncol. 
2018;136(2):327-33. 
45. Qi ZY, Shao C, Huang YL, Hui GZ, Zhou YX, Wang Z. Reproductive and 
exogenous hormone factors in relation to risk of meningioma in women: a meta-
analysis. PLoS One. 2013;8(12):e83261. 
46. Fan ZX, Shen J, Wu YY, Yu H, Zhu Y, Zhan RY. Hormone replacement therapy 
and risk of meningioma in women: a meta-analysis. Cancer Causes Control. 
2013;24(8):1517-25. 
47. Raj R, Korja M, Koroknay-Pál P, Niemelä M. Multiple meningiomas in two 
male-to-female transsexual patients with hormone replacement therapy: A report 
of two cases and a brief literature review. Surg Neurol Int. 2018;9:109. 
48. Mancini I, Rotilio A, Coati I, Seracchioli R, Martelli V, Meriggiola MC. 
Presentation of a meningioma in a transwoman after nine years of cyproterone 
acetate and estradiol intake: case report and literature review. Gynecol Endocrinol. 
2018;34(6):456-9. 
49. Gonçalves AM, Page P, Domigo V, Méder JF, Oppenheim C. Abrupt 
regression of a meningioma after discontinuation of cyproterone treatment. AJNR 
Am J Neuroradiol. 2010;31(8):1504-5. 
50. Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of 
meningiomas. J Neurooncol. 2004;70(2):183-202. 
 
 157 
51. Bailey P, Bucy PC. The Origin and Nature of Meningeal Tumors. The 
American Journal of Cancer. 1931;15(1):15. 
52. Alahmadi H, Croul SE. Pathology and genetics of meningiomas. Semin Diagn 
Pathol. 2011;28(4):314-24. 
53. Lamszus K. Meningioma pathology, genetics, and biology. J Neuropathol Exp 
Neurol. 2004;63(4):275-86. 
54. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, 
Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of 
the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20. 
55. Berhouma M, Jacquesson T, Jouanneau E, Cotton F. Pathogenesis of peri-
tumoral edema in intracranial meningiomas. Neurosurg Rev. 2019;42(1):59-71. 
56. Englot DJ, Magill ST, Han SJ, Chang EF, Berger MS, McDermott MW. Seizures 
in supratentorial meningioma: a systematic review and meta-analysis. J Neurosurg. 
2016;124(6):1552-61. 
57. Baumgarten P, Sarlak M, Baumgarten G, Marquardt G, Seifert V, Strzelczyk 
A, et al. Focused review on seizures caused by meningiomas. Epilepsy Behav. 
2018;88:146-51. 
58. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. 
The 2007 WHO classification of tumours of the central nervous system. Acta 
Neuropathol. 2007;114(2):97-109. 
59. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma 
grading: an analysis of histologic parameters. Am J Surg Pathol. 1997;21(12):1455-
65. 
60. Brokinkel B, Hess K, Mawrin C. Brain invasion in meningiomas-clinical 
considerations and impact of neuropathological evaluation: a systematic review. 
Neuro Oncol. 2017;19(10):1298-307. 
61. Sokratous G, Burford C, Loh D, Ashkan K, Bhangoo R, Vergani F. 
Meningiomas: Brain invasion as a marker for classification. Neuro-Oncology. 
2018;20(suppl_1):i12-i3. 
62. Bi WL, Zhang M, Wu WW, Mei Y, Dunn IF. Meningioma Genomics: 
Diagnostic, Prognostic, and Therapeutic Applications. Front Surg. 2016;3:40. 
63. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global 
variation in copy number in the human genome. Nature. 2006;444(7118):444-54. 
64. Zhang F, Gu W, Hurles ME, Lupski JR. Copy number variation in human 
health, disease, and evolution. Annu Rev Genomics Hum Genet. 2009;10:451-81. 
65. Seizinger BR, de la Monte S, Atkins L, Gusella JF, Martuza RL. Molecular 
genetic approach to human meningioma: loss of genes on chromosome 22. Proc 
Natl Acad Sci U S A. 1987;84(15):5419-23. 
66. Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, et al. Genomic landscape 
of meningiomas. Brain Pathol. 2010;20(4):751-62. 
67. Lee JYK, Finkelstein S, Hamilton RL, Rekha R, King JT, Jr., Omalu B. Loss of 
Heterozygosity Analysis of Benign, Atypical, and Anaplastic Meningiomas. 
Neurosurgery. 2004;55(5):1163-73. 
68. Michael K, Mohammed AA, Hussam A-A-S, Jian G, Ilyas E, Randy LJ, et al. 
Clinical potential of meningioma genomic insights: a practical review for 
neurosurgeons. Neurosurgical Focus FOC. 2018;44(6):E10. 
 158  
69. Petrilli AM, Fernández-Valle C. Role of Merlin/NF2 inactivation in tumor 
biology. Oncogene. 2016;35(5):537-48. 
70. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et 
al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 
mutations. Nat Genet. 2013;45(3):285-9. 
71. De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P, Bigozzi U, et al. 
Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic 
meningiomas. Hum Genet. 1996;97(5):632-7. 
72. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al. 
Evidence for the complete inactivation of the NF2 gene in the majority of sporadic 
meningiomas. Nat Genet. 1994;6(2):180-4. 
73. Yuzawa S, Nishihara H, Tanaka S. Genetic landscape of meningioma. Brain 
Tumor Pathol. 2016;33(4):237-47. 
74. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic 
analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and 
SMO. Science. 2013;339(6123):1077-80. 
75. Carballo GB, Honorato JR, de Lopes GPF, Spohr TCLdSe. A highlight on Sonic 
hedgehog pathway. Cell Communication and Signaling. 2018;16(1):11. 
76. Bello MJ, Amiñoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, Alonso 
ME, et al. DNA methylation of multiple promoter-associated CpG islands in 
meningiomas: relationship with the allelic status at 1p and 22q. Acta 
Neuropathologica. 2004;108(5):413-21. 
77. Antequera F. Structure, function and evolution of CpG island promoters. 
Cellular and Molecular Life Sciences CMLS. 2003;60(8):1647-58. 
78. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA 
methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-96. 
79. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 
2009;1(2):239-59. 
80. Gao F, Shi L, Russin J, Zeng L, Chang X, He S, et al. DNA methylation in the 
malignant transformation of meningiomas. PLoS One. 2013;8(1):e54114-e. 
81. Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An 
overview of meningiomas. Future Oncol. 2018;14(21):2161-77. 
82. Beaumont A, Whittle IR. The pathogenesis of tumour associated epilepsy. 
Acta Neurochir (Wien). 2000;142(1):1-15. 
83. Lieu AS, Howng SL. Intracranial meningiomas and epilepsy: incidence, 
prognosis and influencing factors. Epilepsy Res. 2000;38(1):45-52. 
84. Schmidt-Hansen M, Berendse S, Hamilton W. Symptomatic diagnosis of 
cancer of the brain and central nervous system in primary care: a systematic 
review. Fam Pract. 2015;32(6):618-23. 
85. Kahn K, Finkel A. It IS a tumor -- current review of headache and brain 
tumor. Curr Pain Headache Rep. 2014;18(6):421. 
86. Boiardi A, Salmaggi A, Eoli M, Lamperti E, Silvani A. Headache in brain 
tumours: a symptom to reappraise critically. Neurol Sci. 2004;25 Suppl 3:S143-7. 
87. Meskal I, Gehring K, Rutten GJ, Sitskoorn MM. Cognitive functioning in 
meningioma patients: a systematic review. J Neurooncol. 2016;128(2):195-205. 
88. Freeman WD. Management of Intracranial Pressure. Continuum (Minneap 
Minn). 2015;21(5 Neurocritical Care):1299-323. 
 
 159 
89. Madhusoodanan S, Ting MB, Farah T, Ugur U. Psychiatric aspects of brain 
tumors: A review. World J Psychiatry. 2015;5(3):273-85. 
90. Gyawali S, Sharma P, Mahapatra A. Meningioma and psychiatric symptoms: 
An individual patient data analysis. Asian J Psychiatr. 2019;42:94-103. 
91. Kumar K, Ahmed R, Bajantri B, Singh A, Abbas H, Dejesus E, et al. Tumors 
Presenting as Multiple Cranial Nerve Palsies. Case Rep Neurol. 2017;9(1):54-61. 
92. Wu A, Garcia MA, Magill ST, Chen W, Vasudevan HN, Perry A, et al. 
Presenting Symptoms and Prognostic Factors for Symptomatic Outcomes Following 
Resection of Meningioma. World Neurosurg. 2018;111:e149-e59. 
93. Rausing A, Ybo W, Stenflo J. Intracranial meningioma--a population study of 
ten years. Acta Neurol Scand. 1970;46(1):102-10. 
94. Miller KL, Alfaro-Almagro F, Bangerter NK, Thomas DL, Yacoub E, Xu J, et al. 
Multimodal population brain imaging in the UK Biobank prospective 
epidemiological study. Nat Neurosci. 2016;19(11):1523-36. 
95. Islim AI, Mohan M, Moon RDC, Srikandarajah N, Mills SJ, Brodbelt AR, et al. 
Incidental intracranial meningiomas: a systematic review and meta-analysis of 
prognostic factors and outcomes. J Neurooncol. 2019;142(2):211-21. 
96. Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart 
E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet 
Oncol. 2016;17(9):e383-91. 
97. Mohammad MH, Chavredakis E, Zakaria R, Brodbelt A, Jenkinson MD. A 
national survey of the management of patients with incidental meningioma in the 
United Kingdom. Br J Neurosurg. 2017;31(4):459-63. 
98. Islim AI, Kolamunnage-Dona R, Mohan M, Moon RDC, Crofton A, Haylock BJ, 
et al. A prognostic model to personalize monitoring regimes for patients with 
incidental asymptomatic meningiomas. Neuro Oncol. 2020;22(2):278-89. 
99. Butts AM, Weigand S, Brown PD, Petersen RC, Jack CR, Jr., Machulda MM, et 
al. Neurocognition in individuals with incidentally-identified meningioma. J 
Neurooncol. 2017;134(1):125-32. 
100. van Nieuwenhuizen D, Ambachtsheer N, Heimans JJ, Reijneveld JC, 
Peerdeman SM, Klein M. Neurocognitive functioning and health-related quality of 
life in patients with radiologically suspected meningiomas. J Neurooncol. 
2013;113(3):433-40. 
101. Tognarelli JM, Dawood M, Shariff MIF, Grover VPB, Crossey MME, Cox IJ, et 
al. Magnetic Resonance Spectroscopy: Principles and Techniques: Lessons for 
Clinicians. J Clin Exp Hepatol. 2015;5(4):320-8. 
102. Harting I, Hartmann M, Bonsanto MM, Sommer C, Sartor K. Characterization 
of necrotic meningioma using diffusion MRI, perfusion MRI, and MR spectroscopy: 
case report and review of the literature. Neuroradiology. 2004;46(3):189-93. 
103. (NICE) NIfHaCE. Head injury: assessment and early management clinical 
guideline 2014 [Available from: 
https://www.nice.org.uk/guidance/cg176/resources/head-injury-assessment-and-
early-management-pdf-35109755595493. 
104. O'Leary S, Adams WM, Parrish RW, Mukonoweshuro W. Atypical imaging 
appearances of intracranial meningiomas. Clin Radiol. 2007;62(1):10-7. 
105. Buetow MP, Buetow PC, Smirniotopoulos JG. Typical, atypical, and 
misleading features in meningioma. Radiographics. 1991;11(6):1087-106. 
 160  
106. Dowd CF, Halbach VV, Higashida RT. Meningiomas: the role of preoperative 
angiography and embolization. Neurosurg Focus. 2003;15(1):E10. 
107. Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, et al. Expression of 
somatostatin receptor subtypes in human brain tumors. Int J Cancer. 
1998;76(5):620-7. 
108. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity 
profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin 
radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 
2000;27(3):273-82. 
109. Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Pöschl J, et al. 
Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and 
tumor-free tissue. J Nucl Med. 2015;56(3):347-53. 
110. Gehler B, Paulsen F, Oksüz MO, Hauser TK, Eschmann SM, Bares R, et al. 
[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 
2009;4:56. 
111. Laudicella R, Albano D, Annunziata S, Calabrò D, Argiroffi G, Abenavoli E, et 
al. Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical 
Demand to Future Applications. Cancers (Basel). 2019;11(10). 
112. Starr CJ, Cha S. Meningioma mimics: five key imaging features to 
differentiate them from meningiomas. Clin Radiol. 2017;72(9):722-8. 
113. Kanesen D, Kandasamy R, Idris Z. Occipital Falcine Anaplastic 
Hemangiopericytoma Mimicking Meningioma. J Neurosci Rural Pract. 2016;7(Suppl 
1):S95-s8. 
114. Ribeiro da Cunha P, Alves JL, Rocha A. Supra and infratentorial ectopic 
schwannoma mimicking a meningioma. BMJ Case Rep. 2017;2017. 
115. Johnson MD, Powell SZ, Boyer PJ, Weil RJ, Moots PL. Dural lesions mimicking 
meningiomas. Hum Pathol. 2002;33(12):1211-26. 
116. Backhouse O, Simmons I, Frank A, Cassels-Brown A. Optic nerve breast 
metastasis mimicking meningioma. Aust N Z J Ophthalmol. 1998;26(3):247-9. 
117. Ohba S, Kurokawa R, Yoshida K, Kawase T. Metastatic adenocarcinoma of 
the dura mimicking petroclival meningioma--case report. Neurol Med Chir (Tokyo). 
2004;44(6):317-20. 
118. Simpson D. The recurrence of intracranial meningiomas after surgical 
treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22-39. 
119. Cho B. Intensity-modulated radiation therapy: a review with a physics 
perspective. Radiat Oncol J. 2018;36(1):1-10. 
120. Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc 
therapy: a review of current literature and clinical use in practice. Br J Radiol. 
2011;84(1007):967-96. 
121. Scaringi C, Agolli L, Minniti G. Technical Advances in Radiation Therapy for 
Brain Tumors. Anticancer Res. 2018;38(11):6041-5. 
122. Biau J, Khalil T, Verrelle P, Lemaire JJ. Fractionated radiotherapy and 
radiosurgery of intracranial meningiomas. Neurochirurgie. 2018;64(1):29-36. 
123. Elia AE, Shih HA, Loeffler JS. Stereotactic radiation treatment for benign 
meningiomas. Neurosurg Focus. 2007;23(4):E5. 
 
 161 
124. Tanzler E, Morris CG, Kirwan JM, Amdur RJ, Mendenhall WM. Outcomes of 
WHO Grade I meningiomas receiving definitive or postoperative radiotherapy. Int J 
Radiat Oncol Biol Phys. 2011;79(2):508-13. 
125. Colombo F, Casentini L, Cavedon C, Scalchi P, Cora S, Francescon P. 
Cyberknife radiosurgery for benign meningiomas: short-term results in 199 
patients. Neurosurgery. 2009;64(2 Suppl):A7-13. 
126. Unger KR, Lominska CE, Chanyasulkit J, Randolph-Jackson P, White RL, Aulisi 
E, et al. Risk factors for posttreatment edema in patients treated with stereotactic 
radiosurgery for meningiomas. Neurosurgery. 2012;70(3):639-45. 
127. Mahadevan A, Floyd S, Wong E, Chen C, Kasper E. Clinical outcome after 
hypofractionated stereotactic radiotherapy (HSRT) for benign skull base tumors. 
Comput Aided Surg. 2011;16(3):112-20. 
128. Girvigian MR, Chen JC, Rahimian J, Miller MJ, Tome M. Comparison of early 
complications for patients with convexity and parasagittal meningiomas treated 
with either stereotactic radiosurgery or fractionated stereotactic radiotherapy. 
Neurosurgery. 2008;62(5 Suppl):A19-27; discussion A-8. 
129. Magill ST, Lau D, Raleigh DR, Sneed PK, Fogh SE, McDermott MW. Surgical 
Resection and Interstitial Iodine-125 Brachytherapy for High-Grade Meningiomas: A 
25-Year Series. Neurosurgery. 2017;80(3):409-16. 
130. Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N, et al. 
Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: 
benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro-oncology. 
2016;18(11):1538-47. 
131. Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. 
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory 
meningioma: a RANO review. Neuro Oncol. 2014;16(6):829-40. 
132. Jenkinson MD, Javadpour M, Haylock BJ, Young B, Gillard H, Vinten J, et al. 
The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical 
resection of Atypical Meningioma: study protocol for a randomised controlled trial. 
Trials. 2015;16:519. 
133. Jenkinson MD. 'Meningiomics'-an integration of data on the patient, 
tumour, extent of resection and molecular pathology to optimise the management 
and follow-up for meningiomas. Acta Neurochir (Wien). 2019;161(12):2551-2. 
134. van Alkemade H, de Leau M, Dieleman EM, Kardaun JW, van Os R, 
Vandertop WP, et al. Impaired survival and long-term neurological problems in 
benign meningioma. Neuro Oncol. 2012;14(5):658-66. 
135. Woehrer A, Hackl M, Waldhör T, Weis S, Pichler J, Olschowski A, et al. 
Relative survival of patients with non-malignant central nervous system tumours: a 
descriptive study by the Austrian Brain Tumour Registry. Br J Cancer. 
2014;110(2):286-96. 
136. Brodbelt AR, Barclay ME, Greenberg D, Williams M, Jenkinson MD, 
Karabatsou K. The outcome of patients with surgically treated meningioma in 
England: 1999–2013. A cancer registry data analysis. British Journal of 
Neurosurgery. 2019;33(6):641-7. 
137. Böker DK, Meurer H, Gullotta F. Recurring intracranial meningiomas. 
Evaluation of some factors predisposing for tumor recurrence. J Neurosurg Sci. 
1985;29(1):11-7. 
 162  
138. Gallagher MJ, Jenkinson MD, Brodbelt AR, Mills SJ, Chavredakis E. WHO 
grade 1 meningioma recurrence: Are location and Simpson grade still relevant? Clin 
Neurol Neurosurg. 2016;141:117-21. 
139. Nanda A, Bir SC, Maiti TK, Konar SK, Missios S, Guthikonda B. Relevance of 
Simpson grading system and recurrence-free survival after surgery for World Health 
Organization Grade I meningioma. J Neurosurg. 2017;126(1):201-11. 
140. Gousias K, Schramm J, Simon M. The Simpson grading revisited: aggressive 
surgery and its place in modern meningioma management. J Neurosurg. 
2016;125(3):551-60. 
141. Hasseleid BF, Meling TR, Rønning P, Scheie D, Helseth E. Surgery for 
convexity meningioma: Simpson Grade I resection as the goal: clinical article. J 
Neurosurg. 2012;117(6):999-1006. 
142. Yuzawa S, Nishihara H, Yamaguchi S, Mohri H, Wang L, Kimura T, et al. 
Clinical impact of targeted amplicon sequencing for meningioma as a practical 
clinical-sequencing system. Mod Pathol. 2016;29(7):708-16. 
143. Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, et 
al. Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription 
Factor for Meningioma Proliferation. Cell Reports. 2018;22(13):3672-83. 
144. Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, et al. DNA 
methylation-based classification and grading system for meningioma: a multicentre, 
retrospective analysis. Lancet Oncol. 2017;18(5):682-94. 
145. Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, et al. 
DNA methylation profiling to predict recurrence risk in meningioma: development 
and validation of a nomogram to optimize clinical management. Neuro Oncol. 
2019;21(7):901-10. 
146. Zamanipoor Najafabadi AH, Peeters MCM, Dirven L, Lobatto DJ, Groen JL, 
Broekman MLD, et al. Impaired health-related quality of life in meningioma 
patients-a systematic review. Neuro Oncol. 2017;19(7):897-907. 
147. Organisation WH. Constitution  [Available from: 
https://www.who.int/about/who-we-are/constitution. 
148. Black N. Patient reported outcome measures could help transform 
healthcare. Bmj. 2013;346:f167. 
149. (CHMP) EMACfMPfHU. Appendix 2 to the guideline on the evaluation of 
anticancer medicinal products in man 
The use of patient-reported outcome (PRO) measures in oncology studies 2016 
[Available from: https://www.ema.europa.eu/en/documents/other/appendix-2-
guideline-evaluation-anticancer-medicinal-products-man_en.pdf. 
150. Group. F-NBW. BEST (Biomarkers, EndpointS, and other Tools) Resource: 
Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National 
Institutes of Health (US); 2016-. 2016 [Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK326791/. 
151. Weldring T, Smith SM. Patient-Reported Outcomes (PROs) and Patient-
Reported Outcome Measures (PROMs). Health Serv Insights. 2013;6:61-8. 
152. Angus Campbell PEC, Willard L. Rodgers. The Quality of American Life: 
Perceptions, Evaluations, and Satisfactions. United States of America: Russell Sage 
Foundation; 1976. 597 p. 
 
 163 
153. Cella DF. Quality of life: concepts and definition. J Pain Symptom Manage. 
1994;9(3):186-92. 
154. Organisation WH. WHOQOL: Measuring Quality of Life  [Available from: 
https://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/. 
155. Cella DF. Measuring quality of life in palliative care. Semin Oncol. 1995;22(2 
Suppl 3):73-81. 
156. Cella DF. Measuring Quality of Life: 1995 Update 1995 [Available from: 
https://www.cancernetwork.com/view/measuring-quality-life-1995-update. 
157. Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M. The 
importance of patient-reported outcomes in clinical trials and strategies for future 
optimization. Patient Relat Outcome Meas. 2018;9:353-67. 
158. Health USDo, Human Services FDACfDE, Research, Health USDo, Human 
Services FDACfBE, Research, et al. Guidance for industry: patient-reported outcome 
measures: use in medical product development to support labeling claims: draft 
guidance. Health Qual Life Outcomes. 2006;4:79. 
159. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. 
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for 
symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with 
palliative end points. J Clin Oncol. 1996;14(6):1756-64. 
160. Calvert M, Brundage M, Jacobsen PB, Schünemann HJ, Efficace F. The 
CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials 
and practice. Health Qual Life Outcomes. 2013;11:184. 
161. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, et al. 
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: 
The SPIRIT-PRO Extension. Jama. 2018;319(5):483-94. 
162. Dirven L, Armstrong TS, Blakeley JO, Brown PD, Grant R, Jalali R, et al. 
Working plan for the use of patient-reported outcome measures in adults with 
brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. Lancet 
Oncol. 2018;19(3):e173-e80. 
163. Efficace F, Fayers P, Pusic A, Cemal Y, Yanagawa J, Jacobs M, et al. Quality of 
patient-reported outcome reporting across cancer randomized controlled trials 
according to the CONSORT patient-reported outcome extension: A pooled analysis 
of 557 trials. Cancer. 2015;121(18):3335-42. 
164. Dirven L, Taphoorn MJ, Reijneveld JC, Blazeby J, Jacobs M, Pusic A, et al. The 
level of patient-reported outcome reporting in randomised controlled trials of brain 
tumour patients: a systematic review. Eur J Cancer. 2014;50(14):2432-48. 
165. Rivera SC, Kyte DG, Aiyegbusi OL, Slade AL, McMullan C, Calvert MJ. The 
impact of patient-reported outcome (PRO) data from clinical trials: a systematic 
review and critical analysis. Health Qual Life Outcomes. 2019;17(1):156. 
166. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 
2010;362(10):865-9. 
167. Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL. Agreement between 
patient-reported symptoms and their documentation in the medical record. Am J 
Manag Care. 2008;14(8):530-9. 
168. Weingart SN, Gandhi TK, Seger AC, Seger DL, Borus J, Burdick E, et al. 
Patient-reported medication symptoms in primary care. Arch Intern Med. 
2005;165(2):234-40. 
 164  
169. Hanmer J, Hays RD, Fryback DG. Mode of administration is important in US 
national estimates of health-related quality of life. Med Care. 2007;45(12):1171-9. 
170. Dobrozsi S, Panepinto J. Patient-reported outcomes in clinical practice. 
Hematology. 2015;2015(1):501-6. 
171. Kyte D, Draper H, Calvert M. Patient-Reported Outcome Alerts: Ethical and 
Logistical Considerations in Clinical Trials. JAMA. 2013;310(12):1229-30. 
172. Nilsson E, Orwelius L, Kristenson M. Patient-reported outcomes in the 
Swedish National Quality Registers. J Intern Med. 2016;279(2):141-53. 
173. Kvalitetsregister N. Swedish National Quality Registries 2019 [Available 
from: http://kvalitetsregister.se/englishpages.2040.html. 
174. Adami HO, Hernán MA. Learning how to improve healthcare delivery: the 
Swedish Quality Registers. J Intern Med. 2015;277(1):87-9. 
175. England N. Patient Reported Outcome Measures (PROMs)  [Available from: 
https://www.england.nhs.uk/statistics/statistical-work-areas/proms/. 
176. England N. THE NATIONAL PATIENT REPORTED OUTCOME MEASURES 
(PROMS) PROGRAMME 2018 [Available from: https://www.england.nhs.uk/wp-
content/uploads/2018/08/proms-guide-aug-18-v3.pdf. 
177. Weinberger M, Nagle B, Hanlon JT, Samsa GP, Schmader K, Landsman PB, et 
al. Assessing health-related quality of life in elderly outpatients: telephone versus 
face-to-face administration. J Am Geriatr Soc. 1994;42(12):1295-9. 
178. Hays RD, Kim S, Spritzer KL, Kaplan RM, Tally S, Feeny D, et al. Effects of 
mode and order of administration on generic health-related quality of life scores. 
Value Health. 2009;12(6):1035-9. 
179. Miller DR, Clark JA, Rogers WH, Skinner KM, Spiro A, 3rd, Lee A, et al. The 
influence of place of administration on health-related quality-of-life assessments: 
findings from the Veterans Health Study. J Ambul Care Manage. 2005;28(2):111-24. 
180. Palmen LN, Schrier JCM, Scholten R, Jansen JHW, Koëter S. Is it too early to 
move to full electronic PROM data collection?: A randomized controlled trial 
comparing PROM's after hallux valgus captured by e-mail, traditional mail and 
telephone. Foot and Ankle Surgery. 2016;22(1):46-9. 
181. Harris LE, Weinberger M, Tierney WM. Assessing inner-city patients' hospital 
experiences. A controlled trial of telephone interviews versus mailed surveys. Med 
Care. 1997;35(1):70-6. 
182. Schwartzenberger J, Presson A, Lyle A, O'Farrell A, Tyser AR. Remote 
Collection of Patient-Reported Outcomes Following Outpatient Hand Surgery: A 
Randomized Trial of Telephone, Mail, and E-Mail. J Hand Surg Am. 2017;42(9):693-
9. 
183. Gayet-Ageron A, Agoritsas T, Schiesari L, Kolly V, Perneger TV. Barriers to 
participation in a patient satisfaction survey: who are we missing? PLoS One. 
2011;6(10):e26852. 
184. Hutchings A, Neuburger J, Grosse Frie K, Black N, van der Meulen J. Factors 
associated with non-response in routine use of patient reported outcome measures 
after elective surgery in England. Health Qual Life Outcomes. 2012;10:34. 
185. Emberton M, Black N. Impact of non-response and of late-response by 




186. Mercieca-Bebber R, Palmer MJ, Brundage M, Calvert M, Stockler MR, King 
MT. Design, implementation and reporting strategies to reduce the instance and 
impact of missing patient-reported outcome (PRO) data: a systematic review. BMJ 
Open. 2016;6(6):e010938. 
187. Calvert MJ, Freemantle N. Use of health-related quality of life in prescribing 
research. Part 2: methodological considerations for the assessment of health-
related quality of life in clinical trials. J Clin Pharm Ther. 2004;29(1):85-94. 
188. Bernhard J, Peterson HF, Coates AS, Gusset H, Isley M, Hinkle R, et al. 
Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: 
practical issues and factors associated with missing data. Stat Med. 1998;17(5-
7):587-601. 
189. Kleinpell-Nowell R. Strategies for assessing outcomes in the elderly in acute 
care. AACN Clin Issues. 2000;11(3):442-52. 
190. Nielsen LK, King M, Möller S, Jarden M, Andersen CL, Frederiksen H, et al. 
Strategies to improve patient-reported outcome completion rates in longitudinal 
studies. Qual Life Res. 2020;29(2):335-46. 
191. Weston D, Parsons V, Ntani G, Rushton L, Madan I. Mixed contact methods 
to improve response to a postal questionnaire. Occupational Medicine. 
2017;67(4):305-7. 
192. Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, et al. 
Recommendations for incorporating patient-reported outcomes into clinical 
comparative effectiveness research in adult oncology. J Clin Oncol. 
2012;30(34):4249-55. 
193. Bell ML, Fairclough DL. Practical and statistical issues in missing data for 
longitudinal patient-reported outcomes. Stat Methods Med Res. 2014;23(5):440-
59. 
194. Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, et al. Reliability of 
adverse symptom event reporting by clinicians. Qual Life Res. 2012;21(7):1159-64. 
195. Quinten C, Maringwa J, Gotay CC, Martinelli F, Coens C, Reeve BB, et al. 
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer 
survival. J Natl Cancer Inst. 2011;103(24):1851-8. 
196. Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, et al. 
Symptomatic toxicities experienced during anticancer treatment: agreement 
between patient and physician reporting in three randomized trials. J Clin Oncol. 
2015;33(8):910-5. 
197. Sprangers MA, Aaronson NK. The role of health care providers and 
significant others in evaluating the quality of life of patients with chronic disease: a 
review. J Clin Epidemiol. 1992;45(7):743-60. 
198. Low G, Gutman G. Couples' ratings of chronic obstructive pulmonary disease 
patients' quality of life. Clin Nurs Res. 2003;12(1):28-48. 
199. Tamim H, McCusker J, Dendukuri N. Proxy reporting of quality of life using 
the EQ-5D. Med Care. 2002;40(12):1186-95. 
200. Roydhouse JK, Gutman R, Keating NL, Mor V, Wilson IB. Proxy and patient 
reports of health-related quality of life in a national cancer survey. Health and 
Quality of Life Outcomes. 2018;16(1):6. 
 166  
201. Wennman-Larsen A, Tishelman C Fau - Wengström Y, Wengström Y Fau - 
Gustavsson P, Gustavsson P. Factors influencing agreement in symptom ratings by 
lung cancer patients and their significant others. (0885-3924 (Print)). 
202. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom 
event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl 
Cancer Inst. 2009;101(23):1624-32. 
203. Gotay C. Patient Symptoms and Clinician Toxicity Ratings: Both Have a Role 
in Cancer Care. JNCI: Journal of the National Cancer Institute. 2009;101(23):1602-3. 
204. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. 
The European Organization for Research and Treatment of Cancer QLQ-C30: a 
quality-of-life instrument for use in international clinical trials in oncology. J Natl 
Cancer Inst. 1993;85(5):365-76. 
205. Peter M. Fayers DM. Quality of Life: The Assessment, Analysis and Reporting 
of Patient-Reported Outcomes. Chapter 2: Principles of measurement scales. 3 ed. 
Chichester, [England]: Wiley Blackwell; 2016. 651 p. 
206. Johnston BC PD, Devji T, Maxwell LJ, Bingham III CO, Beaton D, Boers M, 
Briel M, Busse JW, Carrasco-Labra A, Christensen R, da Costa BR, El Dib R, Lyddiatt 
A, Ostelo RW, Shea B, Singh J, Terwee CB, Williamson PR, Gagnier JJ, Tugwell P, 
Guyatt GH. Chapter 18: Patient-reported outcomes. In: Higgins JPT, Thomas J, 
Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for 
Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane; 
2019. 
207. Alrubaiy L, Hutchings HA, Williams JG. Assessing patient reported outcome 
measures: A practical guide for gastroenterologists. United European Gastroenterol 
J. 2014;2(6):463-70. 
208. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. 
Quality criteria were proposed for measurement properties of health status 
questionnaires. J Clin Epidemiol. 2007;60(1):34-42. 
209. Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD. What is sufficient 
evidence for the reliability and validity of patient-reported outcome measures? 
Value Health. 2007;10 Suppl 2:S94-s105. 
210. Zlotnick D, Kalkanis SN, Quinones-Hinojosa A, Chung K, Linskey ME, Jensen 
RL, et al. FACT-MNG: tumor site specific web-based outcome instrument for 
meningioma patients. J Neurooncol. 2010;99(3):423-31. 
211. Tanti MJ, Marson AG, Chavredakis E, Jenkinson MD. The impact of epilepsy 
on the quality of life of patients with meningioma: A systematic review. Br J 
Neurosurg. 2016;30(1):23-8. 
212. Zamanipoor Najafabadi AH, Peeters MCM, Lobatto DJ, Broekman MLD, 
Smith TR, Biermasz NR, et al. Health-related quality of life of cranial WHO grade I 
meningioma patients: are current questionnaires relevant? Acta Neurochir (Wien). 
2017;159(11):2149-59. 
213. Coulman KD, Abdelrahman T, Owen-Smith A, Andrews RC, Welbourn R, 
Blazeby JM. Patient-reported outcomes in bariatric surgery: a systematic review of 
standards of reporting. Obes Rev. 2013;14(9):707-20. 
214. McNair AG, Whistance RN, Forsythe RO, Rees J, Jones JE, Pullyblank AM, et 
al. Synthesis and summary of patient-reported outcome measures to inform the 
 
 167 
development of a core outcome set in colorectal cancer surgery. Colorectal Dis. 
2015;17(11):O217-29. 
215. Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, et 
al. Developing core outcomes sets: methods for identifying and including patient-
reported outcomes (PROs). Trials. 2014;15:49. 
216. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. Bmj. 
2009;339:b2535. 
217. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and 
mobile app for systematic reviews. Syst Rev. 2016;5(1):210. 
218. Johnston BC PD, Devji T, Maxwell LJ, Bingham III CO, Beaton D, Boers M, 
Briel M, Busse JW, Carrasco-Labra A, Christensen R, da Costa BR, El Dib R, Lyddiatt 
A, Ostelo RW, Shea B, Singh J, Terwee CB, Williamson PR, Gagnier JJ, Tugwell P, 
Guyatt GH. Chapter 18: Patient-reported outcomes. : Cochrane; 2019 [Available 
from: www.training.cochrane.org/handbook. 
219. Cella D HE, Jensen SE et al. Patient-Reported Outcomes in Performance 
Measurement: RTI Press; 2015. 
220. McKenna SP. Measuring patient-reported outcomes: moving beyond 
misplaced common sense to hard science. BMC Med. 2011;9(1741-7015 
(Electronic)):86. 
221. Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, et al. 
ISOQOL recommends minimum standards for patient-reported outcome measures 
used in patient-centered outcomes and comparative effectiveness research. Qual 
Life Res. 2013;22(8):1889-905. 
222. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. 
Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO 
extension. Jama. 2013;309(8):814-22. 
223. Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, et al. Patient-
reported outcomes in randomized clinical trials: development of ISOQOL reporting 
standards. Qual Life Res. 2013;22(6):1161-75. 
224. Fountain DM, Allen D, Joannides AJ, Nandi D, Santarius T, Chari A. Reporting 
of patient-reported health-related quality of life in adults with diffuse low-grade 
glioma: a systematic review. Neuro Oncol. 2016;18(11):1475-86. 
225. Efficace F, Feuerstein M, Fayers P, Cafaro V, Eastham J, Pusic A, et al. 
Patient-reported outcomes in randomised controlled trials of prostate cancer: 
methodological quality and impact on clinical decision making. Eur Urol. 
2014;66(3):416-27. 
226. Institute TJB. Checklist for Analytical Cross Sectional Studies 2017 [Available 
from: www.joannabriggs.org. 
227. Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The 
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies 
in meta-analyses  [Available from: 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 
228. Kangas M, Williams JR, Smee RI. The Association Between Post-traumatic 
Stress and Health-Related Quality of Life in Adults Treated for a Benign 
Meningioma. Applied Research in Quality of Life. 2012;7(2):163-82. 
 168  
229. Tanti MJ, Marson AG, Jenkinson MD. Epilepsy and adverse quality of life in 
surgically resected meningioma. Acta Neurol Scand. 2017;136(3):246-53. 
230. Krupp W, Klein C, Koschny R, Holland H, Seifert V, Meixensberger J. 
Assessment of neuropsychological parameters and quality of life to evaluate 
outcome in patients with surgically treated supratentorial meningiomas. 
Neurosurgery. 2009;64(1):40-7; discussion 7. 
231. van Nieuwenhuizen D, Slot KM, Klein M, Verbaan D, Aliaga ES, Heimans JJ, et 
al. The association between preoperative edema and postoperative cognitive 
functioning and health-related quality of life in WHO grade I meningioma patients. 
Acta Neurochir (Wien). 2019;161(3):579-88. 
232. Kangas M, Williams JR, Smee RI. Benefit Finding in Adults Treated for Benign 
Meningioma Brain Tumours: Relations with Psychosocial Wellbeing. Brain 
Impairment. 2011;12(2):105-16. 
233. Owens MA, Craig BM, Egan KM, Reed DR. Birth desires and intentions of 
women diagnosed with a meningioma. J Neurosurg. 2015;122(5):1151-6. 
234. van der Vossen S, Schepers VP, Berkelbach van der Sprenkel JW, Visser-
Meily JM, Post MW. Cognitive and emotional problems in patients after cerebral 
meningioma surgery. J Rehabil Med. 2014;46(5):430-7. 
235. Makarenko S, Carreras EM, Akagami R. Craniotomy for perisellar 
meningiomas: comparison of simple (appropriate for endoscopic approach) versus 
complex anatomy and surgical outcomes. J Neurosurg. 2017;126(4):1191-200. 
236. van Nieuwenhuizen D, Klein M, Stalpers LJ, Leenstra S, Heimans JJ, 
Reijneveld JC. Differential effect of surgery and radiotherapy on neurocognitive 
functioning and health-related quality of life in WHO grade I meningioma patients. J 
Neurooncol. 2007;84(3):271-8. 
237. Mathiesen T, Gerlich A, Kihlström L, Svensson M, Bagger-Sjöbäck D. Effects 
of using combined transpetrosal surgical approaches to treat petroclival 
meningiomas. Neurosurgery. 2007;60(6):982-91; discussion 91-2. 
238. Pintea B, Kandenwein JA, Lorenzen H, Boström JP, Daher F, Velazquez V, et 
al. Factors of influence upon the SF-36-based health related quality of life of 
patients following surgery for petroclival and lateral posterior surface of pyramid 
meningiomas. Clin Neurol Neurosurg. 2018;166:36-43. 
239. Jones SH, Iannone AF, Patel KS, Anchouche K, Raza SM, Anand VK, et al. The 
Impact of Age on Long-Term Quality of Life After Endonasal Endoscopic Resection 
of Skull Base Meningiomas. Neurosurgery. 2016;79(5):736-45. 
240. Jakola AS, Gulati M, Gulati S, Solheim O. The influence of surgery on quality 
of life in patients with intracranial meningiomas: a prospective study. J Neurooncol. 
2012;110(1):137-44. 
241. Waagemans ML, van Nieuwenhuizen D, Dijkstra M, Wumkes M, Dirven CM, 
Leenstra S, et al. Long-term impact of cognitive deficits and epilepsy on quality of 
life in patients with low-grade meningiomas. Neurosurgery. 2011;69(1):72-8; 
discussion 8-9. 
242. Timmer M, Seibl-Leven M, Wittenstein K, Grau S, Stavrinou P, Röhn G, et al. 
Long-Term Outcome and Health-Related Quality of Life of Elderly Patients After 
Meningioma Surgery. World Neurosurg. 2019;125:e697-e710. 
243. Lang DA, Neil-Dwyer G, Garfield J. Outcome after complex neurosurgery: the 
caregiver's burden is forgotten. J Neurosurg. 1999;91(3):359-63. 
 
 169 
244. Neil-Dwyer G, Lang DA, Davis A. Outcome from complex neurosurgery: an 
evidence based approach. Acta Neurochir (Wien). 2000;142(4):367-71. 
245. Konglund A, Rogne SG, Lund-Johansen M, Scheie D, Helseth E, Meling TR. 
Outcome following surgery for intracranial meningiomas in the aging. Acta Neurol 
Scand. 2013;127(3):161-9. 
246. Schepers VPM, van der Vossen S, Berkelbach van der Sprenkel JW, Visser-
Meily JMA, Post MWM. Participation restrictions in patients after surgery for 
cerebral meningioma. J Rehabil Med. 2018;50(10):879-85. 
247. van der Linden SD, Gehring K, Rutten GM, Kop WJ, Sitskoorn MM. 
Prevalence and correlates of fatigue in patients with meningioma before and after 
surgery. Neurooncol Pract. 2020;7(1):77-85. 
248. Zweckberger K, Hallek E, Vogt L, Giese H, Schick U, Unterberg AW. 
Prospective analysis of neuropsychological deficits following resection of benign 
skull base meningiomas. J Neurosurg. 2017;127(6):1242-8. 
249. Henzel M, Fokas E, Sitter H, Wittig A, Engenhart-Cabillic R. Quality of life 
after stereotactic radiotherapy for meningioma: a prospective non-randomized 
study. J Neurooncol. 2013;113(1):135-41. 
250. Benz LS, Wrensch MR, Schildkraut JM, Bondy ML, Warren JL, Wiemels JL, et 
al. Quality of life after surgery for intracranial meningioma. Cancer. 
2018;124(1):161-6. 
251. Kalkanis SN, Quiñones-Hinojosa A, Buzney E, Ribaudo HJ, Black PM. Quality 
of life following surgery for intracranial meningiomas at Brigham and Women's 
Hospital: a study of 164 patients using a modification of the functional assessment 
of cancer therapy-brain questionnaire. J Neurooncol. 2000;48(3):233-41. 
252. Wagner A, Shiban Y, Lange N, Joerger AK, Hoffmann U, Meyer B, et al. The 
relevant psychological burden of having a benign brain tumor: a prospective study 
of patients undergoing surgical treatment of cranial meningiomas. J Neurosurg. 
2019;131(6):1840-7. 
253. Combs SE, Adeberg S, Dittmar JO, Welzel T, Rieken S, Habermehl D, et al. 
Skull base meningiomas: Long-term results and patient self-reported outcome in 
507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity 
modulated radiotherapy (IMRT). Radiother Oncol. 2013;106(2):186-91. 
254. Wirsching HG, Morel C, Roth P, Weller M. Socioeconomic burden and quality 
of life in meningioma patients. Qual Life Res. 2020;29(7):1801-8. 
255. Honeybul S, Neil-Dwyer G, Lang DA, Evans BT, Ellison DW. Sphenoid wing 
meningioma en plaque: a clinical review. Acta Neurochir (Wien). 2001;143(8):749-
57; discussion 58. 
256. van Lonkhuizen PJC, Rijnen SJM, van der Linden SD, Rutten GM, Gehring K, 
Sitskoorn MM. Subjective cognitive functioning in patients with a meningioma: Its 
course and association with objective cognitive functioning and psychological 
symptoms. Psychooncology. 2019;28(8):1654-62. 
257. Akagami R, Napolitano M, Sekhar LN. Patient-evaluated outcome after 
surgery for basal meningiomas. Neurosurgery. 2002;50(5):941-8; discussion 8-9. 
258. dos Santos Camila Batista dSMFG, Aguiar Paulo Henrique. Meningiomas: 
Quality of life before and after surgery. Journal of Neuroscience and Behavioural 
Health. 2011;3(1):8-15. 
 170  
259. Nassiri F, Price B, Shehab A, Au K, Cusimano MD, Jenkinson MD, et al. Life 
after surgical resection of a meningioma: a prospective cross-sectional study 
evaluating health-related quality of life. Neuro Oncol. 2019;21(Suppl 1):i32-i43. 
260. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-
36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-83. 
261. Hunt SM, McEwen J. The development of a subjective health indicator. 
Sociol Health Illn. 1980;2(3):231-46. 
262. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The 
Functional Assessment of Cancer Therapy scale: development and validation of the 
general measure. J Clin Oncol. 1993;11(3):570-9. 
263. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality-of-
life assessment in cancer clinical trials. Recent Results Cancer Res. 1988;111:231-49. 
264. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The 
Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain 
subscale and revalidation of the general version (FACT-G) in patients with primary 
brain tumors. Cancer. 1995;75(5):1151-61. 
265. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, et al. The 
development and psychometric validation of a brain cancer quality-of-life 
questionnaire for use in combination with general cancer-specific questionnaires. 
Qual Life Res. 1996;5(1):139-50. 
266. Gil Z, Abergel A, Spektor S, Shabtai E, Khafif A, Fliss DM. Development of a 
cancer-specific anterior skull base quality-of-life questionnaire. J Neurosurg. 
2004;100(5):813-9. 
267. Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 
22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34(5):447-54. 
268. Piccirillo JF, Merritt MG, Jr., Richards ML. Psychometric and clinimetric 
validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20). Otolaryngol Head Neck 
Surg. 2002;126(1):41-7. 
269. Mohsenipour I, Deusch E, Gabl M, Hofer M, Twerdy K. Quality of life in 
patients after meningioma resection. Acta Neurochir (Wien). 2001;143(6):547-53. 
270. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. 
Development and preliminary testing of the new five-level version of EQ-5D (EQ-
5D-5L). Qual Life Res. 2011;20(10):1727-36. 
271. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta 
Psychiatr Scand. 1983;67(6):361-70. 
272. Weiss DS, Marmar CR, Wilson JP, Keane TM. Assessing psychological trauma 
and PTSD. The Impact of Events Scale—Revised. 1997;19:399-411. 
273. Beck JG, Grant DM, Read JP, Clapp JD, Coffey SF, Miller LM, et al. The impact 
of event scale-revised: psychometric properties in a sample of motor vehicle 
accident survivors. J Anxiety Disord. 2008;22(2):187-98. 
274. Biehl B, Landauer A. Das profile of mood states (POMS). Unpublished 
manuscript, University of Mannheim, Germany. 1975. 
275. Meyer TD, Hautzinger M. Allgemeine Depressions-Skala (ADS). Diagnostica. 
2001;47(4):208-15. 
276. Taylor S, Zvolensky MJ, Cox BJ, Deacon B, Heimberg RG, Ledley DR, et al. 
Robust dimensions of anxiety sensitivity: development and initial validation of the 
Anxiety Sensitivity Index-3. Psychol Assess. 2007;19(2):176-88. 
 
 171 
277. Armstrong TS, Cohen MZ, Eriksen L, Cleeland C. Content validity of self-
report measurement instruments: an illustration from the development of the 
Brain Tumor Module of the M.D. Anderson Symptom Inventory. Oncol Nurs Forum. 
2005;32(3):669-76. 
278. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue 
Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J 
Psychosom Res. 1995;39(3):315-25. 
279. Baker G. Development of a patient-based symptom check list to quantify 
adverse effects in persons receiving antiepileptic drugs. Epilepsia. 1993;34:18. 
280. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures 
Questionnaire (CFQ) and its correlates. British Journal of Clinical Psychology. 
1982;21(1):1-16. 
281. Lawton MP, Brody EM. Assessment of Older People: Self-Maintaining and 
Instrumental Activities of Daily Living1. The Gerontologist. 1969;9(3_Part_1):179-
86. 
282. Post MW, van der Zee CH, Hennink J, Schafrat CG, Visser-Meily JM, van 
Berlekom SB. Validity of the utrecht scale for evaluation of rehabilitation-
participation. Disabil Rehabil. 2012;34(6):478-85. 
283. Antoni MH, Lehman JM, Kilbourn KM, Boyers AE, Culver JL, Alferi SM, et al. 
Cognitive-behavioral stress management intervention decreases the prevalence of 
depression and enhances benefit finding among women under treatment for early-
stage breast cancer. Health Psychol. 2001;20(1):20-32. 
284. Tomich PL, Helgeson VS. Is finding something good in the bad always good? 
Benefit finding among women with breast cancer. Health Psychol. 2004;23(1):16-
23. 
285. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The Multidimensional Scale of 
Perceived Social Support. Journal of Personality Assessment. 1988;52(1):30-41. 
286. Sass C MJ, Gueguen R, Abric L, Dauphinot V, Dupre C, Giordanella JP, Girard 
F, Guenot C, Labbe E, La Rosa E, Magnier P, Martin E, Royer B, Rubirola M, Gerbaud 
L. Le score EPICES: un score individuel de précarité. Construction et évaluation du 
score dans une population de 197389 personnes. Bulletin Epidémiologique 
Hebdomadaire. 2006:93-6. 
287. Islim AI, Ali A, Bagchi A, Ahmad MU, Mills SJ, Chavredakis E, et al. 
Postoperative seizures in meningioma patients: improving patient selection for 
antiepileptic drug therapy. J Neurooncol. 2018;140(1):123-34. 
288. Islim AI, McKeever S, Kusu-Orkar TE, Jenkinson MD. The role of prophylactic 
antiepileptic drugs for seizure prophylaxis in meningioma surgery: A systematic 
review. J Clin Neurosci. 2017;43:47-53. 
289. Jenkinson MD, Ali A, Islim AI, Helmy A, Grant R. Letter to the Editor. 
Establishing the role of prophylactic antiepileptic drugs in glioma and meningioma 
surgery. J Neurosurg. 2019;131(3):985-7. 
290. Dunn EC, Wewiorski NJ, Rogers ES. The meaning and importance of 
employment to people in recovery from serious mental illness: results of a 
qualitative study. Psychiatr Rehabil J. 2008;32(1):59-62. 
291. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A 
taxonomy has been developed for outcomes in medical research to help improve 
knowledge discovery. J Clin Epidemiol. 2018;96:84-92. 
 172  
292. Bekelis K, Bakhoum SF, Desai A, Mackenzie TA, Roberts DW. Outcome 
prediction in intracranial tumor surgery: the National Surgical Quality Improvement 
Program 2005-2010. J Neurooncol. 2013;113(1):57-64. 
293. Chen ZY, Zheng CH, Tang L, Su XY, Lu GH, Zhang CY, et al. Intracranial 
meningioma surgery in the elderly (over 65 years): prognostic factors and outcome. 
Acta Neurochir (Wien). 2015;157(9):1549-57; discussion 57. 
294. Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31-
s4. 
295. Care RH. 36-Item Short Form Survey (SF-36) Scoring Instructions  [Available 
from: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-
form/scoring.html. 
296. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. 
Validating the SF-36 health survey questionnaire: new outcome measure for 
primary care. Bmj. 1992;305(6846):160-4. 
297. Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al. 
An international validation study of the EORTC brain cancer module (EORTC QLQ-
BN20) for assessing health-related quality of life and symptoms in brain cancer 
patients. Eur J Cancer. 2010;46(6):1033-40. 
298. Fayers PM AN, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of 
the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). 
Brussels: European Organisation for Research and Treatment of Cancer; 2001. 
299. Select Statistical Services Ltd. Two-Sample t-test  [Available from: 
https://select-statistics.co.uk/calculators/two-sample-t-test-calculator/. 
300. Cronbach LJ. Coefficient alpha and the internal structure of tests. 
Psychometrika. 1951;16(3):297-334. 
301. Tavakol M, Dennick R. Making sense of Cronbach's alpha. Int J Med Educ. 
2011;2:53-5. 
302. Bender R, Lange S. Adjusting for multiple testing--when and how? J Clin 
Epidemiol. 2001;54(4):343-9. 
303. Burholt V, Nash P. Short Form 36 (SF-36) Health Survey Questionnaire: 
normative data for Wales. Journal of Public Health. 2011;33(4):587-603. 
304. Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers PM, et al. 
General population normative data for the EORTC QLQ-C30 health-related quality 
of life questionnaire based on 15,386 persons across 13 European countries, 
Canada and the Unites States. Eur J Cancer. 2019;107:153-63. 
305. Bowling A, Bond M, Jenkinson C, Lamping DL. Short Form 36 (SF-36) Health 
Survey questionnaire: which normative data should be used? Comparisons between 
the norms provided by the Omnibus Survey in Britain, the Health Survey for 
England and the Oxford Healthy Life Survey. J Public Health Med. 1999;21(3):255-
70. 
306. Kim TK. T test as a parametric statistic. Korean J Anesthesiol. 
2015;68(6):540-6. 
307. Schwartz CE, Andresen EM, Nosek MA, Krahn GL. Response shift theory: 
important implications for measuring quality of life in people with disability. Arch 
Phys Med Rehabil. 2007;88(4):529-36. 
308. Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA, et al. Choosing 
between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of 
 
 173 
life in cancer clinical research: issues, evidence and recommendations. Ann Oncol. 
2011;22(10):2179-90. 
309. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. 
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors 
Diagnosed in the United States in 2011-2015. Neuro Oncol. 2018;20(suppl_4):iv1-
iv86. 
310. Cea-Soriano L, Wallander MA, García Rodríguez LA. Epidemiology of 
meningioma in the United Kingdom. Neuroepidemiology. 2012;39(1):27-34. 
311. Chamoun R, Krisht KM, Couldwell WT. Incidental meningiomas. Neurosurg 
Focus. 2011;31(6):E19. 
312. Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, Larvie M, Curry 
WT, Barker FG, 2nd, et al. Benign meningiomas (WHO Grade I) with atypical 
histological features: correlation of histopathological features with clinical 
outcomes. J Neurosurg. 2016;124(1):106-14. 
313. Tucha O, Smely C, Preier M, Becker G, Paul GM, Lange KW. Preoperative and 
postoperative cognitive functioning in patients with frontal meningiomas. J 
Neurosurg. 2003;98(1):21-31. 
314. Nakamura M, Roser F, Michel J, Jacobs C, Samii M. The natural history of 
incidental meningiomas. Neurosurgery. 2003;53(1):62-70; discussion -1. 
315. Yano S, Kuratsu J. Indications for surgery in patients with asymptomatic 
meningiomas based on an extensive experience. J Neurosurg. 2006;105(4):538-43. 
316. Miao Y, Lu X, Qiu Y, Jiang J, Lin Y. A multivariate analysis of prognostic 
factors for health-related quality of life in patients with surgically managed 
meningioma. J Clin Neurosci. 2010;17(4):446-9. 
317. Dijkstra M, van Nieuwenhuizen D, Stalpers LJ, Wumkes M, Waagemans M, 
Vandertop WP, et al. Late neurocognitive sequelae in patients with WHO grade I 
meningioma. J Neurol Neurosurg Psychiatry. 2009;80(8):910-5. 
318. Collins C, Gehrke A, Feuerstein M. Cognitive tasks challenging brain tumor 
survivors at work. J Occup Environ Med. 2013;55(12):1426-30. 
319. Wong J, Mendelsohn D, Nyhof-Young J, Bernstein M. A qualitative 
assessment of the supportive care and resource needs of patients undergoing 




































3 #1 OR #2 
4 ‘outcome assessment’/de 
5 'patient-reported outcome'/de 
6 ‘self concept’/exp 
7 ‘health status’/exp 
8 ‘patient satisfaction’/de 
9 (‘patient outcome’ OR ‘patient 
outcomes’):ti,ab 
10 (‘patient reported’ OR ‘patient 
rated’ OR ‘patient assessed’ OR 
‘patient evaluated’ OR ‘self 
reported’ OR ‘self rated’ OR ‘self 
assessed’ OR ‘self evaluated’ OR 
‘person reported’ OR ‘person 
rated’ OR ‘person assessed’ OR 
‘person evaluated’):ti,ab 
11 (‘PRO’ OR ‘PROs’):ti,ab  
12 (‘PROM’ OR ‘PROMs’):ti,ab 
13 (‘health outcome’ OR ‘health 
outcomes’):ti,ab 
14 ‘health status’:ti,ab 
15 (‘health profile’ OR ‘health 
profiles’):ti,ab 
16 (‘well being’ OR 
‘wellbeing’):ti,ab 
17 ‘satisfaction’:ti,ab 
18 (‘expectation’ OR 
‘expectations’):ti,ab 
19 ‘quality of life’/de 





























44 (‘cope’ OR ‘coping’):ti,ab 
45 ‘symptom assessment’:ti,ab 
46 (‘functional status’ OR 




49 (‘survey’ OR ‘surveys’):ti,ab 
50 (‘questionnaire’ OR 
‘questionnaires’):ti,ab 
51 (‘scale’ OR ‘scales’):ti,ab 
52 (‘ASK NASAL 12’ OR ‘EORTC’ OR 
‘EuroQoL’ OR ‘EQ5D’ OR ‘EQ 5D’ 
OR ‘FACT’ OR ‘IHDNS’ OR 
‘MDASI’ OR ‘NHP’ OR ‘PCMIS’ 
OR ‘SF36’ OR ‘SF 36’ OR ‘SNAS’ 
OR ‘VAS’ OR ‘WHOQOL’):ti,ab 
53 #4 OR #5 OR #6 OR #7 OR #8 OR 
#9 OR #10 OR #11 OR #12 OR 
#13 OR #14 OR #15 OR #16 OR 
#17 OR #18 OR #19 OR #20 OR 
#21 OR #22 OR #23 OR #24 OR 
#25 OR #26 OR #27 OR #28 OR 
#29 OR #30 OR #31 OR #32 OR 
#33 OR #34 OR #35 OR #36 OR 
#37 OR #38 OR #39 OR #40 OR 
#41 OR #42 OR #43 OR #44 OR 
#45 OR #46 OR #47 OR #48 OR 
#49 OR #50 OR #51 OR #52 
54 #3 AND #53 
55 #3 AND #53 AND [english]/lim 
 
 176  
Appendix 2: Modified ISOQOL criteria 
 
Appendix 2: Modified ISOQOL criteria 
Number Core Recommendation Options 
1 The PRO should be identified as an outcome in the abstract 
 
YES NO 
2 The PRO hypothesis should be stated and should specify the 
relevant PRO domain(s) if applicable 
YES NO  
NA (if 
explorative) 
3 The mode of administration of the PRO tool and the methods of 
collecting data (e.g., telephone, other) should be described 
 
YES NO 
4 a Electronic modes of distribution?  
 
YES NO 
Note to reviewer: this does not account for reporting quality and 
should not be incorporated in final score. 




Note to reviewer: question requires a specific explanation as to 
why a tool was chosen over another  
 
6 Evidence of PRO instrument validity and reliability should be 
provided or cited  
 
YES NO (if all 
PROMs used are 
unvalidated) 
N/A (if new tool) 
Note to reviewer: validation and reliability in population the tool 
was designed for, not necessarily meningioma patients. 
 
7 The intended HRQL data collection schedule should be provided YES NO  
N/A (if not 
prospective) 
8 PROs should be identified in the trial protocol; post hoc analyses 
should be identified  
 
YES NO 




Note to reviewer: not all studies will have a trial protocol 
9 The status of PRO as either a primary or secondary outcome 
should be stated  
 
YES NO 
Note to reviewer: Mark as YES if PRO is the only outcome of the 
study 
 
10 There should be evidence of appropriate statistical analysis and 
tests of statistical significance for each PRO hypothesis tested  
YES NO 
NA (if hypothesis 
not stated) 
11 b Extent of missing data should be stated  
 
YES NO 
Note to reviewer: missing data defined as either whole 
questionnaires not completed because patients did not participate 
or items missing from individual questionnaires. If there is a 100% 
response rate- this question requires the study authors to 
comment that there is no missing data within the questionnaires. 





Appendix 2: Modified ISOQOL criteria (continued) 
Number Core Recommendation Options 
12 b Statistical approaches for dealing with missing data should be 
explicitly stated 
YES NO  
N/A (if no to Q11 








13 A flow diagram or a description of the allocation of participants 
and those lost to follow-up should be provided for PROs 
specifically 
YES NO 
N/A (if not 
prospective) 
Note to reviewer: For prospective studies assessing PROs (where 
allocation of participants to treatment isn’t a feature of the study); 
to score this mark it is sufficient if the study explains if and how 
many patients were lost to follow-up on prospective data 
collection 
14 The reasons for missing data should be explained  YES NO N/A (if no 
missing data) Note to reviewer: Mark as YES if study provides a response rate 
and a summary of non-responder characteristics. 
15 The study patients’ characteristics should be described, including 
baseline PRO scores.  
YES NO 
Note to reviewer: Baseline PROs may not be applicable e.g. to 
cross-sectional studies. Patient characteristics of respondents 
required.  
16 a Are PRO outcomes also reported in a graphical format?  YES NO 
Note to reviewer: this does not account for reporting quality and 
should not be incorporated in final score. 
17 The limitations of the PRO components of the trial should be 
explicitly discussed 
YES NO 
18 Generalizability issues uniquely related to the PRO results should 
be discussed, if applicable 
YES NO N/A 
Note to reviewer: A description of selection/responder bias as a 
limitation OR discussion of the cohort not completely representing 
the community of meningioma patients is satisfactory 
19 a Are PRO interpreted? (not only restated) YES NO 
Note to reviewer: this does not account for reporting quality and 
should not be incorporated in final score. 
20 The clinical significance of the PRO findings should be discussed.  YES NO N/A  





N/A (if no to Q20) 
Note to reviewer: this does not account for reporting quality and 
should not be incorporated in final score. 
22 The PRO results should be discussed in the context of the other 







YES NO  
N/A (if no other 
study outcomes) 
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Appendix 2: Modified ISOQOL criteria (continued) 
Number Additional Recommendation if PRO is primary outcome of study Options 
1 The title of the paper should be explicit as to the RCT including a 
PRO 
YES NO 
2 The introduction should contain a summary of PRO research that 
is relevant to the RCT 
YES NO  
3 Additional details regarding the hypothesis should be provided, 
including the rationale for the selected domain(s), the expected 
direction(s) of change, and the time points for assessment 
YES NO  
N/A (if no 
hypothesis 
provided) Note to reviewer: time points is not relevant to cross-sectional 
studies 
4 A citation for the original development of the PRO instrument 
should be provided 
YES NO N/A (if 
new tool) 
5 Windows for valid PRO responses should be specified and justified 
as being appropriate for the clinical context 
YES NO N/A 
6 There should be a power/sample size calculation relevant to the 
PRO based on a clinical rationale (e.g., anticipated effect size) 
YES NO N/A 
Note to reviewer: this question may not be applicable to all studies 
7 The manner in which multiple comparisons have been addressed 
should be provided 
YES NO  
 
Note to reviewer: this question may not be relevant for exploratory 
studies.  
8 The analysis of PRO data should account for survival differences 
between treatment groups if relevant 
YES NO N/A 
9 Results should be reported for all PRO domains (if multi-
dimensional) and items identified by the reference instrument 
(i.e., not just those that are statistically significant) 
YES NO 
10 The proportion of patients achieving pre- defined responder 
definitions should be provided where relevant 
YES NO 
11 A copy of the instrument should be included if it has not been 
published previously 
YES NO N/A 
 
Modifications in italics 
 
a = new items added by Dirven et al. (164) do not form part of ISOQOL reporting score. 
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QUALITY OF LIFE OUTCOMES IN PATIENTS WITH INCIDENTAL AND 




The aim of this study is to investigate the quality of life (QoL) outcomes in patients 
with incidental or operated meningioma. This will be completed using retrospective 
case note review and cross-sectional surveys of patients, who, between 2007 and 2014 
were either diagnosed with an incidental meningioma or underwent surgical resection 
of their meningioma.  
 
Patients with meningiomas generally have a good prognosis with long-term survival 
and tumour control. Therefore it is important to understand the long-term effects that 
patients experience whilst living with incidental meningiomas or following surgical 
resection. At present, little research has been completed to investigate the long-term 
effects in both of these patient groups. 
  
Methods: 
Patients will be identified from hospital records and existing audit databases. Data 
collection will comprise (i) case note review and (ii) patient self-reported outcomes 
and quality of life assessments. Results of previous outcome audits and quality of life 
studies(229) completed at The Walton Centre NHS Foundation Trust suggest that 
approximately 392 patients will take part in this study. The retrospective case note 
review will identify patient diagnosis, the age of diagnosis, clinical presentation, 
documented comorbidities and long-term problems, documented details of choice of 
management and length of follow-up. In the operated meningioma cohort, case note 
review will identify operative details, postoperative complications, date of discharge 
following surgery and tumour recurrence (where applicable). Patient self-reported 
outcomes and quality of life assessments will be completed by sending questionnaires 
by post or handing to patients at routine follow-up appointments. The SF-36, EORTC-
BN20 and EORTC QLQ-C30 questionnaires will be used. Quality of life outcomes 
will be treated as continuous data and analysed accordingly. A multivariate analysis 
of factors related to quality of life will be performed. 
 




Meningioma is the most common primary brain tumour and originates from the linings 
of the brain. With an estimated annual incidence of 8.33 per 100,000 person-years, it 
accounts for approximately 40% of all intracranial neoplasms(309). The incidence 
increases with age and peaks between the ages of 40 and 60(310).  The World Health 
Organisation classifies these tumours into three groups: benign (grade I), atypical 
(grade II) and anaplastic (grade III)(54). Approximately 80% of these tumours are 
WHO grade I tumours(309).  
The care for patients with meningioma has steadily improved over the past three 
decades due to a combination of better understanding of the natural history and disease 
biology of meningioma, advances in surgical frameworks and increasing adjuvant and 
salvage therapy options. Survival rates and neurological outcomes have consequently 
improved(292, 293). Traditional neurosurgical outcomes have been reported in terms of 
morbidity, mortality and disability. However, these standard metrics are out-dated and 
the metrics for measuring treatment outcomes are appropriately shifting to become 
increasingly patient-centred. The assessment of the quality of life (QoL) of patients 
has become increasingly recognised as an important outcome measure in brain tumour 
research and the correlation between the two needs to be further explored. Health-
related QoL is a broad, multi-dimensional and self-assessed concept encompassing 
physical, mental, emotional and social functioning related to illness and its 
management.  
The rapid advancement in neuroimaging modalities and their increased availability 
mean more of these tumours are being discovered whilst in a clinically dormant state. 
These are referred to as incidental meningiomas(311). In contrast, some meningiomas 
go unnoticed until they clinically manifest with headaches(92), seizures(56) or focal 
neurological deficit (e.g. motor, sensory or language disturbance). These are labelled 
as symptomatic meningiomas. The primary treatment for symptomatic meningiomas 
is surgical resection, which, in the majority of cases is curative(139, 312). Studies suggest 
that patients experience long-lasting effects following surgery, particularly as life 
expectancy is long with the 20-year survival rate exceeding 50%(134). In operated 
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meningiomas, a single prospective study (n=54), reported improvements in 
neurocognitive function (NCF) after surgery, although QoL was not assessed(313). 
Detailed studies assessing QoL and long-term functional, social and cognitive 
outcomes in this patient cohort are lacking. 
The management of incidental meningioma is controversial, with opinions varying 
between active monitoring, surgical resection and stereotactic radiosurgery. However, 
international consensus guidelines suggest that active monitoring with MRI is the most 
appropriate management strategy in the first instance(96), with most patients remaining 
clinically(314, 315) and radiologically stable(95). Quality of life studies which show the 
superiority of any one management option are lacking. There is only one 
underpowered cross-sectional study (n=21) showing that patients have impaired 
QoL(100), and there are no studies examining the effect of stereotactic radiosurgery on 
QoL in patients with incidental meningioma.   
A recent systematic review by Meskal et al. concluded that patients with meningioma 
suffer from dysfunction in several cognitive domains along their treatment journeys 
which impacts on short and long-term QoL(87). Other retrospective studies have shown 
that although there are improvements in the physical domains of QoL, executive 
function is frequently impaired(316, 317). Such impairments in domains of NCF could 
prove problematic for patients at work and in their social lives(230, 318).   
QoL questionnaires such as EORTC-BN20 and QLQ-C30 have been validated for use 
in brain tumour patients, however, none of them are specific to meningiomas(297). A 
recent qualitative study reported that the experiences of meningioma patients are 
different to existing models of cancer survivorship, but that the supportive care and 
resource needs are similar in both groups at the time of surgery(319). The COMET 
(Core Outcome Measures in Effectiveness Trials) initiative facilitates and supports the 
development of agreed standardised core outcome sets in trials for any disease and has 
a key focus on patient involvement. Any prospective meningioma studies performed 
should take this into consideration in an attempt to define meningioma-specific 
patient-reported outcomes.  
Justification for research 
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Patients with incidental and operated meningioma are followed-up long-term in clinic 
to monitor their clinical condition and for tumour recurrence that may need further 
treatment. Whilst objective neurological deficits (e.g. hemiparesis) or symptoms (e.g. 
seizures) can be readily identified, the limited time frame in the outpatient clinic 
precludes the routine assessment of quality of life and the impact of meningioma and 
treatment.  
 
QoL is an important outcome measure of patient wellbeing. Studying how the QoL of 
patients is affected would help healthcare professionals and patients to better 
understand the course of meningioma and its effects over time. Completing this 
research would allow for the identification of subtle or subclinical deficits that are 
difficult to identify in the outpatient setting. Furthermore, understanding which 
domains of QoL are affected in patients would assist healthcare professionals in 
providing relevant and holistic patient-centred care. 
 
Aims and objectives 
 
Research question: ‘In patients with incidental or operated intracranial meningioma, 
what are the physical, cognitive and psychosocial quality of life outcomes?’ 
 
Primary objective 
• To determine the prevalence of physical, cognitive and psychosocial problems 
in patients with either incidental meningioma or operated meningioma 
Secondary objectives 
• Determine the difference in the QoL between patients with incidental and 
operated meningioma 
• Determine the difference in the QoL between patients with operated 
meningioma stratified by anatomical location (skull base versus non-skull 
base) 
• Determine the difference in the QoL between patients with operated 
meningioma stratified by epilepsy status 
• Determine the difference in the QoL between patients with operated 





A cross-sectional study will be conducted at the Walton Centre NHS Foundation 
Trust. This will involve:  
• Retrospective review of patient case notes and pre-existing databases in order 
to establish patient demographics, details of diagnosis and treatment data 
• Analysis of patient self-reported QoL assessments. These will be completed as 
questionnaires sent through the post or given to patients whilst attending for 






Patients who received a radiological diagnosis of incidental meningioma or patients 
who underwent surgery for their meningioma between 2007 and 2014 (inclusive) will 
be identified from pre-existing surgical logs, MDT records and case records held at 
The Walton Centre NHS Foundation Trust. This includes inviting patients who attend 
routine clinic appointments following their meningioma surgery.  Furthermore, 
patients who were discharged and are not currently under active follow-up with 
regards to their meningioma care at The Walton Centre will be invited for participation 
in this study. 
 
A list of medical record numbers of potential study participants will be produced. 
These notes will be anonymised and a paper conversion table containing the patient’s 
hospital number and study number will be produced. Each patient’s individual case 
notes will be reviewed and compared against the inclusion and exclusion criteria to 
determine eligibility for participation in this study. A screening and enrolment log will 
be completed. Patients will only be identified by their study number within the log. 
Previous audit data from The Walton Centre NHS Foundation Trust between 2007-
2015 identified 440 patients with incidental meningioma (approximately 55 new 
diagnoses per year). Audit data from 2010-2015 identified 283 patients with operated 
meningioma (approximately 57 surgeries per year). In total each year there are 
approximately 112 patients with either a newly diagnosed incidental meningioma or a 
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surgically resected meningioma. We estimate that approximately 784 patients will 
meet our inclusion criteria for the period of 2007 to 2014. In a previous QoL study(229) 
investigating patients with meningioma and epilepsy at The Walton Centre NHS 
Foundation Trust, after applying exclusion criteria and taking into account non-
responders and study dropouts, the final response rate was 50%. Assuming a similar 
response rate, we estimate our final study cohort will be approximately 392 patients.  
 
Inclusion criteria 
• Patients aged ≥16 years at the time of diagnosis of meningioma 
• Able to communicate effectively using the English language 
• To be included in the incidental meningioma cohort: 
o Patients who received a radiological diagnosis of meningioma and have 
been followed-up for a minimum of 5 years 
• To be included in the operated meningioma cohort: 
o Patients who have had surgery for their meningioma and have a 
minimum of 5 years follow-up  
Exclusion criteria 
• Patients aged <16 years at the time of diagnosis of meningioma 
• Patients considered to lack capacity in order to consent to participate in this 
study (e.g. due to a significant neurological deficit) 
• In the incidental meningioma cohort: 
o Patients who received a radiological diagnosis of meningioma and have 
been followed-up for less than 5 years 
o Diagnosis of meningioma considered not to be an incidental finding 
(e.g. meningioma is responsible for the patient’s presenting complaint) 
by clinician responsible for patient’s care 
• In the operated meningioma arm: 
o Patients who have had surgical resection of their meningioma and have 
less than 5 years follow-up 
• Patients identified as having suffered a cerebral neurological insult (e.g. 
trauma, meningitis, stroke) prior to presenting with meningioma 
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• Patients diagnosed with any congenital or neurological disease prior to 
diagnosis of meningioma (e.g. cerebral palsy)  
• Patients diagnosed with radiation-induced meningioma or neurofibromatosis 
type II-associated meningioma 
• Patients with a diagnosis of any condition which leads to cognitive decline 
(e.g. Dementias, Parkinson’s disease or intellectual disabilities), either before 
or after the diagnosis of meningioma.  
Patient recruitment 
 
Invitation to participate and consent 
 
Recruitment of patients to this study will be led by the Chief Investigator and Primary 
Investigator of the research team. Using pre-existing surgical logs, MDT records and 
case records, patients who are suitable for participation in the study will be identified. 
Following confirmation of eligibility criteria, the patient cohort will be contacted and 
invited to participate by post.  
 
Each eligible patient will receive three documents by post: 
1. Cover letter summarising the study and the purpose of contacting the patient 
by post  
2. A detailed patient information sheet containing information about the study in 
non-scientific terms 
3. Consent form 




In order to ensure informed consent for participation in the study, patients will receive 
sufficient information about the study and be given sufficient time to consider whether 
they would like to participate in this study. The study information sheet will include a 
description of the study, the purpose of the study, methods, risks of the study, 
advantages and disadvantages of the study, confidentiality, voluntary participation, 
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right to withdraw, dissemination of results and details of investigators conducting the 
study.  
 
In order to ensure the best understanding for patients, the cover letter, patient 
information sheet and consent form will all be written in plain English. Both cover 
letters, patient information sheet and consent form have been reviewed by two lay 
people to ensure the language used is understandable. 
 
This study will assume that all eligible patients have the capacity to consent to 
participate in the study unless proven otherwise, which is in accordance with the 
Mental Health Act 2005. A thorough examination of the patient’s hospital records will 
allow for the study investigators to highlight any factors which may affect a patient’s 
capacity to consent for participation in the study.  
 
The patient information sheet will include the contact details of the research team and 
the Patient Experience Team. Participants can contact these departments in order to 
gain any further information with regards to the study or their participation. 
 
By consenting to participate in this study, patients will consent to complete the 
research study questionnaires. Patients will also be giving consent to the study 
investigators to analyse the answers given in the study questionnaires and complete a 
retrospective review of the patient’s case notes.  
 
Patients will have four weeks to read the cover letter and patient information sheet and 
return the consent form should they wish to participate in the study. A pre-paid 
envelope will be provided for the patient to return their consent form to The Walton 
Centre NHS Foundation Trust. If no consent form has been returned from a patient, 
they will be sent a second cover letter inviting them for participation in the study, 
alongside another patient information sheet and consent form. If there is no response 
from the patient after this, then it will be assumed that the patient does not wish to 
participate in the study and will not be contacted regarding this study any further.  
For patients who do not wish to participate in the study, no explanation will be 
requested. However, if a patient gives a voluntary explanation regarding why they do 




Patients who attend routine clinical follow-up appointments at The Walton Centre 
NHS Foundation Trust will also be approached during the recruitment period and 
invited to participate.  The patient will be given the opportunity to complete the quality 




After receiving the signed consent forms from all patients who would like to 
participate in this study, the research team will ask these patients to complete the study 
questionnaires. Patients will receive the questionnaires through the post along with a 
pre-paid envelope which would allow the patients to send their completed 
questionnaires back to the research team free of charge. For those patients who have 
long-term follow-up at The Walton Centre NHS Foundation Trust and their next clinic 
appointment is due to take place during the time of the data collection stages, 
questionnaires will be provided at the next clinic appointment.  
 
Data from completed questionnaires will be recorded onto a database designed for 
case-report forms, alongside baseline data identified during case note review. All 
patients will be anonymised and assigned a sequential study number, and all 
information gathered from completed questionnaires and case note review will be 













1. Baseline data to be obtained from case note review: 
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• Diagnosis and tumour grade (according to WHO classification) 
• Age of patient at diagnosis 
• Patient gender 
• Clinical presentation 
• Anatomical location of meningioma (using the International Consortium 
on Meningioma classification system) 
• Documented comorbidities 
• Documented neurological problems 
• Past surgical history including any previous neurosurgical operations 
• Documented details of choice of management for meningioma (e.g. active 
monitoring, surgical resection or adjuvant radiotherapy) 
• Operated meningioma arm: 
o Operative details (including date of surgery, type of surgery, the 
extent of surgical resection: Simpson grade 1-5) 
o Immediate postoperative complications 
o Date of discharge following surgery 
• Tumour recurrence and date of recurrence (recurrence-free survival) 
• Treatment for recurrence (e.g. active monitoring, surgery, radiotherapy) 
• Adjuvant radiotherapy after the first operation 
• Length of follow-up 
 
2. All patients will receive a study-specific questionnaire identifying: 
• Active medical problems 





3. All patients participating in the study will complete: 
• General QoL questionnaire 
o Short Form 36 (SF-36) 
• Brain tumour-specific questionnaire 
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o The European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire- Brain Neoplasm (EORTC-BN20) 
• Cancer patient QoL questionnaire 
o The European Organization for Research and Treatment of Cancer 




Ethical approval for research 
 
The University of Liverpool will be the sponsor for the study. 
 
The study protocol, invitation to participate letter and patient information sheet will 
be submitted for local research ethics approval. IRAS ethical application will also be 




The SF-36, EORTC-BN20 and EORTC QLQ-C30 QoL questionnaires have been 
fully validated for use, with permission for academic reproduction for the purposes of 
this study granted by authors where appropriate. All questionnaires and validation 
studies will be referenced in any publication to ensure compliance with licence and 
trademark agreements. 
 
All electronic records will be stored on University or NHS computers which are 
password-protected. Electronic records will be encrypted, and no patient identifiable 
data will be stored digitally on any computers or other electronic devices.  
 
All data will be anonymised by the use of a study number, except a paper conversion 
table detailing patient name, hospital number, address and allocated patient study 
number. All study documentation will include this study number. 
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All paper-based records (including conversion table) will be stored safely in a lockable 
filing cabinet in a university office on NHS property (locked whilst unattended). 
Medical notes and paper-based patient records that are in use will be tracked to and 
held within a lockable filing cabinet within the Chief Investigator’s office at The 
Walton Centre NHS Foundation Trust. Use of this information will comply with all 
information governance policies at The Walton Centre NHS Foundation Trust. 
Medical notes and paper-based patient records will be returned back to the Health 
Records Library when they are no longer required.  
 
All data will be stored for 10 years following the completion of this study as per 
University of Liverpool protocol. Following this, all data will be archived with the 
permission of the Chief Investigator, who is the custodian, as per University of 
Liverpool Data Management Policy. 
 
The Chief Investigator will act as the data custodian and will lead the research team 
in ensuring appropriate security of all patient and study information. The Chief 
Investigator will ensure full compliance of The Walton Centre NHS Foundation 
Trust’s and The University of Liverpool’s data security and information governance 
policies. Access to patient identifiable information will be on a strict need-to-know 
basis between investigators and all patient personally-identifiable information will be 
kept strictly confidential. No confidential patient data or study information will be 
transferred outside of The Walton Centre NHS Foundation Trust or University of 
Liverpool. 
 
For those patients who are not included in the study (e.g. patients that would not like 
to participate in the study, patients not meeting inclusion/exclusion criteria or those 
removed due to non-response) the research team will destroy all stored data pertaining 
to the patient (deleting electronic data or shredding paper records). Any requested 
medical notes or paper-based patient records relating to these patients will be returned 
back to the Health Records Library.  
 
There is a small risk of the invitation to participate letter, patient information sheet, 
consent form and the study questionnaires being sent to a household where the patient 
no longer resides. This is particularly the case with patients that have been discharged 
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from long-term follow-up at The Walton Centre NHS Foundation Trust. The research 
team will make every effort to ensure that up-to-date patient contact information is 
used. For those patients who have been discharged from having long-term follow-up, 
up-to-date patient contact details and postal address will be obtained from hospital 
case notes and NHS summary care records which are accessible through the NHS 
spine.  
 
Patients will be able to consent to the use and storage of their data, with the exception 
of this first contact. This is an unavoidable situation, but as described above, any risks 
will be minimised during this process.  
 
Risks and benefits to participants 
 
Participation in this study provides no risk to the patients in terms of pain, discomfort, 
change in lifestyle or risk from physical intervention. Participating or choosing not to 
participate in this study will in no way alter the ongoing or future medical care that 
the patient receives.  
 
There is a risk that participating in this study and completing the study questionnaires 
may generate strong emotions for some participants regarding their medical condition. 
The study information literature will include the details of the research team and The 
Patient Experience Team (an independent advisory service), and participants would 
be able to contact these departments for further support. At the discretion of the Chief 
Investigator, if it is felt necessary and the participant consents, there may be a referral 
made to psychological services for support as per the current standard of care. 
 
If patients that are discharged from ongoing care complete this study and experience 
any further issues, then they would be able to contact the research team who would be 
able to book an appointment at The Walton Centre. From this appointment, patients 
can be directed to the appropriate supporting services if required. For patients who are 
under long-term follow-up at The Walton Centre NHS Foundation Trust that require 
additional clinical support, the Chief Investigator may book a follow-up appointment 
with the clinician responsible for the patient’s care. This will only be done if deemed 
 196  
appropriate and necessary by the Chief Investigator and the patient has given 
permission for the Chief Investigator to do so.   
 
Completing the study questionnaires will take approximately 30 minutes to 1 hour and 
may be an inconvenience for some participants. Pre-paid envelopes will be included 
with the questionnaires to reduce any costs to the participant.  
 
The patient study information literature and consent forms will detail all of the above 
points clearly so that patients are fully informed of what participation in this study will 
involve for them. It will explain that patients have a right to withdraw from the study 
completely at any point. This study has selected the most appropriate questionnaires 
so that any intrusion to patients is minimised.   
 
There are no potential risks to the members of the research team as a result of 




The Chief Investigator of this study (Mr Michael Jenkinson) is an honorary consultant 
neurosurgeon and is part of the neuro-oncology team at The Walton Centre NHS 
Foundation Trust. He is also a Reader within the Institute of Translational Medicine 
at The University of Liverpool. The Primary Investigator of this study (Sumirat 
Keshwara) is currently a fourth year student doctor (medical student) at The University 
of Liverpool. He will conduct this research study as part of his intercalated MPhil 




Descriptive statistical analysis will be undertaken. For the quality of life questionnaire 
data, an analysis will be undertaken and values compared to reference values from 
validation studies.  Each questionnaire will be scored according to the scoring systems 




The study results will be analysed and reported using the ‘Strengthening the Reporting 
of Observational studies in Epidemiology’ STROBE checklist for cohort studies. QoL 
outcomes will be treated as continuous data and analysed accordingly. A multivariate 
analysis of factors related to QoL will be performed. 
 
Dissemination of findings 
 
This study will form the basis of the Primary Investigator’s MPhil thesis and will be 
submitted to the University of Liverpool for assessment. The research team will 
disseminate findings of this study at local, national, international scientific and clinical 
meetings. The research team will publish the study results in peer-reviewed journals. 
The results will be shared with charitable organisations such as The Brain Tumour 
Charity and brainstrust. 
 
Patients who have participated in this study will also be given the opportunity to 
receive a break-down of the results and explanation of the findings at the end of the 
study. On the consent form, patients will be given the choice of whether they want to 
be made aware of the study results or not. Any patients who have consented to receive 




The planned study start date is 01/08/19.  Recruitment will be open for 6 months until 
31/01/20.  Data analysis and interpretation will take 6 months until 31/07/20.  The 




Funding for this quality of life study has been received by the Chief Investigator 
(Michael Jenkinson) as part of a larger programme grant from The Brain Tumour 
Charity (‘Deciphering the genetic and epigenetic landscape of clinically aggressive 
meningioma’ Objective 1: Establishing quality of life and symptoms in patients with 
meningioma. The overall principle investigator for the Brain Tumour Charity grant is 
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Dr Gelareh Zadeh, University of Toronto). The principle investigator for the 
QUALMS study is Michael Jenkinson, University of Liverpool. 
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Appendix 9: Additional systematic review articles 
 
The articles named below meet the inclusion criteria for the systematic review 
but were not initially identified from the screening process as it was incomplete 
at the time of writing the chapter. Therefore, the following articles are not 
represented in the PRISMA diagram, results or discussion of Chapter 2.  
 
1. Williams T, Brechin D, Muncer S, Mukerji N, Evans S, Anderson N. 
Meningioma and mood: exploring the potential for meningioma to affect 
psychological distress before and after surgical removal. Br J Neurosurg. 2019 
2. Kondziolka D, Levy EI, Niranjan A, Flickinger JC, Lunsford LD. Long-term 
outcomes after meningioma radiosurgery: physician and patient 
perspectives. J Neurosurg. 1999 
3. Steinvorth S, Welzel G, Fuss M, Debus J, Wildermuth S, Wannenmacher M, 
Wenz F. Neuropsychological outcome after fractionated stereotactic 
radiotherapy (FSRT) for base of skull meningiomas: a prospective 1-year 
follow-up. Radiother Oncol. 2003 
4. Guenther F, Swozil F, Heber S, Buchfelder M, Messlinger K, Fischer MJ. Pre- 
and postoperative headache in patients with meningioma. Cephalalgia. 2019 
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